Process for improved protein expression by strain engineering

ABSTRACT

This invention is a process for improving the production levels of recombinant proteins or peptides or improving the level of active recombinant proteins or peptides expressed in host cells. The invention is a process of comparing two genetic profiles of a cell that expresses a recombinant protein and modifying the cell to change the expression of a gene product that is upregulated in response to the recombinant protein expression. The process can improve protein production or can improve protein quality, for example, by increasing solubility of a recombinant protein.

CROSS REFERENCE TO RELATED APPLICATION

This application claims priority to U.S. Provisional Application No.60/591,489, filed Jul. 26, 2004.

FIELD OF THE INVENTION

This invention is in the field of protein production, and in particularis a process for improving the production levels of recombinant proteinsor peptides or improving the level of active recombinant proteins orpeptides expressed in host cells.

BACKGROUND

More than 155 recombinantly produced proteins and peptides have beenapproved by the U.S. Food and Drug Administration (FDA) for use asbiotechnology drugs and vaccines, with another 370 in clinical trials.Unlike small molecule therapeutics that are produced through chemicalsynthesis, proteins and peptides are most efficiently produced in livingcells. In many cases, the cell or organism has been genetically modifiedto produce or increase the production of the protein.

When a cell is modified to produce large quantities of a target protein,the cell is placed under stress and often reacts by inducing orsuppressing other proteins. The stress that a host cell undergoes duringproduction of recombinant proteins can increase expression of, forexample, specific proteins or cofactors to cause degradation of theoverexpressed recombinant protein. The increased expression ofcompensatory proteins can be counterproductive to the goal of expressinghigh levels of active, full-length recombinant protein. Decreasedexpression or lack of adequate expression of other proteins can causemisfolding and aggregation of the recombinant protein. While it is knownthat a cell under stress will change its profile of protein expression,it is not known in any given example which specific proteins will beupregulated or downregulated.

Microarrays

Microarray technology can be used to identify the presence and level ofexpression of a large number of polynucleotides in a single assay. Seefor eg. U.S. Pat. No. 6,040,138, filed Sep. 15, 1995, U.S. Pat. No.6,344,316, filed Jun. 25, 1997, U.S. Pat. No. 6,261,776, filed Apr. 15,1999, U.S. Pat. No. 6,403,957, filed Oct. 16, 2000, U.S. Pat. No.6,451,536, filed Sep. 27, 2000, U.S. Pat. No. 6,532,462, filed Aug. 27,2001, U.S. Pat. No. 6,551,784, filed May 9, 2001, U.S. Pat. No.6,420,108, filed Feb. 9, 1998, U.S. Pat. No. 6,410,229, filed Dec. 14,1998, U.S. Pat. No. 6,576,424, filed Jan. 25, 2001, U.S. Pat. No.6,687,692, filed Nov. 2, 2000, U.S. Pat. No. 6,600,031, filed Apr. 21,1998, and U.S. Pat. No. 6,567,540, filed Apr. 16, 2001, all assigned toAffymetrix, Inc.

U.S. Pat. No. 6,607,885 to E. I. duPont de Nemours and Co. describesmethods to profile and identify gene expression changes after subjectinga bacterial cell to expression altering conditions by comparing a firstand second microarray measurement. Wei et al. used a microarray analysisto investigate gene expression profiles of E. coli with lac geneinduction (Wei Y., et al. (2001) High-density microarray-mediated geneexpression profiling of Escherichia coli. J Bacteriol. 183(2):545-56).Other groups have also investigated transcriptional profiles regulatedafter mutation of endogenous genes or deletion of regulatory genes(Sabina, J. et al (2003) Interfering with Different Steps of ProteinSynthesis Explored by Transcriptional Profiling of Escherichia coli K-12J Bacteriol. 185:6158-6170; Lee J H (2003) Global analyses oftranscriptomes and proteomes of a parent strain and anL-threonine-overproducing mutant strain. J Bacteriol. 185(18):5442-51;Kabir M M, et al. (2003) Gene expression patterns for metabolic pathwayin pgi knockout Escherichia coli with and without phb genes based onRT-PCR J Biotechnol. 105(1-2): 11-31; Eymann C., et al. (2002) Bacillussubtilis functional genomics: global characterization of the stringentresponse by proteome and transcriptome analysis. J Bacteriol.184(9):2500-20).

Gill et al. disclose the use of microarray technology to identifychanges in the expression of stress related genes in E. coli afterexpression of recombinant chloramphenicol acetyltransferase fusionproteins (Gill et al. (2001) Genomic Analysis of High-Cell-DensityRecombinant Escherichia coli Fermentation and “Cell Conditioning” forImproved Recombinant Protein Yield Biotech. Bioengin. 72:85-95). Thestress gene transcription profile, comprising only 16% of the totalgenome, at high cell density was used to evaluate “cell conditioning”strategies to alter the levels of chaperones, proteases, and otherintracellular proteins prior to recombinant protein overexpression. Thestrategies for “conditioning” involved pharmacological manipulation ofthe cells, including through dithiothreitol and ethanol treatments.

Asai et al. described the use of microarray analysis to identify targetgenes activated by over-expression of certain sigma factors that aretypically induced after cell stresses (Asai K., et al. (2003) DNAmicroarray analysis of Bacillus subtilis sigma factors ofextracytoplasmic function family. FEMS Microbiol. Lett. 220(1):155-60).Cells overexpressing sigma factors as well as reporter genes linked tosigma factor promoters were used to show stress regulated geneinduction.

Choi et al. described the analysis and up-regulation of metabolic genesthat are down-regulated in high-density batch cultures of E. coliexpressing human insulin-like growth factor fusion protein (IGF-I_(f))(Choi et al. (2003) Enhanced Production of Insulin-Like Growth Factor IFusion Protein in Escherichia coli by Coexpression of the Down-RegulatedGenes Identified by Transcriptome Profiling App. Envir. Microbio.69:4737-4742). The focus of this work was on the metabolic changes thatoccur during high-density conditions after protein induction. Genes thatwere down regulated after induction of recombinant protein productionduring high density growth conditions were identified and specificmetabolic genes that had been down-regulated were expressed in cellsproducing recombinant IGF-I_(f). The work showed that increasingmetabolic production of certain nucleotide bases and amino acids couldincrease protein production and that growth rates could be modified byincreasing expression of a down-regulated metabolic transportermolecule. These strategies were designed to alter the cellularenvironment to reduce metabolic stresses associated with the proteinproduction generally or with high density culture.

Protein Degradation

Unwanted degradation of recombinant protein presents an obstacle to theefficient use of certain expression systems. The expression of exogenousproteins often induces stress responses in host cells, which can be, forexample, natural defenses to a limited carbon source. All cells containa large number of genes capable of producing degradative proteins. It isnot possible to predict which proteases will be regulated by a givenhost in response to expression of a particular recombinant protein. Forexample, the bacteria P. fluorescens contains up to 200 proteases andprotease related proteins.

In the cytoplasm of E. coli, proteolysis is generally carried out by agroup of proteases and cofactor molecules. Most early degradation stepsare carried out by five ATP-dependent Hsps: Lon/La FtsH/HflB, ClpAP,ClpXP, and ClpYQ/HslUV (Gottesman S (1996) Proteases and their targetsin Escherichia coli. Annu. Rev. Genet. 30:465-506). Along with FtsH (aninner membrane-associated protease the active site of which faces thecytoplasm), ClpAP and ClpXP are responsible for the degradation ofproteins modified at their carboxyl termini by addition of the non-polardestabilizing tail AANDENYALAA (Gottesman S, et al. (1998) The ClpXP andClpAP proteases degrade proteins with carboxyl-terminal peptide tailsadded by the SsrA-tagging system. Genes Dev. 12:1338-1347; Herman C, etal. (1998) Degradation of carboxy-terminal-tagged cytoplasmic proteinsby the Escherichia coli protease HflB (FtsH). Genes Dev. 12:1348-1355).

Several approaches have been taken to avoid degradation duringrecombinant protein production. One approach is to produce host strainsbearing mutations in a protease gene. Baneyx and Georgiou, for example,utilized a protease-deficient strain to improve the yield of a proteinA-β-lactamase fusion protein (Baneyx F, Georgiou G. (1991) Constructionand characterization of Escherichia coli strains deficient in multiplesecreted proteases: protease III degrades high-molecular-weightsubstrates in vivo. J Bacteriol 173: 2696-2703). Park et al. used asimilar mutational approach to improve recombinant protein activity 30%compared with the parent strain of E. coli (Park S. et al. (1999)Secretory production of recombinant protein by a high cell densityculture of a protease negative mutant Escherichia coli strain.Biotechnol. Progr. 15:164-167). U.S. Pat. Nos. 5,264,365 and 5,264,365describe the construction of protease-deficient E. coli, particularlymultiply protease deficient strains, to produce proteolyticallysensitive polypeptides. PCT Publication No. WO 90/03438 describes theproduction of strains of E. coli that include protease deficient strainsor strains including a protease inhibitor. Similarly, PCT PublicationNo. WO 02/48376 describes E. coli strains deficient in proteases DegPand Prc.

Protein Folding

Another major obstacle in the production of recombinant proteins in hostcells is that the cell often is not adequately equipped to produceeither soluble or active protein. While the primary structure of aprotein is defined by its amino acid sequence, the secondary structureis defined by the presence of alpha helixes or beta sheets, and theternary structure by covalent bonds between adjacent protein stretches,such as disulfide bonds. When expressing recombinant proteins,particularly in large-scale production, the secondary and tertiarystructure of the protein itself is of critical importance. Anysignificant change in protein structure can yield a functionallyinactive molecule, or a protein with significantly reduced biologicalactivity. In many cases, a host cell expresses folding modulators (FMs)that are necessary for proper production of active recombinant protein.However, at the high levels of expression generally required to produceusable, economically satisfactory biotechnology products, a cell oftencan not produce enough native folding modulator or modulators to processthe recombinant protein.

In certain expression systems, overproduction of exogenous proteins canbe accompanied by their misfolding and segregation into insolubleaggregates. In bacterial cells these aggregates are known as inclusionbodies. In E. coli, the network of folding modulators/chaperonesincludes the Hsp70 family. The major Hsp70 chaperone, DnaK, efficientlyprevents protein aggregation and supports the refolding of damagedproteins. The incorporation of heat shock proteins into proteinaggregates can facilitate disaggregation. However, proteins processed toinclusion bodies can, in certain cases, be recovered through additionalprocessing of the insoluble fraction. Proteins found in inclusion bodiestypically have to be purified through multiple steps, includingdenaturation and renaturation. Typical renaturation processes forinclusion body targeted proteins involve attempts to dissolve theaggregate in concentrated denaturant and subsequent removal of thedenaturant by dilution. Aggregates are frequently formed again in thisstage. The additional processing adds cost, there is no guarantee thatthe in vitro refolding will yield biologically active product, and therecovered proteins can include large amounts of fragment impurities.

One approach to reduce protein aggregation is through fermentationengineering, most commonly by reducing the cultivation temperature (seeBaneyx F (1999) In vivo folding of recombinant proteins in Escherichiacoli. In Manual of Industrial Microbiology and Biotechnology, Ed. Davieset al. Washington, DC: American Society for Microbiology ed. 2:551-565and references therein). The more recent realization that in vivoprotein folding is assisted by molecular chaperones, which promote theproper isomerization and cellular targeting of other polypeptides bytransiently interacting with folding intermediates, and by foldases,which accelerate rate-limiting steps along the folding pathway, hasprovided additional approaches combat the problem of inclusion bodyformation (see for e.g. Thomas J G et al. (1997). Molecular chaperones,folding catalysts and the recovery of active recombinant proteins fromE. coli: to fold or to refold. Appl Biochem Biotechnol, 66:197-238).

In certain cases, the overexpression of chaperones has been found toincrease the soluble yields of aggregation-prone proteins (see Baneyx,F. (1999) Recombinant Protein Expression in E. coli Curr. Opin. Biotech.10:411-421 and references therein). The process does not appear toinvolve dissolution of preformed recombinant inclusion bodies but isrelated to improved folding of newly synthesized protein chains. Forexample, Nishihara et al. coexpressed groESL and dnaJK/grpE in thecytoplasm to improve the stability and accumulation of recombinant Cryj2(an allergen of Japanese cedar pollen) (Nishihara K, Kanemori M,Kitagawa M, Yanagi H, Yura T. 1998. Chaperone coexpression plasmids:differential and synergistic roles of DnaK-DnaJ-GrpE and GroEL-GroES inassisting folding of an allergen of Japanese cedar pollen, Cryj2, inEscherichia coli. Appl. Environ. Microbiol. 64:1694). Lee and Olins alsocoexpressed GroESL and DnaK and increased the accumulation of humanprocollagenase by tenfold (Lee S, Olins P. 1992. Effect ofoverproduction of heat shock chaperones GroESL and DnaK on humanprocollagenase production in Escherichia coli. JBC 267:2849-2852). Thebeneficial effect associated with an increase in the intracellularconcentration of these chaperones appears highly dependent on the natureof the overproduced protein, and success is by no means guaranteed.

A need exists for processes for development of host strains that showimproved recombinant protein or peptide production, activity orsolubility in order to reduce manufacturing costs and increase the yieldof active products.

It is therefore an object of the invention to provide processes forimproving recombinant protein expression in a host.

It is a further object of the invention to provide processes thatincrease expression levels in host cells expressing recombinant proteinsor peptides.

It is another object of the invention to provide processes to increasethe levels of soluble protein made in recombinant expression systems.

It is yet another object of the invention to provide processes toincrease the levels of active protein made in recombinant expressionsystems.

SUMMARY

A process is provided for improving the expression of a recombinantprotein or peptide comprising:

i) expressing the recombinant protein or peptide in a host cell;

ii) analyzing a genetic profile of the cell and identifying one or moreendogenous gene products that are up-regulated upon expression oroverexpression of the recombinant protein or peptide; and

iii) changing expression of one or more identified endogenous geneproducts by genetically modifying the cell.

The process can provide improved expression as measured by improvedyields of protein, or can improve the recovery of active protein, forexample by increasing solubility of the expressed recombinant protein,or a related protein or peptide.

Using this process, it can be determined which of the many cellularproteins are “chosen” by the cell to compensate for the expression ofthe foreign recombinant protein, and this information can lead todevelopment of more effective protein expression systems. For example,it is known that, typically, a cell will selectively upregulate one ormore proteases to degrade an overexpressed recombinant protein. However,it cannot be predicted in advance which protease(s) the cell willupregulate to compensate for the stress caused by any given recombinantprotein. Analysis of the cell's genetic profile by microarray orequivalent technology can identify which proteases are upregulated in agiven cell in response to exogenous protein production. This informationis then used to genetically modify the cell to decrease the expressionof these particular proteases, while sparing other proteins that areuseful or even necessary for cell homeostasis.

As another example, a cell may selectively upregulate one or morefolding modulators or cofactors to increase the folding capability orsolubility of the recombinant protein. Again, it cannot be predicted inadvance which folding modulators or cofactors will be selected in agiven system to assist in the processing of a specific recombinantprotein. Analyzing the genetic profile by microarray or equivalenttechnology allows identification of the folding modulators or cofactorsthat have been upregulated. Based on this information, the cell isgenetically modified to increase the expression of the selected foldingmodulators or cofactors preferred by the cell for the given recombinantprotein. This modification can increase the percent of active proteinrecovered, while minimizing the detrimental impact on cell homeostasis.

Therefore, the yield and/or activity and/or solubility of therecombinant protein can be increased by modifying the host organism viaeither increasing or decreasing the expression of a compensatory protein(i.e. a protein that is upregulated in response to given cell stress) ina manner that is selective and that leaves whole other beneficialmechanisms of the cell.

The process can be used iteratively until the expression of activerecombinant protein is optimized. For example, using the processdescribed above, the host cell or organism is genetically modified toupregulate, down regulate, knock-in or knock-out one or more identifiedcompensatory proteins. The host cell or organism so modified can then becultured to express the recombinant protein, or a related protein orpeptide, and additional compensatory proteins identified via microarrayor equivalent analysis. The modified host cell or organism is then againgenetically modified to upregulate, down regulate, knock-in or knock-outthe additional selected compensatory proteins. This process can beiterated until a host cell or organism is obtained that exhibits maximumexpression of active and/or soluble protein without undue weakening ofthe host organism or cell. These steps for example can be repeated forexample, one, two, three, four, five, six, seven, eight, nine, or ten ormore times.

In another embodiment, the process further comprises: iv) expressing therecombinant protein or peptide in a genetically modified cell. In yetanother embodiment, the process further comprises: v) analyzing a secondgenetic profile of the genetically modified cell expressing recombinantprotein or peptide and identifying one or more additional gene productsthat are differentially expressed in the modified cell expressingrecombinant protein or peptide. In a further embodiment, the processadditionally comprises: vi) changing the expression of one or moreidentified additional gene products to provide a double modified cell.Optionally, the recombinant protein or peptide, or a related protein orpeptide, can be expressed in the double modified cell. Thedifferentially regulated gene products identified in the modified cellcan be up- or down-regulated when compared to the host cell or whencompared to the modified cell not expressing recombinant protein orpeptide.

In yet another embodiment, the process further comprises: iv) analyzinga second genetic profile of a genetically modified cell expressingrecombinant protein or peptide and identifying one or more additionalgene products that are differentially expressed in the modified cellthat is not expressing recombinant protein or peptide. In a furtherembodiment, the process additionally comprises: v) changing theexpression of one or more additional identified gene products in themodified cell to provide a double modified cell. The differentiallyregulated gene products identified in the modified cell can be up- ordown-regulated when compared to the host cell or organism or whencompared to the modified cell not expressing recombinant protein orpeptide.

In one specific embodiment, a process is provided for improving theexpression of a recombinant protein or peptide comprising: i) expressingthe recombinant protein or peptide in a host cell; ii) analyzing agenetic profile of the cell and identifying at least one protease thatis up-regulated when the recombinant protein or peptide is expressed;and iii) changing expression of an identified protease by geneticallymodifying the host cell or organism to reduce the expression of theupregulated protease. In a further embodiment, the process compriseschanging the expression of at least a second identified protease in themodified cell to provide a double protease modified cell. In anotherembodiment, the process further comprises: iv) expressing therecombinant protein or peptide, or a related protein or peptide, in aprotease modified cell. In another embodiment, the process furthercomprises analyzing a second genetic profile of the protease modifiedcell to identify one or more additional gene products that aredifferentially expressed in the modified cell.

In another embodiment, a process is provided for improving theexpression of a recombinant protein or peptide comprising: i) expressingthe recombinant protein or peptide in a host cell; ii) analyzing agenetic profile of the cell and identifying at least one up-regulatedfolding modulator (FM) that is up-regulated after overexpression of therecombinant protein or peptide; and iii) changing expression of at leastone identified folding modulator by genetically modifying the cell toprovide a FM modified cell. In a further embodiment, the processcomprises changing the expression of at least a second identifiedfolding modulator in the modified cell to provide a double FM modifiedcell. In another embodiment, the process further comprises: iv)expressing the recombinant protein or peptide, or a related protein orpeptide, in a FM modified cell. In another embodiment, the processfurther comprises analyzing a second genetic profile of the FM modifiedcell to identify one or more additional gene products that aredifferentially expressed in the modified cell.

The term “genetic profile” as used herein is meant to include ananalysis of genes in a genome, mRNA transcribed from genes in the genome(or the equivalent cDNA), transcription products that have been modifiedby a cell such as splice variants of genes in eukaryotic systems, orproteins or peptides translated from genes in a genome, includingproteins that are modified by the cell or translated from splicevariants of mRNA translated from the genome. A genetic profile is meantto include more than one gene or gene product, and typically includes agroup of at least 5, 10, 50, 100 or more genes or gene products that areanalyzed.

In one embodiment, the genetic profile analyzed can be a transcriptomeprofile, i.e. a profile of the transcription products of genes from thegenome. The process can include analyzing the transcriptome profileusing a microarray or equivalent technology. In this embodiment, themicroarray can include binding partners to at least a portion of thetranscriptome of the host cell, and typically includes samples frombinding partners to gene products of at least 50% of the genome of theorganism. More typically, the microarray includes samples from at least80%, 90%, 95%, 98%, 99% or 100% of the binding partners to gene productsin the genome of the host cell.

In a separate embodiment, the microarray can include a selected subsetof binding partners to genes or gene products which represent classes ofproducts that are affected by the recombinant protein expression.Nonlimiting examples include putative or known proteases, co-factors ofproteases or protease-like proteins; folding modulators, co-factors offolding modulators or proteins that may improve protein folding orsolubility; transcription factors; proteins involved in nucleic acidstability or translational initiation; kinases; extracellular orintracellular receptors; metabolic enzymes; metabolic cofactors;envelope proteins; sigma factors; membrane bound proteins; transmembraneproteins; membrane associated proteins and housekeeping genes. Thegenetic profile can be analyzed by measuring the binding of theexpressed genes of the host cell expressing the recombinant protein orpeptide to the microarray. The transcriptome profile can also beanalyzed using non-microarray assays such as blot assays, includingnorthern blot assays, or columns coated with binding partners.

In another embodiment, the genetic profile analyzed can be a proteomeprofile, i.e. a profile of the proteins produced from genes in a givenorganism. The process can include analyzing the proteome profile using,for example, two-dimensional electrophoresis. Techniques like massspectrometry in combination with separation tools such astwo-dimensional gel electrophoresis or multidimensional liquidchromatography, can also be used in the process. In two dimensionalelectrophoresis, the proteins separated can include proteins from atleast 10% of the proteome of the organism. More typically, proteins fromat least 20%, 30%, 40%, 60%, 80% or 90% of the proteins in the proteomeof the host cell are separated and analysed by techniques such asstaining of proteins and/or mass spectrometry.

In additional embodiment, the proteome profile is analyzed using massspectrometry. There are several related techniques that use liquidchromatography (LC) coupled to mass spectrometry (MS) and tandem massspectrometry (MS/MS) to identify proteins and measure their relativeabundance. Often, one sample is labeled with a heavy-isotope tag thatallows for comparison to another sample without changing the chemicalproperties. For example, in one sample the amino acid cysteine can belabeled with a tag containing eight hydrogen atoms. The other sample islabeled with a tag that contains eight deuterium (“heavy”) atoms instead(+8 Daltons). MS data can be used to find pairs of peptides 8 Daltonsapart and quantitate the difference. MS/MS data from the same peptidesprovides an approximation of primary sequence, and the protein ID. Otherexperiments label the proteins in vivo by growing cells with “heavy”amino acids. These types of techniques can be used to identify thousandsof proteins in a single experiment and estimate relative abundance ifpresent in both samples (see Goodlett D R and Aebersold R H (2001). MassSpectrometry in Proteomics. Chem Rev 101:269-295). ICAT is a type ofMS/MS, it stands for Isotope Coded Affinity Tags (see Gygi S P, Rist B,Gerber S A, Turecek F, Gelb M H, and Aebersold R H (1999). Quantitativeanalysis of complex protein mixtures using isotope-coded affinity tags.Nat Biotech 17:994-999).

In another embodiment, the process can include analyzing the proteomeprofile using, for example, a microarray. In this embodiment, the arraycan include binding partners to at least a portion of the proteinsexpressed by the host cell under appropriate growth conditions, andtypically includes binding partners to proteins from at least 10% of theproteome of the organism. More typically, the microarray includesbinding partners to proteins from at least 20%, 30%, 40%, 60%, 80% or90% of the proteins in the proteome of the host cell. The bindingpartners can be antibodies, which can be antibody fragments such assingle chain antibody fragments. In a separate embodiment, themicroarray can include binding partners for a selected subset ofproteins from the proteome, including, for example, putative proteaseproteins or putative folding modulators. The microarray can typicallyalso include a set of binding partners to proteins that are used ascontrols. The genetic profile can be analyzed by measuring the bindingof the proteins of the host cell expressing the recombinant protein orpeptide to the binding partners on the microarray. The proteome profilecan also be analyzed in a standard assay format, such as an Elisa assayor a standard western blot assay.

The samples in the genetic profile can be analyzed individually orgrouped into clusters. The clusters can typically be grouped bysimilarity in gene expression. In particular embodiments, the clusterscan be grouped as genes that are upregulated to a similar extent orgenes that are down-regulated to a similar extent.

The identified up-regulated gene is typically identified by comparing agenetic profile of the host cell expressing the recombinant protein orpeptide to a genetic profile of the host cell not expressing therecombinant protein or peptide. In a further embodiment, a host cellexpressing a protein homologous to the first recombinant protein isanalyzed.

The genome of the host cell expressing the recombinant protein orpeptide can be modified by recombination, for example homologousrecombination or heterologous recombination. The genome can also bemodified by mutation of one or more nucleotides in an open reading frameencoding a gene, particularly an identified protease. In anotherembodiment, the host cell is modified by including one or more vectorsthat encode an inhibitor of an identified gene or gene product, such asa protease inhibitor. In another embodiment, the host cell is modifiedby inhibition of a promoter, which can be a native promoter. In aseparate embodiment, the host cell is modified by including one or morevectors that encode a gene, typically a folding modulator or a cofactorof a folding modulator. In another embodiment, the host cell is modifiedby enhancing a promoter for an identified folding modulator or acofactor for a folding modulator, including by adding an exogenouspromoter to the host cell genome.

The host cell can be any cell capable of producing recombinant proteinor peptide. In one embodiment, the host cell is a prokaryote, such as abacterial cell including, but not limited to an Escherichia or aPseudomonas species. The host cell may be a Pseudomonad cell such as aP. fluorescens cell. In other embodiments, the host cell is an E. colicell. In another embodiment the host cell is a eukaryotic cell, forexample an insect cell, including but not limited to a cell from aSpodoptera, Trichoplusia Drosophila or an Estigmene species, or amammalian cell, including but not limited to a murine cell, a hamstercell, a monkey, a primate or a human cell. In another embodiment, thehost cell is a plant cell, including, but not limited to, a tobaccocell, corn, a cell from an Arabidopsis species, potato or rice cell. Inanother embodiment, a whole organism is analyzed in the process,including but not limited to a transgenic organism.

In one embodiment, the identified upregulated compensatory genes or geneproducts are one or more proteases and/or one or more foldingmodulators. In certain embodiments, an identified gene or gene productcan also be a subunit of a protease or a folding modulator or a cofactorof a protease or a cofactor of a folding modulator. In one embodiment,the identified gene can be selected from a serine, threonine, cysteine,aspartic or metallo peptidase. In certain other embodiments, theidentified gene or gene product can be selected from hsIV, hsIU, clpA,clpB and clpX. The identified gene or gene product can also be acofactor of a protease. In another embodiment, the identified gene orgene product is a folding modulator. In certain embodiments, theidentified gene or gene product can be selected from a chaperoneprotein, a foldase, a peptidyl prolyl isomerase and a disulfide bondisomerase. In one embodiment, the identified gene or gene product can beselected from htpG, cbpA, dnaJ, dnaK and fkbP. In one embodiment, a geneor gene product homologous to the identified up-regulated gene ismodified in the genome of the host.

The process can lead to increased production of recombinant protein orpeptide in a host cell, by for example, increasing the amount of proteinper gram of host protein (total cell protein) in a given amount of time,or increasing the amount of length of time during which the cell ororganism is producing the recombinant protein. The increased productionmay optimize the efficiency of the cell or organism by for example,decreasing the energy expenditure, increasing the use of availableresources, or decreasing the requirements for growth supplements ingrowth media. The increased production may also result in an increasedlevel of recoverable protein or peptide, such as soluble protein,produced per gram of recombinant or per gram of host cell protein.

The invention also includes an improved recombinant host cell that isproduced by the claimed process.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a graph of a growth comparison (optical density over time) ofdifferent strains of P. fluorescens. The cells were induced with 0.3 Mof IPTG at 24 hr after inoculation. The strains are: DC280 harboring theempty vector pDOW1339, DC240 that produces the soluble cytoplasmicnitrilase enzyme, and DC271 that produces the partially insolubleperiplasmic hGH. DC206, the parental strain of DC280, DC240, and DC271was included as a control. Samples were taken at 0 and 4 hrs post-IPTGinduction for RNA isolation and gene expression profiling, as indicatedby arrows.

FIG. 2 is an graph of hierarchical clustering of all genes from P.fluorescens strains DC280, DC240 and DC271 into 12 clusters at 4 hrafter IPTG when compared to 0 hr IPTG (indicated at the bottom of thefigure). Based on the value and trend, genes were clustered and groupedusing the hierarchical clustering algorithm from Spotfire DecisionSite.Broken lines indicate data points that were filtered out due to poorspots quality or low level of expression. The x-axis represents thecomparison of each strain; the y-axis represents the relative expressionvalue 4 hrs after to before IPTG induction. All the identified FMs arehighlighted. Cluster 7 shows 2 FM and 2 protease subunit genes that arehighly expressed in strain DC271, which overproduces the periplasmic hGHprotein. The remaining FM genes are grouped in cluster 6.

FIG. 3 is a hierarchical cluster analysis of cluster 6 from FIG. 2. Inthe new cluster 8, two folding modulators, DnaK and DnaJ, wereidentified both of which showed higher expression levels for periplasmicrecombinant protein production similar to the previously identifiedHslVU, CbpA, and HtpG. Cluster 6 shows where the rest of the FMs aregrouped.

FIG. 4 is a Venn diagram showing the up-regulated protease and FMs fromthe three sets of experiments in Table 5, 6 and 7. As summarized inTable 5, 6 and 7, the list of genes were organized in Venn diagram tohighlight the overlap of the gene list among the three sets ofexperiments indicated at the corner. For each gene, the ratio of eachexperiment was shown with 2 as a cut off.

FIG. 5 is a graph of the sequence analysis of the hslV (RXF01961) andhslU (RXF01957) genes from P. fluorescens generated by Artemis. Thecodon usage plot (top panel) indicates that the gene boundary arecorrect. This is corroborated by the best homologues of HslV and HslUprotein sequences to P. aeruginosa as indicated beneath the genes ofRXF01961 and RXF01957. The Phrap quality score plot shows that thesequence quality is good, i.e. the score line is above the horizontalline indicating a better quality than 1 error in 10 kb (middle panel).The open white pointed boxes below the genes show the location of theprobes generated for use in the DNA microarray experiments.

FIG. 6 is a schematic illustration of an hslU mutant construction wherean approximately 550 bp PCR product of hslU (light blue box) was ligatedinto TOPO TA2.1 cloning vector (circle). The resulting plasmid wastransformed into competent P. fluorescens cells and kanamycin(kan)-resistant colonies were analyzed in diagnostic PCR to confirm theconstruction of an insertion mutation in the hslU gene.

FIG. 7 is a graph of a growth curve assays comparing wild type with hslUmutant strain overproducing hGH or pbp::hGH in shake flask productionmedium. The arrows indicate time points where samples were taken.

FIG. 8 is an image of SDS-PAGE analysis of strains DC271 and DC373expressing pbp::hGH. Samples were taken from DC271 (wild-type, W) andDC373 (hslU mutant, M) just before protein induction (0 hr) and then 4hr, 8 hr, 24 hr, and 30 hr after IPTG addition. Soluble (S) andinsoluble (I) fractions were prepared for each sample analyzed. Theproduction of unprocessed and processed hGH is indicated by arrows. Themolecular weight (MW) marker (Ma) is shown on the right hand side of thegels.

FIG. 9 is an image of the SDS-PAGE analysis of strains DC369 and DC372expressing hGH in the cytoplasm. Samples were taken from DC369(wild-type, W) and DC372 (hslU mutant, M) just before protein induction(0 hr) and then 4 hrs, 8 hrs, 24 hrs, 30 hrs, and 50 hrs after IPTGaddition. Soluble (S) and insoluble (I) fractions were prepared for eachsample analyzed. The production of hGH is indicated by an arrow. Themolecular weight (MW) marker (Ma) is shown on the right hand side of thegels.

FIG. 10 is a graph of growth curves of strains expressing the hGH::COPfusion protein. The strains include: DC369 expressing hGH only (notfused to COP) as a negative control; HJ104, the wild type expressinghGH::COP; HJ105, the hslU mutant expressing hGH::COP.

FIG. 11 is a graph of the green fluorescence activity measurements forstrains expressing the hGH::COP fusion protein using a fluorimeter. FiveOD600 of cell culture were sampled for each strain harboring hGH orhGH::COP at different time points after IPTG induction. The strainstested include: DC369 expressing hGH only (not fused to COP) as anegative control; HJ104, the wild type expressing hGH::COP; HJ105, thehslU mutant expressing hGH::COP. The inserted table shows percentincrease of relative fluorescence in the hslU mutant compared to thewild type at different time points after IPTG induction.

FIG. 12 is a pictoral representation of the process of measuringrelative abundance of mRNA between two samples.

FIG. 13 is a representation of the construction of chromosomal deletionof hslUV gene in pyrF-negative strain. A. Plasmid pDOW2050 contains 505bp and 634 bp DNA fragments flanking the hslUV gene. Since suicideplasmid pDOW2050 can not replicate in P. fluorescens,tetracycline-resistant cells will only be generated after a singlerecombination event at one of the homologous regions that integrates theentire plasmid into the genome. B. Tetracycline-resistant cells containsthe entire plasmid integrated into the genome. These cells also containthe pyrF gene encoded from the plasmid. Selection for cells that has thesecond recombinant event occurred by plating cells on agar platessupplemented with FOA, which in pyrF-positive strains, is converted intoa toxic compound. C. The chromosomal deletion strain was confirmed bysequencing analysis

FIG. 14 is a graph of relative fluorescence over time for greenfluorescence activity measurements for the strains expressing the hGH::COP fusion protein using a fluorimeter. Duplicates were used for boththe wild type (HJ104) and hslUV deletion strain (HJ117).

FIG. 15 is images of SDS-PAGE gels of strains expressing hGH with orwithout folding modulators GrpE-DnakJ. Samples were removed at varioustimes after induction by IPTG (0, 4, 8, 24 and 48 hr), normalized toOD600 of 20 and lysed using EasyLyse. The soluble (S) insoluble (I)fractions were separated on a BioRad Criterion 15% Tris HCl SDS-PAGE geland stained with Coomassie.

DETAILED DESCRIPTION

A process is provided for improving the expression of a recombinantprotein or peptide comprising i) expressing the recombinant protein orpeptide in a host cell; ii) analyzing a genetic profile of the cell andidentifying one or more endogenous up-regulated gene products, includingone or more proteases or folding modulators that are up-regulated uponexpression of the recombinant protein or peptide; and iii) changingexpression of one or more identified gene products by geneticallymodifying the cell. In another embodiment, the process further comprisesexpressing the recombinant protein or peptide in a genetically modifiedcell. In another embodiment, the process further comprises analyzing asecond genetic profile of the genetically modified cell to identify oneor more additional gene products that are differentially expressed inthe modified cell. In a further embodiment, the process compriseschanging the expression of at least a second identified gene product inthe modified cell to provide a double modified cell. The process canprovide improved expression as measured by improved yields of protein,or can improve the recovery of active protein, for example by increasingsolubility of the expressed recombinant protein.

More generally, the invention includes a process for improving theexpression of a recombinant protein or peptide in a host cell ororganism comprising:

i) expressing the recombinant protein or peptide in the recombinant hostcell or organism;

ii) analyzing a genetic profile of the recombinant cell to identify acompensatory gene or gene product that is expressed at a higher level inthe recombinant cell than in one of either a host cell that has not beenmodified to express the recombinant protein or a recombinant cell thatis not expressing the recombinant protein; and

iii) changing expression of the identified compensatory gene or geneproduct in the recombinant cell by genetic modification to provide amodified recombinant cell that achieves an increase in recombinantprotein expression, activity or solubility.

Throughout the specification, when a range is provided, it should beunderstood that the components are meant to be independent. For example,a range of 1-6 means independently 1, 2, 3, 4, 5 or 6.

The steps of the process are described in more detail below.

Step I: Genetic Modification of Host Cell or Organism to Express aRecombinant Protein or Peptide in a Host Cell

In the first step of the process, a host cell is modified to have thecapacity to express a recombinant protein or peptide. The host cell canbe modified using any techniques known in the art. For example, therecombinant protein can be expressed from an expression vector that isexogenous to the genome of the cell and that is transfected ortransformed into the cell. The construction of expression vectors aswell as techniques for transfection or transformation are describedbelow. The host cell can also be modified to express a recombinantprotein or peptide from a genomic insert as described below. A geneencoding the recombinant protein or peptide can be inserted into thegenome of the host cell or organism by techniques such as homologous orheterologous recombination. These techniques are described below.

The recombinant protein or peptide can be expressed under the control ofan element that requires further manipulation of the cell. For example,chemical treatment of the cell may be required to initiate or enhanceprotein or peptide expression. Promoter and repressor elements thatgovern the expression of recombinant proteins or peptides in host cellsare described below and are well known in the art. These can includepromoter elements based on the “tac” promoter, responsive to IPTG.

Selection of a Host Cell or Organism

The process of the invention can be used in any given host system,including of either eukaryotic or prokaryotic origin. The process isgenerally limited only by the availability of enough genetic informationfor analysis of a genetic profile to identify a identified gene.Although it is generally typical that representative sequences from alarge percentage of the genome is available, for example at least 50%,60%, 70%, 80%, 90%, 95%, 98%, 99% or 100% of the sequences expressed orfound in the genome, transcriptome, or proteome, the invention can bepracticed using only a portion of the sequences in the genome,transcriptome, or proteome. In particular, in instances when theinformation available includes information on a group of relatedsequences, such as a metabolically linked group, only a small portion ofrepresentative sequences from the genome can be used for the process ofthe invention. The process is also not limited to particular recombinantproteins being expressed, as a key aspect of the process is the capacityto rationally and iteratively design expression systems based ontechniques for identifying cellular changes that occur in a host cellupon expression of recombinant proteins or peptides and modulating thehost cell using procedures known in the art.

The host cell can be any cell capable of producing recombinant proteinor peptide. In one embodiment, the host cell is a microbial cell, ie. acell from a bacteria, fungus, yeast, or other unicellular eukaryotes,prokaryotes and viruses. The most commonly used systems to producerecombinant proteins or peptides include certain bacterial cells,particularly E. coli, because of their relatively inexpensive growthrequirements and potential capacity to produce protein in large batchcultures. Yeast are also used to express biologically relevant proteinsand peptides, particularly for research purposes. Systems includeSaccharomyces cerevisiae or Pichia pastoris. These systems are wellcharacterized, provide generally acceptable levels of total proteinexpression and are comparatively fast and inexpensive. Insect cellexpression systems have also emerged as an alternative for expressingrecombinant proteins in biologically active form. In some cases,correctly folded proteins that are post-translationally modified can beproduced. Mammalian cell expression systems, such as Chinese hamsterovary cells, have also been used for the expression of recombinantproteins. On a small scale, these expression systems are ofteneffective. Certain biologics can be derived from mammalian proteins,particularly in animal or human health applications. In anotherembodiment, the host cell is a plant cell, including, but not limitedto, a tobacco cell, corn, a cell from an Arabidopsis species, potato orrice cell. In another embodiment, a multicellular organism is analyzedor is modified in the process, including but not limited to a transgenicorganism. Techniques for analyzing and/or modifying a multicellularorganism are generally based on techniques described for modifying cellsdescribed below.

In one embodiment, the host cell can be a prokaryote such as a bacterialcell including, but not limited to an Escherichia or a Pseudomonasspecies. Typical bacterial cells are described, for example, in“Biological Diversity: Bacteria and Archaeans”, a chapter of the On-LineBiology Book, provided by Dr M J Farabee of the Estrella MountainCommunity College, Arizona, USA at URL:http://www.emc.maricopa.edu/faculty/farabee/BIOBK/BioBookDiversity_(—)2.html.In certain embodiments, the host cell can be a Pseudomonad cell, and cantypically be a P. fluorescens cell. In other embodiments, the host cellcan also be an E. coli cell. In another embodiment the host cell can bea eukaryotic cell, for example an insect cell, including but not limitedto a cell from a Spodoptera, Trichoplusia Drosophila or an Estigmenespecies, or a mammalian cell, including but not limited to a murinecell, a hamster cell, a monkey, a primate or a human cell.

In certain embodiments, the host cell is a Pseudomonad cell, and can befor example a P. fluorescens organism.

In one embodiment, the host cell can be a member of any of the bacterialtaxa. The cell can, for example, be a member of any species ofeubacteria. The host can be a member any one of the taxa: Acidobacteria,Actinobacteira, Aquificae, Bacteroidetes, Chlorobi, Chlamydiae,Choroflexi, Chrysiogenetes, Cyanobacteria, Deferribacteres, Deinococcus,Dictyoglomi, Fibrobacteres, Firmicutes, Fusobacteria, Gemmatimonadetes,Lentisphaerae, Nitrospirae, Planctomycetes, Proteobacteria,Spirochaetes, Thermodesulfobacteria, Thermomicrobia, Thermotogae,Thermus (Thermales), or Verrucomicrobia. In one embodiment of aeubacterial host cell, the cell can be a member of any species ofeubacteria, excluding Cyanobacteria.

The bacterial host can also be a member of any species ofProteobacteria. A proteobacterial host cell can be a member of any oneof the taxa Alphaproteobacteria, Betaproteobacteria,Gammaproteobacteria, Deltaproteobacteria, or Epsilonproteobacteria. Inaddition, the host can be a member of any one of the taxaAlphaproteobacteria, Betaproteobacteria, or Gammaproteobacteria, and amember of any species of Gammaproteobacteria.

In one embodiment of a Gammaproteobacterial host, the host will bemember of any one of the taxa Aeromonadales, Alteromonadales,Enterobacteriales, Pseudomonadales, or Xanthomonadales; or a member ofany species of the Enterobacteriales or Pseudomonadales. In oneembodiment, the host cell can be of the order Enterobacteriales, thehost cell will be a member of the family Enterobacteriaceae, or a memberof any one of the genera Erwinia, Escherichia, or Serratia; or a memberof the genus Escherichia. In one embodiment of a host cell of the orderPseudomonadales, the host cell will be a member of the familyPseudomonadaceae, even of the genus Pseudomonas. Gamma Proteobacterialhosts include members of the species Escherichia coli and members of thespecies Pseudomonas fluorescens.

Other Pseudomonas organisms may also be useful. Pseudomonads and closelyrelated species include Gram(−) Proteobacteria Subgroup 1, which includethe group of Proteobacteria belonging to the families and/or generadescribed as “Gram-Negative Aerobic Rods and Cocci” by R. E. Buchananand N. E. Gibbons (eds.), Bergey's Manual of Determinative Bacteriology,pp. 217-289 (8th ed., 1974) (The Williams & Wilkins Co., Baltimore, Md.,USA) (hereinafter “Bergey (1974)”). The following table presents thesefamilies and genera of organisms. Families and Genera Listed in thePart, “Gram-Negative Aerobic Rods and Cocci” (in Bergey (1974)) FamilyI. Pseudomonadaceae Gluconobacter Pseudomonas Xanthomonas ZoogloeaFamily II. Azotobacteraceae Azomonas Azotobacter Beijerinckia DerxiaFamily III. Rhizobiaceae Agrobacterium Rhizobium Family IV.Methylomonadaceae Methylococcus Methylomonas Family V. HalobacteriaceaeHalobacterium Halococcus Other Genera Acetobacter Alcaligenes BordetellaBrucella Francisella Thermus

“Gram(−) Proteobacteria Subgroup 1” also includes Proteobacteria thatwould be classified in this heading according to the criteria used inthe classification. The heading also includes groups that werepreviously classified in this section but are no longer, such as thegenera Acidovorax, Brevundimonas, Burkholderia, Hydrogenophaga,Oceanimonas, Ralstonia, and Stenotrophomonas, the genus Sphingomonas(and the genus Blastomonas, derived therefrom), which was created byregrouping organisms belonging to (and previously called species of) thegenus Xanthomonas, the genus Acidomonas, which was created by regroupingorganisms belonging to the genus Acetobacter as defined in Bergey(1974). In addition hosts can include cells from the genus Pseudomonas,Pseudomonas enalia (ATCC 14393), Pseudomonas nigrifaciens (ATCC 19375),and Pseudomonas putrefaciens (ATCC 8071), which have been reclassifiedrespectively as Alteromonas haloplanktis, Alteromonas nigrifaciens, andAlteromonas putrefaciens. Similarly, e.g., Pseudomonas acidovorans (ATCC15668) and Pseudomonas testosteroni (ATCC 11996) have since beenreclassified as Comamonas acidovorans and Comamonas testosteroni,respectively; and Pseudomonas nigrifaciens (ATCC 19375) and Pseudomonaspiscicida (ATCC 15057) have been reclassified respectively asPseudoalteromonas nigrifaciens and Pseudoalteromonas piscicida. “Gram(−)Proteobacteria Subgroup 1” also includes Proteobacteria classified asbelonging to any of the families: Pseudomonadaceae, Azotobacteraceae(now often called by the synonym, the “Azotobacter group” ofPseudomonadaceae), Rhizobiaceae, and Methylomonadaceae (now often calledby the synonym, “Methylococcaceae”). Consequently, in addition to thosegenera otherwise described herein, further Proteobacterial generafalling within “Gram(−) Proteobacteria Subgroup 1” include: 1)Azotobacter group bacteria of the genus Azorhizophilus; 2)Pseudomonadaceae family bacteria of the genera Cellvibrio, Oligella, andTeredinibacter; 3) Rhizobiaceae family bacteria of the generaChelatobacter, Ensifer, Liberibacter (also called “CandidatusLiberibacter”), and Sinorhizobium; and 4) Methylococcaceae familybacteria of the genera Methylobacter, Methylocaldum, Methylomicrobium,Methylosarcina, and Methylosphaera.

In another embodiment, the host cell is selected from “Gram(−)Proteobacteria Subgroup 2.” “Gram(−) Proteobacteria Subgroup 2” isdefined as the group of Proteobacteria of the following genera (with thetotal numbers of catalog-listed, publicly-available, deposited strainsthereof indicated in parenthesis, all deposited at ATCC, except asotherwise indicated): Acidomonas (2); Acetobacter (93); Gluconobacter(37); Brevundimonas (23); Beijerinckia (13); Derxia (2); Brucella (4);Agrobacterium (79); Chelatobacter (2); Ensifer (3); Rhizobium (144);Sinorhizobium (24); Blastomonas (1); Sphingomonas (27); Alcaligenes(88); Bordetella (43); Burkholderia (73); Ralstonia (33); Acidovorax(20); Hydrogenophaga (9); Zoogloea (9); Methylobacter (2); Methylocaldum(1 at NCIMB); Methylococcus (2); Methylomicrobium (2); Methylomonas (9);Methylosarcina (1); Methylosphaera; Azomonas (9); Azorhizophilus (5);Azotobacter (64); Cellvibrio (3); Oligella (5); Pseudomonas (1139);Francisella (4); Xanthomonas (229); Stenotrophomonas (50); andOceanimonas (4).

Exemplary host cell species of “Gram(−) Proteobacteria Subgroup 2”include, but are not limited to the following bacteria (with the ATCC orother deposit numbers of exemplary strain(s) thereof shown inparenthesis): Acidomonas methanolica (ATCC 43581); Acetobacter aceti(ATCC 15973); Gluconobacter oxydans (ATCC 19357); Brevundimonas diminuta(ATCC 11568); Beijerinckia indica (ATCC 9039 and ATCC 19361); Derxiagummosa (ATCC 15994); Brucella melitensis (ATCC 23456), Brucella abortus(ATCC 23448); Agrobacterium tumefaciens (ATCC 23308), Agrobacteriumradiobacter (ATCC 19358), Agrobacterium rhizogenes (ATCC 11325);Chelatobacter heintzii (ATCC 29600); Ensifer adhaerens (ATCC 33212);Rhizobium leguminosarum (ATCC 10004); Sinorhizobium fredii (ATCC 35423);Blastomonas natatoria (ATCC 35951); Sphingomonas paucimobilis (ATCC29837); Alcaligenes faecalis (ATCC 8750); Bordetella pertussis (ATCC9797); Burkholderia cepacia (ATCC 25416); Ralstonia pickettii (ATCC27511); Acidovorax facilis (ATCC 11228); Hydrogenophaga flava (ATCC33667); Zoogloea ramigera (ATCC 19544); Methylobacter luteus (ATCC49878); Methylocaldum gracile (NCIMB 11912); Methylococcus capsulatus(ATCC 19069); Methylomicrobium agile (ATCC 35068); Methylomonasmethanica (ATCC 35067); Methylosarcina fibrata (ATCC 700909);Methylosphaera hansonii (ACAM 549); Azomonas agilis (ATCC 7494);Azorhizophilus paspali (ATCC 23833); Azotobacter chroococcum (ATCC9043); Cellvibrio mixtus (UQM 2601); Oligella urethralis (ATCC 17960);Pseudomonas aeruginosa (ATCC 10145), Pseudomonas fluorescens (ATCC35858); Francisella tularensis (ATCC 6223); Stenotrophomonas maltophilia(ATCC 13637); Xanthomonas campestris (ATCC 33913); and Oceanimonasdoudoroffii (ATCC 27123).

In another embodiment, the host cell is selected from “Gram(−)Proteobacteria Subgroup 3.” “Gram(−) Proteobacteria Subgroup 3” isdefined as the group of Proteobacteria of the following genera:Brevundimonas; Agrobacterium; Rhizobium; Sinorhizobium; Blastomonas;Sphingomonas; Alcaligenes; Burkholderia; Ralstonia; Acidovorax;Hydrogenophaga; Methylobacter; Methylocaldum; Methylococcus;Methylomicrobium; Methylomonas; Methylosarcina; Methylosphaera;Azomonas; Azorhizophilus; Azotobacter; Cellvibrio; Oligella;Pseudomonas; Teredinibacter; Francisella; Stenotrophomonas; Xanthomonas;and Oceanimonas.

In another embodiment, the host cell is selected from “Gram(−)Proteobacteria Subgroup 4.” “Gram(−) Proteobacteria Subgroup 4” isdefined as the group of Proteobacteria of the following genera:Brevundimonas; Blastomonas; Sphingomonas; Burkholderia; Ralstonia;Acidovorax; Hydrogenophaga; Methylobacter; Methylocaldum; Methylococcus;Methylomicrobium; Methylomonas; Methylosarcina; Methylosphaera;Azomonas; Azorhizophilus; Azotobacter; Cellvibrio; Oligella;Pseudomonas; Teredinibacter; Francisella; Stenotrophomonas; Xanthomonas;and Oceanimonas.

In an embodiment, the host cell is selected from “Gram(−) ProteobacteriaSubgroup 5.” “Gram(−) Proteobacteria Subgroup 5” is defined as the groupof Proteobacteria of the following genera: Methylobacter; Methylocaldum;Methylococcus; Methylomicrobium; Methylomonas; Methylosarcina;Methylosphaera; Azomonas; Azorhizophilus; Azotobacter; Cellvibrio;Oligella; Pseudomonas; Teredinibacter; Francisella; Stenotrophomonas;Xanthomonas; and Oceanimonas.

The host cell can be selected from “Gram(−) Proteobacteria Subgroup 6.”“Gram(−) Proteobacteria Subgroup 6” is defined as the group ofProteobacteria of the following genera: Brevundimonas; Blastomonas;Sphingomonas; Burkholderia; Ralstonia; Acidovorax; Hydrogenophaga;Azomonas; Azorhizophilus; Azotobacter; Cellvibrio; Oligella;Pseudomonas; Teredinibacter; Stenotrophomonas; Xanthomonas; andOceanimonas.

The host cell can be selected from “Gram(−) Proteobacteria Subgroup 7.”“Gram(−) Proteobacteria Subgroup 7” is defined as the group ofProteobacteria of the following genera: Azomonas; Azorhizophilus;Azotobacter; Cellvibrio; Oligella; Pseudomonas; Teredinibacter;Stenotrophomonas; Xanthomonas; and Oceanimonas. The host cell can beselected from “Gram(−) Proteobacteria Subgroup 8.” “Gram(−)Proteobacteria Subgroup 8” is defined as the group of Proteobacteria ofthe following genera: Brevundimonas; Blastomonas; Sphingomonas;Burkholderia; Ralstonia; Acidovorax; Hydrogenophaga; Pseudomonas;Stenotrophomonas; Xanthomonas; and Oceanimonas.

The host cell can be selected from “Gram(−) Proteobacteria Subgroup 9.”“Gram(−) Proteobacteria Subgroup 9” is defined as the group ofProteobacteria of the following genera: Brevundimonas; Burkholderia;Ralstonia; Acidovorax; Hydrogenophaga; Pseudomonas; Stenotrophomonas;and Oceanimonas.

The host cell can be selected from “Gram(−) Proteobacteria Subgroup 10.”“Gram(−) Proteobacteria Subgroup 10” is defined as the group ofProteobacteria of the following genera: Burkholderia; Ralstonia;Pseudomonas; Stenotrophomonas; and Xanthomonas.

The host cell can be selected from “Gram(−) Proteobacteria Subgroup 11.”“Gram(−) Proteobacteria Subgroup 11” is defined as the group ofProteobacteria of the genera: Pseudomonas; Stenotrophomonas; andXanthomonas. The host cell can be selected from “Gram(−) ProteobacteriaSubgroup 12.” “Gram(−) Proteobacteria Subgroup 12” is defined as thegroup of Proteobacteria of the following genera: Burkholderia;Ralstonia; Pseudomonas. The host cell can be selected from “Gram(−)Proteobacteria Subgroup 13.” “Gram(−) Proteobacteria Subgroup 13” isdefined as the group of Proteobacteria of the following genera:Burkholderia; Ralstonia; Pseudomonas; and Xanthomonas. The host cell canbe selected from “Gram(−) Proteobacteria Subgroup 14.” “Gram(−)Proteobacteria Subgroup 14” is defined as the group of Proteobacteria ofthe following genera: Pseudomonas and Xanthomonas. The host cell can beselected from “Gram(−) Proteobacteria Subgroup 15.” “Gram(−)Proteobacteria Subgroup 15” is defined as the group of Proteobacteria ofthe genus Pseudomonas.

The host cell can be selected from “Gram(−) Proteobacteria Subgroup 16.”“Gram(−) Proteobacteria Subgroup 16” is defined as the group ofProteobacteria of the following Pseudomonas species (with the ATCC orother deposit numbers of exemplary strain(s) shown in parenthesis):Pseudomonas abietaniphila (ATCC 700689); Pseudomonas aeruginosa (ATCC10145); Pseudomonas alcaligenes (ATCC 14909); Pseudomonasanguilliseptica (ATCC 33660); Pseudomonas citronellolis (ATCC 13674);Pseudomonas flavescens (ATCC 51555); Pseudomonas mendocina (ATCC 25411);Pseudomonas nitroreducens (ATCC 33634); Pseudomonas oleovorans (ATCC8062); Pseudomonas pseudoalcaligenes (ATCC 17440); Pseudomonasresinovorans (ATCC 14235); Pseudomonas straminea (ATCC 33636);Pseudomonas agarici (ATCC 25941); Pseudomonas alcaliphila; Pseudomonasalginovora; Pseudomonas andersonii; Pseudomonas asplenii (ATCC 23835);Pseudomonas azelaica (ATCC 27162); Pseudomonas beijerinckii (ATCC19372); Pseudomonas borealis; Pseudomonas boreopolis (ATCC 33662);Pseudomonas brassicacearum; Pseudomonas butanovora (ATCC 43655);Pseudomonas cellulosa (ATCC 55703); Pseudomonas aurantiaca (ATCC 33663);Pseudomonas chlororaphis (ATCC 9446, ATCC 13985, ATCC 17418, ATCC17461); Pseudomonas fragi (ATCC 4973); Pseudomonas lundensis (ATCC49968); Pseudomonas taetrolens (ATCC 4683); Pseudomonas cissicola (ATCC33616); Pseudomonas coronafaciens; Pseudomonas diterpeniphila;Pseudomonas elongata (ATCC 10144); Pseudomonas flectens (ATCC 12775);Pseudomonas azotoformans; Pseudomonas brenneri; Pseudomonas cedrella;Pseudomonas corrugata (ATCC 29736); Pseudomonas extremorientalis;Pseudomonas fluorescens (ATCC 35858); Pseudomonas gessardii; Pseudomonaslibanensis; Pseudomonas mandelii (ATCC 700871); Pseudomonas marginalis(ATCC 10844); Pseudomonas migulae; Pseudomonas mucidolens (ATCC 4685);Pseudomonas orientalis; Pseudomonas rhodesiae; Pseudomonas synxantha(ATCC 9890); Pseudomonas tolaasii (ATCC 33618); Pseudomonas veronii(ATCC 700474); Pseudomonas frederiksbergensis; Pseudomonas geniculata(ATCC 19374); Pseudomonas gingeri; Pseudomonas graminis; Pseudomonasgrimontii; Pseudomonas halodenitrificans; Pseudomonas halophila;Pseudomonas hibiscicola (ATCC 19867); Pseudomonas huttiensis (ATCC14670); Pseudomonas hydrogenovora; Pseudomonas jessenii (ATCC 700870);Pseudomonas kilonensis; Pseudomonas lanceolata (ATCC 14669); Pseudomonaslini; Pseudomonas marginata (ATCC 25417); Pseudomonas mephitica (ATCC33665); Pseudomonas denitrificans (ATCC 19244); Pseudomonaspertucinogena (ATCC 190); Pseudomonas pictorum (ATCC 23328); Pseudomonaspsychrophila; Pseudomonas fulva (ATCC 31418); Pseudomonas monteilii(ATCC 700476); Pseudomonas mosselii; Pseudomonas oryzihabitans (ATCC43272); Pseudomonas plecoglossicida (ATCC 700383); Pseudomonas putida(ATCC 12633); Pseudomonas reactans; Pseudomonas spinosa (ATCC 14606);Pseudomonas balearica; Pseudomonas luteola (ATCC 43273); Pseudomonasstutzeri (ATCC 17588); Pseudomonas amygdali (ATCC 33614); Pseudomonasavellanae (ATCC 700331); Pseudomonas caricapapayae (ATCC 33615);Pseudomonas cichorii (ATCC 10857); Pseudomonas ficuserectae (ATCC35104); Pseudomonas fuscovaginae; Pseudomonas meliae (ATCC 33050);Pseudomonas syringae (ATCC 19310); Pseudomonas viridiflava (ATCC 13223);Pseudomonas thermocarboxydovorans (ATCC 35961); Pseudomonasthermotolerans; Pseudomonas thivervalensis; Pseudomonas vancouverensis(ATCC 700688); Pseudomonas wisconsinensis; and Pseudomonas xiamenensis.

The host cell can be selected from “Gram(−) Proteobacteria Subgroup 17.”“Gram(−) Proteobacteria Subgroup 17” is defined as the group ofProteobacteria known in the art as the “fluorescent Pseudomonads”including those belonging, e.g., to the following Pseudomonas species:Pseudomonas azotoformans; Pseudomonas brenneri; Pseudomonas cedrella;Pseudomonas corrugata; Pseudomonas extremorientalis; Pseudomonasfluorescens; Pseudomonas gessardii; Pseudomonas libanensis; Pseudomonasmandelii; Pseudomonas marginalis; Pseudomonas migulae; Pseudomonasmucidolens; Pseudomonas orientalis; Pseudomonas rhodesiae; Pseudomonassynxantha; Pseudomonas tolaasii; and Pseudomonas veronii.

The host cell can be selected from “Gram(−) Proteobacteria Subgroup 18.”“Gram(−) Proteobacteria Subgroup 18” is defined as the group of allsubspecies, varieties, strains, and other sub-special units of thespecies Pseudomonas fluorescens, including those belonging, e.g., to thefollowing (with the ATCC or other deposit numbers of exemplary strain(s)shown in parenthesis): Pseudomonas fluorescens biotype A, also calledbiovar 1 or biovar I (ATCC 13525); Pseudomonas fluorescens biotype B,also called biovar 2 or biovar II (ATCC 17816); Pseudomonas fluorescensbiotype C, also called biovar 3 or biovar III (ATCC 17400); Pseudomonasfluorescens biotype F, also called biovar 4 or biovar IV (ATCC 12983);Pseudomonas fluorescens biotype G, also called biovar 5 or biovar V(ATCC 17518); Pseudomonas fluorescens biovar VI; Pseudomonas fluorescensPf0-1; Pseudomonas fluorescens Pf-5 (ATCC BAA-477); Pseudomonasfluorescens SBW25; and Pseudomonas fluorescens subsp. cellulosa (NCIMB10462).

The host cell can be selected from “Gram(−) Proteobacteria Subgroup 19.”“Gram(−) Proteobacteria Subgroup 19” is defined as the group of allstrains of Pseudomonas fluorescens biotype A. A typical strain of thisbiotype is P. fluorescens strain MB101 (see U.S. Pat. No. 5,169,760 toWilcox), and derivatives thereof. An example of a derivative thereof isP. fluorescens strain MB214, constructed by inserting into the MB101chromosomal asd (aspartate dehydrogenase gene) locus, a native E. coliPlacI-lacI-lacZYA construct (i.e. in which PlacZ was deleted).

Additional P. fluorescens strains that can be used in the presentinvention include Pseudomonas fluorescens Migula and Pseudomonasfluorescens Loitokitok, having the following ATCC designations: [NCIB8286]; NRRL B-1244; NCIB 8865 strain CO1; NCIB 8866 strain CO2; 1291[ATCC 17458; IFO 15837; NCIB 8917; LA; NRRL B-1864; pyrrolidine; PW2[ICMP 3966; NCPPB 967; NRRL B-899]; 13475; NCTC 10038; NRRL B-1603 [6;IFO 15840]; 52-IC; CCEB 488-A [BU 140]; CCEB 553 [IEM 15/47]; IAM 1008[AHH-27]; IAM 1055 [AHH-23]; 1 [IFO 15842]; 12 [ATCC 25323; NIH 11; denDooren de Jong 216]; 18 [IFO 15833; WRRL P-7]; 93 [TR-10]; 108 [52-22;IFO 15832]; 143 [IFO 15836; PL]; 149 [2-40-40; IFO 15838]; 182 [IFO3081; PJ 73]; 184 [IFO 15830]; 185 [W2 L-1]; 186 [IFO 15829; PJ 79]; 187[NCPPB 263]; 188 [NCPPB 316]; 189 [PJ227; 1208]; 191 [IFO 15834; PJ 236;22/1]; 194 [Klinge R-60; PJ 253]; 196 [PJ 288]; 197 [PJ 290]; 198 [PJ302]; 201 [PJ 368]; 202 [PJ 372]; 203 [PJ 376]; 204 [IFO 15835; PJ 682];205 [PJ 686]; 206 [PJ 692]; 207 [PJ 693]; 208 [PJ 722]; 212 [PJ 832];215 [PJ 849]; 216 [PJ 885]; 267 [B-9]; 271 [B-1612]; 401 [C71A; IFO15831; PJ 187]; NRRL B-3178 [4; IFO 15841]; KY 8521; 3081; 30-21; [IFO3081]; N; PYR; PW; D946-B83 [BU 2183; FERM-P 3328]; P-2563 [FERM-P 2894;IFO 13658]; IAM-1126 [43F]; M-1; A506 [A5-06]; A505 [A5-05-1]; A526[A5-26]; B69; 72; NRRL B-4290; PMW6 [NCIB 11615]; SC 12936; A1 [IFO15839]; F 1847 [CDC-EB]; F 1848 [CDC 93]; NCIB 10586; P17; F-12; AmMS257; PRA25; 6133D02; 6519E01; N1; SC15208; BNL-WVC; NCTC 2583 [NCIB8194]; H13; 1013 [ATCC 11251; CCEB 295]; IFO 3903; 1062; or Pf-5.

Other suitable hosts include those classified in other parts of thereference, such as Gram (+) Proteobacteria. In one embodiment, the hostcell is an E. coli. The genome sequence for E. coli has been establishedfor E. coli MG1655 (Blattner, et al. (1997) The complete genome sequenceof Escherichia coli K-12 Science 277(5331): 1453-74) and DNA microarraysare available commercially for E. coli K12 (MWG Inc, High Point, N.C.).E. coli can be cultured in either a rich medium such as Luria-Bertani(LB) (10 g/L tryptone, 5 g/L NaCl, 5 g/L yeast extract) or a definedminimal medium such as M9 (6 g/L Na₂HPO₄, 3 g/L KH₂PO₄, 1 g/L NH₄Cl, 0.5g/L NaCl, pH 7.4) with an appropriate carbon source such as 1% glucose.Routinely, an over night culture of E. coli cells is diluted andinoculated into fresh rich or minimal medium in either a shake flask ora fermentor and grown at 37° C.

A host can also be of mammalian origin, such as a cell derived from amammal including any human or non-human mammal. Mammals can include, butare not limited to primates, monkeys, porcine, ovine, bovine, rodents,ungulates, pigs, swine, sheep, lambs, goats, cattle, deer, mules,horses, monkeys, apes, dogs, cats, rats, and mice.

A host cell may also be of plant origin. Any plant can be selected forthe identification of genes and regulatory sequences. Examples ofsuitable plant targets for the isolation of genes and regulatorysequences would include but are not limited to alfalfa, apple, apricot,Arabidopsis, artichoke, arugula, asparagus, avocado, banana, barley,beans, beet, blackberry, blueberry, broccoli, brussels sprouts, cabbage,canola, cantaloupe, carrot, cassava, castorbean, cauliflower, celery,cherry, chicory, cilantro, citrus, clementines, clover, coconut, coffee,corn, cotton, cranberry, cucumber, Douglas fir, eggplant, endive,escarole, eucalyptus, fennel, figs, garlic, gourd, grape, grapefruit,honey dew, jicama, kiwifruit, lettuce, leeks, lemon, lime, Loblollypine, linseed, mango, melon, mushroom, nectarine, nut, oat, oil palm,oil seed rape, okra, olive, onion, orange, an ornamental plant, palm,papaya, parsley, parsnip, pea, peach, peanut, pear, pepper, persimmon,pine, pineapple, plantain, plum, pomegranate, poplar, potato, pumpkin,quince, radiata pine, radiscchio, radish, rapeseed, raspberry, rice,rye, sorghum, Southern pine, soybean, spinach, squash, strawberry,sugarbeet, sugarcane, sunflower, sweet potato, sweetgum, tangerine, tea,tobacco, tomato, triticale, turf, turnip, a vine, watermelon, wheat,yams, and zucchini. In some embodiments, plants useful in the processare Arabidopsis, corn, wheat, soybean, and cotton.

For expression of a recombinant protein or peptide, or for modulation ofan identified compensatory gene, any plant promoter can be used. Apromoter may be a plant RNA polymerase II promoter. Elements included inplant promoters can be a TATA box or Goldberg-Hogness box, typicallypositioned approximately 25 to 35 basepairs upstream (5′) of thetranscription initiation site, and the CCAAT box, located between 70 and100 basepairs upstream. In plants, the CCAAT box may have a differentconsensus sequence than the functionally analogous sequence of mammalianpromoters (Messing et al., In: Genetic Engineering of Plants, Kosuge etal., eds., pp. 211-227, 1983). In addition, virtually all promotersinclude additional upstream activating sequences or enhancers (Benoistand Chambon, Nature 290:304-310, 1981; Gruss et al., Proc. Nat. Acad.Sci. USA 78:943-947, 1981; and Khoury and Gruss, Cell 27:313-314, 1983)extending from around −100 bp to −1,000 bp or more upstream of thetranscription initiation site.

Expression of Recombinant Protein or Peptide

As described below, a host cell or organism can be engineered to expressrecombinant protein or peptide using standard techniques. For example,recombinant protein can be expressed from a vector or from an exogenousgene inserted into the genome of the host. Vectors that can be used toexpress exogenous proteins are well known in the art and are describedbelow. Genes for expressing recombinant protein or peptide can also beinserted into the genome using techniques such as homologous orheterologous recombination, as described below.

The recombinant protein or peptide can be expressed after induction witha chemical compound or upon expression of an endogenous gene or geneproduct. The recombinant protein can also be expressed when the hostcell is placed in a particular environment. Specific promoter elementsare described below. These include, but are not limited to, promotersthat can be induced upon treatment of the cell with chemicals such asIPTG, benzoate or anthranilate.

Recombinant Proteins/Peptides

The host cell has been designed to express a recombinant protein orpeptide. These can be of any species and of any size. However, incertain embodiments, the recombinant protein or peptide is atherapeutically useful protein or peptide. In some embodiments, theprotein can be a mammalian protein, for example a human protein, and canbe, for example, a growth factor, a cytokine, a chemokine or a bloodprotein. The recombinant protein or peptide can be expressed primarilyin an inactive form in the host cell. In certain embodiments, therecombinant protein or peptide is less than 100 kD, less than 50 kD, orless than 30 kD in size. In ceratin embodiments, the recombinant proteinor peptide is a peptide of at least 5, 10, 15, 20, 30, 40, 50 or 100amino acids.

Expression vectors exist that enable recombinant protein production inE. coli. For all these protein expression systems routine cloningprocedures as described earlier can be followed (Sambrook, et al. (2000)Molecular cloning: A laboratory manual, third edition Cold SpringHarbor, N.Y., Cold Spring Harbor Laboratory Press).

The Champion™ pET expression system provides a high level of proteinproduction. Expression is induced from the strong T7lac promoter. Thissystem takes advantage of the high activity and specificity of thebacteriophage T7 RNA polymerase for high level transcription of the geneof interest. The lac operator located in the promoter region providestighter regulation than traditional T7-based vectors, improving plasmidstability and cell viability (Studier, F. W. and B. A. Moffatt (1986)Use of bacteriophage T7 RNA polymerase to direct selective high-levelexpression of cloned genes Journal of Molecular Biology 189(1): 113-30;Rosenberg, et al. (1987) Vectors for selective expression of cloned DNAsby T7 RNA polymerase Gene 56(1): 125-35). The T7 expression system usesthe T7 promoter and T7 RNA polymerase (T7 RNAP) for high-leveltranscription of the gene of interest. High-level expression is achievedin T7 expression systems because the T7 RNAP is more processive thannative E. coli RNAP and is dedicated to the transcription of the gene ofinterest. Expression of the identified gene is induced by providing asource of T7 RNAP in the host cell. This is accomplished by using a BL21E. coli host containing a chromosomal copy of the T7 RNAP gene. The T7RNAP gene is under the control of the lacUV5 promoter which can beinduced by IPTG. T7 RNAP is expressed upon induction and transcribes thegene of interest.

The pBAD expression system allows tightly controlled, titratableexpression of recombinant protein through the presence of specificcarbon sources such as glucose, glycerol and arabinose (Guzman, et al.(1995) Tight regulation, modulation, and high-level expression byvectors containing the arabinose PBAD promote” Journal of Bacteriology177(14): 4121-30). The pBAD vectors are uniquely designed to giveprecise control over expression levels. Heterologous gene expressionfrom the pBAD vectors is initiated at the araBAD promoter. The promoteris both positively and negatively regulated by the product of the araCgene. AraC is a transcriptional regulator that forms a complex withL-arabinose. In the absence of L-arabinose, the AraC dimer blockstranscription. For maximum transcriptional activation two events arerequired: (i.) L-arabinose binds to AraC allowing transcription tobegin. (ii.) The cAMP activator protein (CAP)-cAMP complex binds to theDNA and stimulates binding of AraC to the correct location of thepromoter region.

The trc expression system allows high-level, regulated expression in E.coli from the trc promoter. The trc expression vectors have beenoptimized for expression of eukaryotic genes in E. coli. The trcpromoter is a strong hybrid promoter derived from the tryptophane (trp)and lactose (lac) promoters. It is regulated by the lacO operator andthe product of the lacl^(Q) gene (Brosius, J. (1984) Toxicity of anoverproduced foreign gene product in Escherichia coli and its use inplasmid vectors for the selection of transcription terminators Gene27(2): 161-72).

The invention also includes the improved recombinant host cell that isproduced by the claimed process. In one embodiment, the inventionincludes a cell produced by the described process. In anotherembodiment, the invention includes a host cell or organism thatexpresses a recombinant protein that has been genetically modified toreduce the expression of at least two proteases. In other embodiments,the invention includes a host cell or organism that expresses arecombinant protein that has been genetically modified to reduce theexpression of at least one protease selected from the group consistingof products of hslV, hslU, clpX, clpA and clpB genes, and in certainsubembodiments, the cell or organism has been modified to reduce theexpression of HslV or HslU. In certain embodiments, the modified hostcell or organism expresses a recombinant mammalian derived protein, andmay express a recombinant human derived protein, which may be humangrowth hormone. The cell can be modified by any techniques known in theart, for example by a technique wherein at least one protease gene isknocked out of the genome, or by mutating at least one protease gene toreduce expression of a protease, or by altering at least one promoter ofat least one protease gene to reduce expression of a protease.

In another embodiment, a host or organism that expresses a recombinantprotein that is presented that has been genetically modified to increasethe expression of at least one, at least two folding modulators, or atleast three folding modulators. In certain subembodiments, the foldingmodulators that are not folding modulator subunits. The foldingmodulator may be selected from the group consisting of products of cbpA,htpG, dnaK, dnaJ, fkbP2, groES and groEL genes, and, in certainsubembodiments, can be htpG or cbpA. The host cell or organism can in anon-limiting example, express a mammalian protein, such as a humanprotein. The protein may be human growth hormone. The folding modulatoror modulators can be increased by, for example, including an expressionvector as described herein in the cell. The folding modulator expressioncan also be increased by, for example, mutating a promoter of a foldingmodulator or folding modulator subunit. A host cell or organism thatexpresses a recombinant protein can also be genetically modified toincrease the expression of at least one folding modulators and decreasethe expression of at least one protease or protease protein. Organismscomprising one or more cells produced by the described process are alsoincluded in the invention.

Step II: Analyzing a Genetic Profile to Identify a Compensatory Gene orGene Product that is Expressed at a Higher Level in the Recombinant Cell

The process of the invention includes analyzing a genetic profile of therecombinant cell to identify a compensatory gene or gene product that isexpressed at a higher level in the recombinant cell than in either ahost cell that has not been modified to express the recombinant proteinor a recombinant cell that is not expressing the recombinant protein.

A “genetic profile” as used herein can include genes in a genome, mRNAtranscribed from genes in the genome or cDNA derived from mRNAtranscribed from genes in the genome. A gentic profile can also includetranscription products that have been modified by a cell such as splicevariants of genes in eukaryotic systems, or proteins translated fromgenes in a genome, including proteins that are modified by the cell ortranslated from splice variants of mRNA translated from the genome. Agenetic profile is meant to refer solely to the simultaneous analysis ofmultiple entitities, such as in an array or other multiplex system,including multiple simultaneous blot analysis or column chromatographywith multiple binding partners attached to the packing. According to theinvention, at least 5, 10, 25, 50, 70, 80, 90 or 100 or more genes orgene products that are analyzed simultaneously.

Transcriptome

In one embodiment, the genetic profile analyzed is a transcriptomeprofile. A complete transcriptome refers to the complete set of mRNAtranscripts produced by the genome at any one time. Unlike the genome,the transcriptome is dynamic and varies considerably in differingcircumstances due to different patterns of gene expression.Transcriptomics, the study of the transcriptome, is a comprehensivemeans of identifying gene expression patterns. The transcriptomeanalyzed can include the complete known set of genes transcribed, i.e.the mRNA content or corresponding cDNA of a host cell or host organism.The cDNA can be a chain of nucleotides, an isolated polynucleotide,nucleotide, nucleic acid molecule, or any fragment or complement thereofthat originated recombinantly or synthetically and be double-stranded orsingle-stranded, coding and/or noncoding, an exon or an intron of agenomic DNA molecule, or combined with carbohydrate, lipids, protein orinorganic elements or substances. The nucleotide chain can be at least5, 10, 15, 30, 40, 50, 60, 70, 80, 90 or 100 nucleotides in length. Thetranscriptome can also include only a portion of the known set ofgenetic transcripts. For example, the transcriptome can include lessthan 98%, 95, 90, 85, 80, 70, 60, or 50% of the known transcripts in ahost. The transcriptome can also be targeted to a specific set of genes.

In one embodiment, the screening process can include screening using anarray or a microarray to identify a genetic profile. In anotherembodiment, the transcriptome profile can be analyzed by using knownprocesses such as hybridization in blot assays such as northern blots.In another embodiment, the process can include PCR-based processes suchas RT-PCR that can quantify expression of a particular set of genes. Inone embodiment of the invention, an identified gene, for example afolding modulator protein (FM) or protease protein, i.e. a protease,peptidase, or associated polypeptide or cofactor, is identified by ahigh throughput screening process.

The process can include analyzing the transcriptome profile using amicroarray or equivalent technique. In this embodiment, the microarraycan include at least a portion of the transcribed genome of the hostcell, and typically includes binding partners to samples from genes ofat least 50% of the transcribed genes of the organism. More typically,the microarray or equivalent technique includes binding partners forsamples from at least 80%, 90%, 95%, 98%, 99% or 100% of the transcribedgenes in the genome of the host cell. However, in a separate embodiment,the microarray can include binding partners to a selected subset ofgenes from the genome, including but not limited to putative proteasegenes or putative folding modulator genes. A microarray or equivalenttechnique can typically also include binding partners to a set of genesthat are used as controls, such as housekeeper genes. A microarray orequivalent technique can also include genes clustered into groups suchas genes coding for degradative proteins, folding modulators andcofactors, metabolic proteins such as proteins involved in glucosemetabolism or amino acid or nucleobase synthesis, transcription factors,nucleic acid stabilizing factors, extracellular signal regulated genessuch as kinases and receptors or scaffolding proteins.

A microarray is generally formed by linking a large number of discretebinding partners, which can include polynucleotides, aptamers,chemicals, antibodies or other proteins or peptides, to a solid supportsuch as a microchip, glass slide, or the like, in a defined pattern. Bycontacting the microarray with a sample obtained from a cell of interestand detecting binding of the binding partners expressed in the cell thathybridize to sequences on the chip, the pattern formed by thehybridizing polynucleotides allows the identification of genes orclusters of genes that are expressed in the cell. Furthermore, whereeach member linked to the solid support is known, the identity of thehybridizing partners from the nucleic acid sample can be identified. Onestrength of microarray technology is that it allows the identificationof differential gene expression simply by comparing patterns ofhybridization.

Examples of high throughput screening processes include hybridization ofhost cell mRNA or substantially corresponding cDNA, to a hybridizablearray(s) or microarray(s). The array or microarray can be one or morearray(s) of nucleic acid or nucleic acid analog oligomers or polymers.In one embodiment, the array(s) or microarray(s) will be independentlyor collectively a host-cell-genome-wide array(s) or microarray(s),containing a population of nucleic acid or nucleic acid analog oligomersor polymers whose nucleotide sequences are hybridizable torepresentative portions of all genes known to encode or predicted asencoding FMs in the host cell strain or all genes known to encode orpredicted to encode proteases or protease proteins in the host cellstrain. A genome-wide microarray includes sequences that bind to arepresentative portion of all of the known or predicted open readingframe (ORF) sequences, such as from mRNA or corresponding cDNA of thehost.

The oligonucleotide sequences or analogs in the array typicallyhybridize to the mRNA or corresponding cDNA sequences from the host celland typically comprise a nucleotide sequence complimentary to at least aportion of a host mRNA or cDNA sequence, or a sequence homologous to thehost mRNA or cDNA sequence. Single DNA strands with complementarysequences can pair with each other and form double-stranded molecules.

Microarrays generally apply the hybridization principle in a highlyparallel format. Instead of one identified, thousands of differentpotential identifieds can be arrayed on a miniature solid support.Instead of a unique labeled DNA probe, a complex mixture of labeled DNAmolecules is used, prepared from the RNA of a particular cell type ortissue. The abundances of individual labeled DNA molecules in thiscomplex probe typically reflect the expression levels of thecorresponding genes. In a simplified process, when hybridized to thearray, abundant sequences will generate strong signals and raresequences will generate weak signals. The strength of the signal canrepresent the level of gene expression in the original sample.

In one embodiment, a genome-wide array or microarray will be used. Inone embodiment, the array represents more than 50% of the open readingframes in the genome of the host, or more than 55%, 60%, 65%, 70%, 75%,80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% ofthe known open reading frames in the genome. The array can alsorepresent at least a portion of at least 50% of the sequences known toencode protein in the host cell. In separate embodiments, the arrayrepresents more than 50% of the genes or putative genes of the hostcell, or more than 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%,93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% of the known genes or putativegenes. In one embodiment, more than one oligonucleotide or analog can beused for each gene or putative gene sequence or open reading frame. Inone embodiment, these multiple oligonucleotide or analogs representdifferent portions of a known gene or putative gene sequence. For eachgene or putative gene sequence, from about 1 to about 10000 or from 1 toabout 100 or from 1 to about 50, 45, 40, 35, 30, 25, 20, 15, 10 or lessoligonucleotides or analogs can be present on the array.

A microarray or a complete genome-wide array or microarray may beprepared according to any process known in the art, based on knowledgeof the sequence(s) of the host cell genome, or the proposed codingsequences in the genome, or based on the knowledge of expressed mRNAsequences in the host cell or host organism.

For different types of host cells, the same type of microarray can beapplied. The types of microarrays include complementary DNA (cDNA)microarrays (Schena, M. et al. (1995) Quantitative monitoring of geneexpression patterns with a complementary DNA microarray. Science270:467-70) and oligonucleotide microarrays (Lockhart, et al. (1996)Expression monitoring by hybridization to high-density oligonucleotidearrays. Nat Biotechnol 14:1675-80). For cDNA microarray, the DNAfragment of a partial or entire open reading frame is printed on theslides. The hybridization characteristics can be different throughoutthe slide because different portions of the molecules can be printed indifferent locations. For the oligonucleotide arrays, 20-80-mer oligoscan be synthesized either in situ (on-chip) or by conventional synthesisfollowed by on-chip immobilization, however in general all probes aredesigned to be similar with regard to hybridization temperature andbinding affinity (Butte, A. (2002) The use and analysis of microarraydata. Nat Rev Drug Discov 1:951-60).

In analyzing the transcriptome profile, the nucleic acid or nucleic acidanalog oligomers or polymers can be RNA, DNA, or an analog of RNA orDNA. Such nucleic acid analogs are known in the art and include, e.g.:peptide nucleic acids (PNA); arabinose nucleic acids; altritol nucleicacids; bridged nucleic acids (BNA), e.g., 2′-O,4′-C-ethylene bridgednucleic acids, and 2′-O,4′-C-methylene bridged nucleic acids;cyclohexenyl nucleic acids; 2′,5′-linked nucleotide-based nucleic acids;morpholino nucleic acids (nucleobase-substituted morpholino unitsconnected, e.g., by phosphorodiamidate linkages); backbone-substitutednucleic acid analogs, e.g., 2′-substituted nucleic acids, wherein atleast one of the 2′ carbon atoms of an oligo- or poly-saccharide-typenucleic acid or analog is independently substituted with, e.g., any oneof a halo, thio, amino, aliphatic, oxyaliphatic, thioaliphatic, oraminoaliphatic group (wherein aliphatic is typically C₁-C₁₀ aliphatic).

Oligonucleotides or oligonucleotide analogs in the array can be ofuniform size and, in one embodiment, can be about 10 to about 1000nucleotides, about 20 to about 1000, 20 to about 500, 20 to about 100,about 20, about 25, about 30, about 40, about 50, about 60, about 70,about 80, about 90 or about 100 nucleotides long.

The array of oligonucleotide probes can be a high density arraycomprising greater than about 100, or greater than about 1,000 or moredifferent oligonucleotide probes. Such high density arrays can comprisea probe density of greater than about 60, more generally greater thanabout 100, most generally greater than about 600, often greater thanabout 1000, more often greater than about 5,000, most often greater thanabout 10,000, typically greater than about 40,000 more typically greaterthan about 100,000, and in certain instances is greater than about400,000 different oligonucleotide probes per cm² (where differentoligonucleotides refers to oligonucleotides having different sequences).The oligonucleotide probes range from about 5 to about 500, or about 5to 50, or from about 5 to about 45 nucleotides, or from about 10 toabout 40 nucleotides and most typically from about 15 to about 40nucleotides in length. Particular arrays contain probes ranging fromabout 20 to about 25 oligonucleotides in length. The array may comprisemore than 10, or more than 50, or more than 100, and typically more than1000 oligonucleotide probes specific for each identified gene. In oneembodiment, the array comprises at least 10 different oligonucleotideprobes for each gene. In another embodiment, the array has 20 or feweroligonucleotides complementary each gene. Although a planar arraysurface is typical, the array may be fabricated on a surface ofvirtually any shape or even on multiple surfaces.

The array may further comprise mismatch control probes. Where suchmismatch controls are present, the quantifying step may comprisecalculating the difference in hybridization signal intensity betweeneach of the oligonucleotide probes and its corresponding mismatchcontrol probe. The quantifying may further comprise calculating theaverage difference in hybridization signal intensity between each of theoligonucleotide probes and its corresponding mismatch control probe foreach gene.

In some assay formats, the oligonucleotide probe can be tethered, i.e.,by covalent attachment, to a solid support. Oligonucleotide arrays canbe chemically synthesized by parallel immobilized polymer synthesisprocesses or by light directed polymer synthesis processes, for exampleon poly-L-lysine substrates such as slides. Chemically synthesizedarrays are advantageous in that probe preparation does not requirecloning, a nucleic acid amplification step, or enzymatic synthesis. Thearray includes test probes which are oligonucleotide probes each ofwhich has a sequence that is complementary to a subsequence of one ofthe genes (or the mRNA or the corresponding antisense cRNA) whoseexpression is to be detected. In addition, the array can containnormalization controls, mismatch controls and expression level controlsas described herein.

An array may be designed to include one hybridizing oligonucleotide perknown gene in a genome. The oligonucleotides or equivalent bindingpartners can be 5′-amino modified to support covalent binding toepoxy-coated slides. The oligonucleotides can be designed to reducecross-hybridization, for example by reducing sequence identity to lessthan 25% between oligonucleotides. Generally, melting temperature ofoligonucleotides is analyzed before design of the array to ensureconsistent GC content and Tm, and secondary structure of oligonucleotidebinding partners is optimized. For transcriptome profiling, secondarystructure is typically minimized. In one embodiment, eacholigonucleotide is printed at at least two different locations on theslide to increase accuracy. Control oligonucleotides can also bedesigned based on sequences from different species than the host cell ororganism to show background binding.

The samples in the genetic profile can be analyzed individually orgrouped into clusters. The clusters can typically be grouped bysimilarity in gene expression. In one embodiment, the clusters may begrouped individually as genes that are regulated to a similar extent ina host cell. The clusters may also include groups of genes that areregulated to a similar extent in a recombinant host cell, for examplegenes that are up-regulated or down-regulated to a similar extentcompared to a host cell or a modified or an unmodified cell. Theclusters can also include groups related by gene or protein structure,function or, in the case of a transcriptome array, by placement orgrouping of binding partners to genes in the genome of the host. Groupsof binding partners or groups of genes or proteins analyzed can includegenes selected from, but not limited to: genes coding for putative orknown proteases, co-factors of proteases or protease-like proteins;folding modulators, co-factors of folding modulators or proteins thatcould improve protein folding or solubility; transcription factors;proteins involved in nucleic acid stability or translational initiation;kinases; extracellular or intracellular receptors; metabolic enzymes;metabolic cofactors; envelope proteins; sigma factors; membrane boundproteins; transmembrane proteins; membrane associated proteins andhousekeeping genes.

Proteome

In another embodiment, the genetic profile analyzed is a proteomeprofile. The proteome of a host is the complete set of proteins producedby the genome at any one time. The proteome is generally much morecomplex than either the genome or the transcriptome because each proteincan be chemically modified after synthesis. Many proteins are cleavedduring production, are phosphorylated, acetylated, methylated, or havecarbohydrate groups added to them, depending on the host cell. Theproteome is also very dynamic. Proteomics, the study of the proteome,can cover a number of different aspects of protein structure, proteinexpression, and function. The techniques for proteome analysis are notas straightforward as those used in transcriptomics. However, anadvantage of proteomics is that the functional molecules of the cell arebeing studied.

The process can include techniques that measure protein expressionlevels, protein-protein interactions, protein-small moleculeinteractions or enzymatic activities. In one embodiment, the proteome isanalyzed using a screening process that includes measurement of size ofcertain proteins, typically using mass spectrometry. In one embodiment,the technique to analyze the proteome profile includes hybridization ofan antibody to a protein of interest. For example, the process caninclude Western blot processes as known in the art or can include columnchromatography. The process can also include standard processes such asElisa screening known in the art. The process can also include bindingof nucleic acid modified binding partners, which can be aptamers or canbe protein or chemical binding partners for proteins or peptidefragments in the proteome and a screening process can includeamplification of the nucleic acids. The process can also includechemical compounds that bind to the proteins or fragments of proteins ina proteome and the process can include measurement of the binding bychemical means. The measurement can also include measurement of reactionproducts in a chemical reaction, or by activation of a fluorophore.Techniques like mass spectrometry in combination with separation toolssuch as two-dimensional gel electrophoresis or multidimensional liquidchromatography, can also be used in the process. Typically, the processincludes a high throughput screening technique.

The process of the invention can include analyzing the proteome profileusing, for example, two-dimensional electrophoresis. This is a methodfor the separation and identification of proteins in a sample bydisplacement in two dimensions oriented at right angles to one another.This allows the sample to separate over a larger area, increasing theresolution of each component. The first dimension is typically based onthe charge of a particular molecule while the second dimension may bebased on the size of a molecule. In the first dimension, proteins areresolved in according to their isoelectric points using immobilized pHgradient electrophoresis (IPGE), isoelectric focusing (IEF), ornon-equilibrium pH gradient electrophoresis. Under standard conditionsof temperature and urea concentration, the observed focusing points ofthe great majority of proteins closely approximate the predictedisoelectric points calculated from the proteins' amino acidcompositions. Generally, the first step after preparation of a hostsample includes running the sample against a pH gradient, a processknown as isoelectric focusing. The pH gradients can be generated byadding ampholytes to an acrylamide gel. These are a mixture ofamphoteric species with a range of pI values. The pH gradients can alsobe generated by adding Immobilines, which are similar to ampholytes buthave been immobilised within the polyacrylamide gel producing animmobilised pH gradient that does not need to be pre-focused.

The second dimension in two-dimensional electrophoresis may beseparation by size of proteins. Proteins may be separated according totheir approximate molecular weight using sodium dodecyl sulfatepoly-acrylamide-electrophoresis (SDS-PAGE). The technique is widely usedand known in the art. The basic idea is to coat proteins with adetergent (SDS), which coats all proteins in a sample and negativelycharges them. The proteins are then subjected to gel electrophoresis.The gels can typically be acrylamide gels and can be in a gradient ofdensity. The charge placed on the gel pushes the proteins through thegel based on size. In two dimensional electrophoresis, the proteinsseparated can include proteins from at least 10% of the proteome of theorganism. More typically, proteins from at least 20%, 30%, 40%, 60%, 80%or 90% of the proteins in the proteome of the host cell are separatedand analysed by techniques such as staining of proteins and/or massspectrometry.

The process of the invention can also include analyzing the proteomeprofile using a microarray. In this embodiment, the microarray caninclude binding partners to at least a portion of the proteins expressedby the host cell under appropriate growth conditions, and typicallyincludes binding partners to proteins from at least 5% of the proteomeof the organism. More typically, the microarray includes bindingpartners to proteins from at least 10%, 20%, 30%, 40%, 60%, 80% or 90%of the proteins in the proteome of the host cell. The binding partnerscan be antibodies, which can be antibody fragments such as single chainantibody fragments. The binding partners can also include aptamers,which are molecules including nucleic acids that bind to specificproteins or portions of proteins. In a separate embodiment, themicroarray can include binding partners for a selected subset ofproteins from the proteome, including, for example, putative proteaseproteins or putative folding modulators. The microarray can typicallyalso include a set of binding partners to proteins that are used ascontrols. The genetic profile can be analyzed by measuring the bindingof the proteins of the host cell expressing the recombinant protein orpeptide to the binding partners on the microarray.

The simplest protein array format generally consists of a large numberof protein capture reagents bound to defined spots on a planar supportmaterial. This array is then exposed to a complex protein sample. Thebinding of the specific analyte proteins to the individual spots canthen be monitored using different approaches. In cases where theanalytes have been pre-labeled with a fluorescent dye, the binding canbe monitored directly using a fluorescence scanner. Often the classicalantibody sandwich type format is used, in which two protein bindingreagents simultaneously bind to the same antigen: one antibody isimmobilized onto the surface, and the other one is fluorescently labeledor conjugated to an enzyme that can produce a fluorescent, luminescentor colored product when supplied with the appropriate substrate.

Monoclonal antibodies or their antigen-binding fragments are currentlyone choice for capture agents due to their high specificity, affinityand stability. They have been used in a variety of classical singleanalyte protein profiling assays such as enzyme-linked immunosorbentassays (ELISA) since the seventies. Additionally, phage-displaylibraries of antibody fragments offer the potential for antibodyproduction at proteomic scales. These libraries can be used to isolatehigh-affinity binding agents against protein identified in asignificantly shorter time frame than it is possible withimmunization-based processes. Ribosome display and mRNA display areadditional, completely in vitro, processes that rely on physicallylinking the library proteins to their encoding mRNA sequences. Suchprocesses have successfully been used to select high-affinity bindingreagents to identified proteins (Wilson, D S, et al. (2001) The use ofmRNA display to select high-affinity protein-binding peptides Proc NatlAcad Sci USA 98:3750-3755). Several groups have taken a differentapproach to develop high affinity protein capture reagents for proteinbiochips. For example, aptamers have been used, which are singlestranded RNA or DNA molecules originating from in vitro selectionexperiments (termed SELEX: systematic evolution of ligands byexponential enrichment) with high affinities to proteins. A furtherdevelopment in aptamer technologies are so called photoaptamers. Thesemolecules have an additional attribute that enhances their utility asprotein capture reagents. They carry the photoactivatible crosslinkinggroup 5′-bromodeoxyuridine, which, when activated by UV light, can causecovalent crosslinking with bound identified proteins (Petach, H & Gold,L (2002) Dimensionality is the issue: use of photoaptamers in proteinmicroarrays Curr Opin Biotechnol 13:309-314). The photo-crosslinkingevent provides a second dimension of specificity similar to the bindingof a secondary detection antibody in a sandwich immunoassay.

A wide variety of surface substrates and attachment chemistries havebeen evaluated for the immobilization of capture agents on proteinmicroarrays. One way to immobilize proteins on a solid support relies onnon-covalent interactions based on hydrophobic or van der Waalsinteractions, hydrogen bonding or electrostatic forces. Examples ofelectrostatic immobilization include the use of materials such asnitrocellulose and poly-lysine- or aminopropyl silane-coated glassslides. Protein microarrays were also fabricated by means of physicaladsorption onto plastic surfaces of 96-well plates. An example ofcovalent attachment of proteins to the surface has been described byMacBeath and Schreiber (MacBeath, G & Schreiber, S L (2000) Printingproteins as microarrays for high-throughput function determinationScience 289:1760-1763). Due to the very high affinity of streptavidin tobiotin, the immobilization of biotinylated proteins onto streptavidinsurfaces can be considered quasi covalent (Peluso, P et al. (2003)Optimizing antibody immobilization strategies for the construction ofprotein microarrays Anal Biochem 312:113-124). Further strategies havebeen described (Ruiz-Taylor, L A, et al (2001) X-ray photoelectronspectroscopy and radiometry studies of biotin-derivatizedpoly(L-lysine)-grafted-poly(ethylene glycol) monolayers on metal oxides(Langmuir) 7313-7322; Ruiz-Taylor, L A et al. (2001) Monolayers ofderivatized poly(L-lysine)-grafted poly(ethylene glycol) on metal oxidesas a class of biomolecular interfaces Proc Natl Acad Sci USA 2001,98:852-857; Espejo A, Bedford Mont. (2004) Protein-domain microarraysProcesses Mol Biol. 264:173-81; Zhu, H. et al. (2001) Global analysis ofprotein activities using proteome chips. Science Express).

The samples in the genetic profile can be analyzed individually orgrouped into clusters. The clusters can typically be grouped bysimilarity in gene expression. In one embodiment, the clusters may begrouped individually as proteins that are regulated to a similar extentin a host cell. The clusters may also include groups of proteins thatare regulated to a similar extent in a recombinant host cell, forexample, that are up-regulated or down-regulated to a similar extentcompared to a host cell or a modified or an unmodified cell. Theclusters can also include groups related by protein structure, function,or processing. Groups of protein binding partners in an array, or groupsof proteins analyzed in a different assay such as two-dimensionalelectrophoresis can be selected from, but are not limited to: putativeor known proteases, co-factors of proteases or protease-like proteins;folding modulators, co-factors of folding modulators or proteins thatcould improve protein folding or solubility; transcription factors;proteins involved in nucleic acid stability or translational initiation;kinases; extracellular or intracellular receptors; metabolic enzymes;metabolic cofactors; envelope proteins; and housekeeping genes.

Metabolome

Proteomic analysis processes allow the abundance and distribution ofmany proteins to be determined simultaneously. However, the functionalconsequences of changes to the proteome are reported only indirectly.Another approach is to measure the levels of these small molecules, ormetabolites. A genetic profile analyzed in the process of the inventioncan thus include a metabolomic profile. Processes for analyzing themetabolome of a specific host include gas chromatography, high-pressureliquid chromatography and capillary electrophoresis to separatemetabolites according to various chemical and physical properties. Themolecules can then be identified using processes such as massspectrometry.

Detection/Analysis

The process includes analyzing a genetic profile to identify acompensatory gene or gene product that is expressed at a higher level inthe recombinant cell. In general, this step includes the monitoring ofthe expression (e.g. detecting and or quantifying the expression) of amultitude of genes or gene products. The expression is generallymonitored by detecting binding of host cell gene products to atranscriptome, proteome or metabolome profile as described above. Theanalysis of the binding may involve a comparison of binding between arecombinant host cell expressing recombinant protein or peptide and anaive host cell or a recombinant host cell not expressing the protein orpeptide.

Detection

This step includes the monitoring of the expression (e.g. detecting andor quantifying the expression) of a multitude of genes or gene products.The expression is generally monitored by detecting binding of host cellgene products to a transcriptome, proteome or metabolome profile asdescribed above. Typically, at least about 10 genes, or at least about100, or at least about 1000 and or at least about 10,000 different genescan be assayed at one time. The process can involve providing a pool ofidentified nucleic acids comprising RNA transcripts of one or more ofsaid genes, or nucleic acids derived from the RNA transcripts;hybridizing the pool of nucleic acids to an array of oligonucleotideprobes immobilized on a surface, where the array comprises more than 100different oligonucleotides and each different oligonucleotide islocalized in a predetermined region of said surface, each differentoligonucleotide is attached to the surface through at least one covalentbond, and the oligonucleotide probes are complementary to the RNAtranscripts or nucleic acids derived from the RNA transcripts; andquantifying the hybridized nucleic acids in the array. A pictoralrepresentation of one technique for monitoring expression of a geneproduct between two samples is depicted in FIG. 12.

The process can also involve providing a pool of cellular proteins.These can be derived from cellular lysates that are made by lysing cellsusing detergents or surfactants; using osmotic lysis; using thermalchanges, such as freeze-thaw cycles; using mechanical means or usingpressure changes. Typically chemicals are included in the process oflysing a cell or cell system that inhibit certain proteins, such asproteases, particularly non-specific proteases, to limit degradation ofproteins. In addition, cell lysates are typically kept at or below 4°C., and can be kept at or below 0° C. or at or below 20° C. duringprocessing. Cell lysates can be separated before further processing, forexample by size exclusion chromatography, ion exchange or affinitymatrix chromatography such as by using HPLC.

Typically, the identified genetic product, mRNA, cDNA, protein ormetabolite is labeled with a detectable marker or probe. The marker orprobe can be one or more fluorescent molecules or fluorophores. Thesecan include commercially available molecules such as Cy3 and Cy5 linkedto, for example, particular nucleotides that can be incorporated into areverse transcribed cDNA to provide detectable molecules for screening.In one embodiment, a first fluorophores is incorporated into a samplefrom the host and a second fluorophore is incorporated into a samplefrom a host expressing recombinant protein or peptide. In oneembodiment, the first fluorophore and second fluorophore emit differentwavelengths of light. In this embodiment, the binding of samples fromthe host and the host expressing recombinant protein can be monitored inthe same assay. In another embodiment, the fluorophores are excited atdifferent wavelengths of light. In another embodiment, the first andsecond fluorophore are excited or emit light at the same wavelength. Inthis embodiment, the samples from the host and from the host expressingrecombinant protein are typically monitored in different assays.

The process can additionally include a step of quantifying thehybridization of the identified nucleic acids or proteins or chemicalmetabolites. The quantification can include measurement of the levels oftranscription of one or more genes. Typically the pool of identifiednucleic acids for example, is one in which the concentration of theidentified nucleic acids (pre-mRNA transcripts, mRNA transcripts ornucleic acids derived from the RNA transcripts) is proportional to theexpression levels of genes encoding those identified nucleic acids.

For transcriptome analysis, the pool of nucleic acids may be labeledbefore, during, or after hybridization, although typically the nucleicacids are labeled before hybridization. Fluorescence labels aretypically used, often with a single fluorophore, and, where fluorescencelabeling is used, quantification of the hybridized nucleic acids can beby quantification of fluorescence from the hybridized fluorescentlylabeled nucleic acid. Such quantification is facilitated by the use of aconfocal laser scanner or fluorescence microscope, such as a confocalfluorescence microscope, which can be equipped with an automated stageto permit automatic scanning of the array, and which can be equippedwith a data acquisition system for the automated measurement recordingand subsequent processing of the fluorescence intensity information.Devices for reading such arrays include the CloneTracker™, ImaGene™,GeneSight™ modules and the GeneDirector™ database, available fromBiodiscovery, Inc., El Segundo, Calif., or the GeneChip™ reader,available from Affymetrix, Inc. of Santa Clara, Calif. In oneembodiment, hybridization occurs at low stringency (e.g. about 20° C. toabout 50° C., or about 30° C. to about 40° C., or about 37° C.).Hybridization may include subsequent washes at progressively increasingstringency until a desired level of hybridization specificity isreached.

Quantification of the hybridization signal can be by any means known toone of skill in the art. However, in one embodiment, quantification isachieved by use of a confocal fluorescence scanner. Data is typicallyevaluated by calculating the difference in hybridization signalintensity between each oligonucleotide probe and its correspondingmismatch control probe. Typically, this difference can be calculated andevaluated for each gene. Certain analytical processes are providedherein.

Techniques have been developed to prepare appropriate bacterialhybridization probes (see for eg. Choi et al. (2003) App. Envir.Microbio. 69:4737-4742). For example, cells can be stored in an RNAstabilizing agent such as RNAlater (Ambion, Austin, Tex.). RNA isgenerally purified in three steps: (1) isolation of the total RNA, (2)removal of contaminating DNA and (3) clean-up of the total RNA. TotalRNA can be isolated and then mixed with random hexamer primers andreverse transcriptase to make cDNA. Typically at least one fluorescentprobe is incorporated into the cDNA. In one embodiment, one fluorescentprobe is incorporated, in another embodiment more than one probe, forexample 2, 3, 4, 5 or more fluorescent probes are incorporated into thesame or different samples of cDNA. In a eukaryotic host, the pool ofidentified nucleic acids can also be the total polyA⁺ mRNA isolated froma biological sample, or cDNA made by reverse transcription of the RNA orsecond strand cDNA or RNA transcribed from the double stranded cDNAintermediate.

Fluorescent dyes are typically incorporated into cDNA molecules duringthe reverse transcription reaction. Due to the different mRNA structurebetween prokaryotes (bacteria) and eukaryotes (yeast, mammalian cells,etc.), different primers can be used, however random primers can be usedin both cases, and oligo-dT primers can be used in eukaryots, which havepolyA tails. An alternative process is amino-allyl labeling to increasethe signal intensity. This process incorporates nucleotide analogsfeaturing a chemically reactive group to which a fluorescent dye may beattached after the reverse transcription reaction (Manduchi, E. et al.(2002) Comparison of different labeling processes for two-channelhigh-density microarray experiments. Physiol Genomics 10:169-79).

The pool of identified nucleic acids can be treated to reduce thecomplexity of the sample and thereby reduce the background signalobtained in hybridization. The terms “background” or “background signal”refer to hybridization signals resulting from non-specific binding, orother interactions, between the labeled identified nucleic acids andcomponents of the oligonucleotide array (e.g., the oligonucleotideprobes, control probes, the array substrate, etc.). In one approach, apool of mRNAs, derived from a biological sample, is hybridized with apool of oligonucleotides comprising the oligonucleotide probes presentin the array. The pool of hybridized nucleic acids is then treated withRNase A which digests the single stranded regions. The remaining doublestranded hybridization complexes are then denatured and theoligonucleotide probes are removed, leaving a pool of mRNAs enhanced forthose mRNAs complementary to the oligonucleotide probes in the array.

In another approach to background reduction, a pool of mRNAs derivedfrom a biological sample is hybridized with paired identified specificoligonucleotides where the paired identified specific oligonucleotidesare complementary to regions flanking subsequences of the mRNAscomplementary to the oligonucleotide probes in the array. The pool ofhybridized nucleic acids is treated with RNase H which digests thehybridized (double stranded) nucleic acid sequences. The remainingsingle stranded nucleic acid sequences which have a length aboutequivalent to the region flanked by the paired identified specificoligonucleotides are then isolated (e.g. by electrophoresis) and used asthe pool of nucleic acids for monitoring gene expression.

A third approach to background reduction involves eliminating orreducing the representation in the pool of particular preselectedidentified mRNA messages (e.g., messages that are characteristicallyoverexpressed in the sample). This process involves hybridizing anoligonucleotide probe that is complementary to the preselectedidentified mRNA message to the pool of polyA⁺ mRNAs derived from abiological sample. The oligonucleotide probe hybridizes with theparticular preselected polyA⁺ mRNA to which it is complementary. Thepool of hybridized nucleic acids is treated with RNase H which digeststhe double stranded (hybridized) region thereby separating the messagefrom its polyA⁺ tail. Isolating or amplifying (e.g., using an oligo dTcolumn) the polyA⁺ mRNA in the pool then provides a pool having areduced or no representation of the preselected identified mRNA message.

Analysis

The identified gene is typically identified by comparing a geneticprofile of the host cell expressing the recombinant protein or peptideto a genetic profile of the host cell not expressing the recombinantprotein or peptide. In iterative embodiments, the identified gene to bemodified is identified by comparing a genetic profile of the cell thatis to be modified (the second cell) to the cell that it was modifiedfrom (the first cell). The identified gene is identified by comparing agenetic profile of the second cell to a genetic profile of the firstcell and identifying one or more genes the expression of which isincreased in the second cell.

cDNA microarrays measure the relative mRNA abundance between twosamples. A series of post-induction time point samples can be comparedto the pre-induction sample for the same strain (temporal expressionprofile), or post-induction samples can be compared with differentstrains at the same time point. The comparison can be through the use ofa computer program, such as GeneSight™. For example, when using amicroarray using a fluorescent tag, a spot intensity can be measured foreach sample attached to the array (for example a DNA sequence). The spotintensity can then be corrected for background and the ratio of theintensity for samples from the host versus the host expressing therecombinant protein or peptide, or for the host expressing therecombinant protein or peptide compared to the modified host expressingthe recombinant protein or peptide can be measured. The ratio provides ameasure to identify the genes that are up-regulated or the expression ofwhich is increased upon expression of the recombinant protein orpeptide, or upon modification of the host cell to allow identificationof a identified gene.

To identify whether a gene is up-regulated, a standard or “cut off”ratio is established. The cut off ratio may be designed to overcome theeffects of background noise associated with a particular assay. Ingeneral, any ratio of greater than 1 between the measurements candesignate an up-regulated gene. However, variation between assays canrequire a ratio higher than 1, for example 1.5, or more than 2, or morethan 2.5, or more than 3, or more than 3.5 or more than 4 or more than4.5, or more than 5 or more than 6, or more than 7, or more than 8, ormore than 9 or more than 10. The standard may be established before theprocess, relying on standards known in the art, or may be establishedduring measurements by comparing ratios of levels of control genes orgene products, such as housekeeper genes.

Step III: Changing Expression of the Identified Compensatory Gene orGene Product by Genetically Modifying the Cell to Provide a ModifiedRecombinant Cell that Achieves an Increase in Recombinant ProteinExpression, Activity or Solubility.

Identified Compensatory Genes

The compensatory genes or gene products that are identified in step ii),or homologous analogues, cofactors or subunits thereof, are used todesign strategies to genetically modify the cell to either increase,decrease, knock in or knock out expression of one or more identifiedgenes. The gene sequences identified in public databases can be used todesign strategies, particularly to design constructs to modulateexpression of a gene by techniques described above. Such techniques arewell known.

In one embodiment, the identified gene or genes is at least one putativeprotease, a protease-like protein, a cofactor or subunit of a protease.In other embodiments, the identified gene or genes is at least onefolding modulator, putative folding modulator, cofactor or subunit of afolding modulator. In certain embodiments, a identified gene is asubunit of a protease. In one embodiment, the identified gene or genescan be a serine, threonine, cysteine, aspartic or metallo peptidase. Inone embodiment, the identified gene or genes can be selected from hslV,hslU, clpA, clpB and clpX. The identified gene can also be a cofactor ofa protease. In another embodiment, the identified gene or genes is afolding modulator. In some embodiments, the identified gene or genes canbe selected from a chaperone protein, a foldase, a peptidyl prolylisomerase and a disulfide bond isomerase. In some embodiments, theidentified gene or genes can be selected from htpG, cbpA, dnaJ, dnaK andfkbP.

Bacterial genes are organized into operons, which are gene clusters thatencode the proteins necessary to perform coordinated function, such asbiosynthesis of a given amino acid. Therefore, in one embodiment, theidentified gene is part of an operon. In a particular embodiment, theidentified gene is in an operon that encodes for one or more proteinswith protease activity alone or in combination, or is an operon thatencodes for one or more proteins with folding modulator activity,including foldases, chaperones, and isomerases.

Proteases

In one embodiment of the invention, the host cell is modified byreducing expression of, inhibiting or removing at least one proteasefrom the genome. The modification can also be to more than one proteasein some embodiments. In a related embodiment, the cell is modified byreducing expression of a protease cofactor or protease protein. Inanother embodiment, the host cell is modified by inhibition of apromoter for a protease or related protein, which can be a nativepromoter. The gene modification can be to modulate a protein homologousto the identified identified gene.

In the MEROPS database, peptidases are grouped into clans and families.The families are groups of closely related functionally similarpeptidases. Families are grouped by their catalytic type: S, serine; T,threonine; C, cysteine; A, aspartic; M, metallo and U, unknown. Over 20families (denoted S1- S27) of serine protease have been identified,these being grouped into 6 clans (SA, SB, SC, SE, SF and SG) on thebasis of structural similarity and other functional evidence. Structuresare known for four of the clans (SA, SB, SC and SE). Threoninepeptidases are characterized by a threonine nucleophile at the Nterminus of the mature enzyme. The type example for this clan is thearchaean proteasome beta component of Thermoplasma acidophilum. Cysteinepeptidases have characteristic molecular topologies and are peptidasesin which the nucleophile is the sulphydryl group of a cysteine residue.Cysteine proteases are divided into clans (proteins which areevolutionary related), and further sub-divided into families, on thebasis of the architecture of their catalytic dyad or triad:

Clan CA contains the families of papain (C1), calpain (C2), streptopain(C10) and the ubiquitin-specific peptidases (C12, C19), as well as manyfamilies of viral cysteine endopeptidases.

Clan CD contains the families of clostripain (C11), gingipain R (C25),legumain (C13), caspase-1 (C14) and separin (C50). These enzymes havespecificities dominated by the interactions of the S1 subsite.

Clan CE contains the families of adenain (C5) from adenoviruses, theeukaryotic Ulp1 protease (C48) and the bacterial YopJ proteases (C55).

Clan CF contains only pyroglutamyl peptidase I (C15).

Clan PA contains the picornains (C3), which have probably evolved fromserine peptidases and which form the majority of enzymes in this clan.

Clans PB and CH contain the autolytic cysteine peptidases.

Aspartic endopeptidases of vertebrate, fungal and retroviral origin havebeen characterised. Aspartate peptidases are so named because Aspresidues are the ligands of the activated water molecule in all exampleswhere the catalytic residues have been identifed, although at least oneviral enzyme is believed to have as Asp and an Asn as its catalyticdyad. All or most aspartate peptidases are endopeptidases. These enzymeshave been assigned into clans (proteins which are evolutionary related),and further sub-divided into families, largely on the basis of theirtertiary structure.

Metalloproteases are the most diverse of the four main types ofprotease, with more than 30 families identified to date. In theseenzymes, a divalent cation, usually zinc, activates the water molecule.The metal ion is held in place by amino acid ligands, usually three innumber. The known metal ligands are His, Glu, Asp or Lys and at leastone other residue is required for catalysis, which may play anelectrophillic role. Of the known metalloproteases, around half containan HEXXH motif, which has been shown in crystallographic studies to formpart of the metal-binding site. The HEXXH motif is relatively common,but can be more stringently defined for metalloproteases as abXHEbbHbc,where ‘a’ is most often valine or threonine and forms part of the S1′subsite in thermolysin and neprilysin, ‘b’ is an uncharged residue, and‘c’ a hydrophobic residue. Proline is never found in this site, possiblybecause it would break the helical structure adopted by this motif inmetalloproteases.

The peptidases associated with clan U-have an unknown catalyticmechanism as the protein fold of the active site domain and the activesite residues have not been reported.

Certain proteases (e.g. OmpT) can adsorb to the surface of inclusionbodies and may degrade the desired protein while it is being refolded.Therefore, certain identified proteins can be proteases or proteaseproteins that adhere to inclusion bodies and these can be modified to,for example, reduce attachment.

Proteases or protease proteins can also be classified asAminopeptidases; Dipeptidases; Dipeptidyl-peptidases and tripeptidylpeptidases; Peptidyl-dipeptidases; Serine-type carboxypeptidases;Metallocarboxypeptidases; Cysteine-type carboxypeptidases;Omegapeptidases; Serine proteinases; Cysteine proteinases; Asparticproteinases; Metallo proteinases; or Proteinases of unknown mechanism.

Aminopeptidases include cytosol aminopeptidase (leucyl aminopeptidase),membrane alanyl aminopeptidase, cystinyl aminopeptidase, tripeptideaminopeptidase, prolyl aminopeptidase, arginyl aminopeptidase, glutamylaminopeptidase, x-pro aminopeptidase, bacterial leucyl aminopeptidase,thermophilic aminopeptidase, clostridial aminopeptidase, cytosol alanylaminopeptidase, lysyl aminopeptidase, x-trp aminopeptidase, tryptophanylaminopeptidase, methionyl aminopeptidas, d-stereospecificaminopeptidase, aminopeptidase ey. Dipeptidases include x-hisdipeptidase, x-arg dipeptidase, x-methyl-his dipeptidase, cys-glydipeptidase, glu-glu dipeptidase, pro-x dipeptidase, x-pro dipeptidase,met-x dipeptidase, non-stereospecific dipeptidase, cytosol non-specificdipeptidase, membrane dipeptidase, beta-ala-his dipeptidase.Dipeptidyl-peptidases and tripeptidyl peptidases includedipeptidyl-peptidase i, dipeptidyl-peptidase ii, dipeptidyl peptidaseiii, dipeptidyl-peptidase iv, dipeptidyl-dipeptidase,tripeptidyl-peptidase I, tripeptidyl-peptidase II. Peptidyl-dipeptidasesinclude peptidyl-dipeptidase a and peptidyl-dipeptidase b. Serine-typecarboxypeptidases include lysosomal pro-x carboxypeptidase, serine-typeD-ala-D-ala carboxypeptidase, carboxypeptidase C, carboxypeptidase D.Metallocarboxypeptidases include carboxypeptidase a, carboxypeptidase B,lysine(arginine) carboxypeptidase, gly-X carboxypeptidase, alaninecarboxypeptidase, muramoylpentapeptide carboxypeptidase,carboxypeptidase h, glutamate carboxypeptidase, carboxypeptidase M,muramoyltetrapeptide carboxypeptidase, zinc d-ala-d-alacarboxypeptidase, carboxypeptidase A2, membrane pro-x carboxypeptidase,tubulinyl-tyr carboxypeptidase, carboxypeptidase t. Omegapeptidasesinclude acylaminoacyl-peptidase, peptidyl-glycinamidase,pyroglutamyl-peptidase I, beta-aspartyl-peptidase,pyroglutamyl-peptidase II, n-formylmethionyl-peptidase,pteroylpoly-[gamma]-glutamate carboxypeptidase, gamma-glu-Xcarboxypeptidase, acylmuramoyl-ala peptidase. Serine proteinases includechymotrypsin, chymotrypsin c, metridin, trypsin, thrombin, coagulationfactor Xa, plasmin, enteropeptidase, acrosin, alpha-lytic protease,glutamyl, endopeptidase, cathepsin G, coagulation factor viia,coagulation factor ixa, cucumisi, prolyl oligopeptidase, coagulationfactor xia, brachyurin, plasma kallikrein, tissue kallikrein, pancreaticelastase, leukocyte elastase, coagulation factor xiia, chymase,complement component c1r55, complement component c1s55,classical-complement pathway c3/c5 convertase, complement factor I,complement factor D, alternative-complement pathway c3/c5 convertase,cerevisin, hypodermin C, lysyl endopeptidase, endopeptidase 1a,gamma-reni, venombin ab, leucyl endopeptidase, tryptase, scutelarin,kexin, subtilisin, oryzin, endopeptidase k, thermomycolin, thermitase,endopeptidase SO, T-plasminogen activator, protein C, pancreaticendopeptidase E, pancreatic elastase ii, IGA-specific serineendopeptidase, U-plasminogen, activator, venombin A, furin,myeloblastin, semenogelase, granzyme A or cytotoxic T-lymphocyteproteinase 1, granzyme B or cytotoxic T-lymphocyte proteinase 2,streptogrisin A, treptogrisin B, glutamyl endopeptidase II,oligopeptidase B, limulus clotting factor c, limulus clotting factor,limulus clotting enzyme, omptin, repressor lexa, bacterial leaderpeptidase I, togavirin, flavirin. Cysteine proteinases include cathepsinB, papain, ficin, chymopapain, asclepain, clostripain, streptopain,actinide, cathepsin 1, cathepsin H, calpain, cathepsin t, glycyl,endopeptidase, cancer procoagulant, cathepsin S, picornain 3C, picornain2A, caricain, ananain, stem bromelain, fruit bromelain, legumain,histolysain, interleukin 1-beta converting enzyme. Aspartic proteinasesinclude pepsin A, pepsin B, gastricsin, chymosin, cathepsin D,neopenthesin, renin, retropepsin, pro-opiomelanocortin convertingenzyme, aspergillopepsin I, aspergillopepsin II, penicillopepsin,rhizopuspepsin, endothiapepsin, mucoropepsin, candidapepsin,saccharopepsin, rhodotorulapepsin, physaropepsin, acrocylindropepsin,polyporopepsin, pycnoporopepsin, scytalidopepsin a, scytalidopepsin b,xanthomonapepsin, cathepsin e, barrierpepsin, bacterial leader peptidaseI, pseudomonapepsin, plasmepsin. Metallo proteinases include atrolysina, microbial collagenase, leucolysin, interstitial collagenase,neprilysin, envelysin, iga-specific metalloendopeptidase, procollagenN-endopeptidase, thimet oligopeptidase, neurolysin, stromelysin 1,meprin A, procollagen C-endopeptidase, peptidyl-lysmetalloendopeptidase, astacin, stromelysin, 2, matrilysin gelatinase,aeromonolysin, pseudolysin, thermolysin, bacillolysin, aureolysin,coccolysin, mycolysin, beta-lytic metalloendopeptidase, peptidyl-aspmetalloendopeptidase, neutrophil collagenase, gelatinase B,leishmanolysin, saccharolysin, autolysin, deuterolysin, serralysin,atrolysin B, atrolysin C, atroxase, atrolysin E, atrolysin F,adamalysin, horrilysin, ruberlysin, bothropasin, bothrolysin,ophiolysin, trimerelysin I, trimerelysin II, mucrolysin, pitrilysin,insulysin, O-syaloglycoprotein endopeptidase, russellysin,mitochondrial, intermediate, peptidase, dactylysin, nardilysin,magnolysin, meprin B, mitochondrial processing peptidase, macrophageelastase, choriolysin, toxilysin. Proteinases of unknown mechanisminclude thermopsin and multicatalytic endopeptidase complex.

Certain protease of P. fluorescens are listed in Table A. TABLE A ClassFamily RXF Curated Function Gene Physiology MEROPS Homologs Aspartic A8(signal peptidase II family) RXF05383 Lipoprotein signal Processing ofnumerous bacterial Peptidases peptidase (ec secreted lipoproteins.3.4.23.36) A24 (type IV prepilin peptidase family) RXF05379 type 4prepilin This membrane-bound peptidase peptidase pild (ec cleaves aspecialized leader 3.4.99.—) peptide from type 4 prepilin during itssecretion from many bacterial species. Once secreted, the processedproteins are required for functions including type 4 pilus formation,toxin and other enzyme secretion, gene transfer, and biofilm formation.Cysteine C15 (pyroglutamyl peptidase I family) RXF02161 Pyrrolidone-Removal of pyroglutamyl groups Peptidases carboxylate peptidase frompeptides in protein (ec 3.4.19.3) catabolism. C40 RXF01968invasion-associated protein, P60 RXF04920 invasion-associated protein,P60 RXF04923 phosphatase-associated protein papq C56 (PfpI endopeptidasefamily) RXF01816 protease I (ec 3.4.—.—) Metallopeptidases M1 RXF08773Membrane alanine aminopeptidase (ec 3.4.11.2) M3 RXF00561 OligopeptidaseA (ec prlC Degradation of lipoprotein signal 3.4.24.70) peptides, andother Intracellular oligopeptides. Role in maturation of bacteriophageP22 gp7 precursor. RXF04631 Zn-dependent oligopeptidases M4 (thermolysinfamily) RXF05113 Extracellular metalloprotease precursor (ec 3.4.24.—)M41 (FtsH endopeptidase family) RXF05400 Cell division protein Proposedrole in proteolytic ftsH (ec 3.4.24.—) quality control of regulatorymolecules and membrane proteins, in yeast. M10 RXF04304 Serralysin (ec3.4.24.40) RXF04500 Serralysin (ec 3.4.24.40) RXF01590 Serralysin (ec3.4.24.40) RXF04495 Serralysin (ec 3.4.24.40) RXF02796 Serralysin (ec3.4.24.40) M14 (carboxypeptidase A family) RXF09091Zinc-carboxypeptidase precursor (ec 3.4.17.—) M16 (pitrilysin family)RXF03441 Coenzyme pqq synthesis protein F (ec 3.4.99.—) RXF01918 zincprotease (ec 3.4.99.—) RXF01919 zinc protease (ec 3.4.99.—) RXF03699processing peptidase (ec 3.4.24.64) M17 (leucyl aminopeptidase family)RXF00285 Cytosol Contributes to bacterial nutrition. aminopeptidase (ec3.4.11.1) M18 RXF07879 Aspartyl aminopeptidase (ec 3.4.11.21) M20RXF00811 Succinyl- dapE diaminopimelate desuccinylase (ec 3.5.1.18)RXF04052 Xaa-His dipeptidase (ec 3.4.13.3) RXF01822 Carboxypeptidase G2precursor (ec 3.4.17.11) RXF04892 N-acyl-L-amino acid amidohydrolase (ec3.5.1.14) M28 (aminopeptidase Y family) RXF03488 Alkaline phosphataseisozyme conversion protein precursor (ec 3.4.11.—) M42 (glutamylaminopeptidase family) RXF05615 Deblocking aminopeptidase (ec 3.4.11.—)M22 RXF05817 O-sialoglycoprotein endopeptidase (ec 3.4.24.57) RXF03065Glycoprotease protein family M23 RXF01291 Cell wall endopeptidase,family M23/M37 RXF03916 Membrane proteins related tometalloendopeptidases RXF09147 Cell wall endopeptidase, family M23/M37M24 RXF04693 Methionine Probable role in cotranslational aminopeptidase(ec removal of N-terminal 3.4.11.18) methionine. RXF03364 MethionineProbable role in cotranslational aminopeptidase (ec removal ofN-terminal 3.4.11.18) methionine. RXF02980 Xaa-Pro Involved inintracellular protein aminopeptidase (ec turnover, in bacteria.3.4.11.9) RXF06564 Xaa-Pro aminopeptidase (ec 3.4.11.9) M48 (Ste24endopeptidase family) RXF05137 Heat shock protein HtpX RXF05081 Zincmetalloprotease (ec 3.4.24.—) M50 (S2P protease family) RXF04692Membrane metalloprotease Serine Peptidases S1 (chymotrypsin family)RXF01250 protease do (ec 3.4.21.—) RXF07210 protease do (ec 3.4.21.—) S8(subtilisin family) RXF06755 serine protease (ec 3.4.21.—) RXF08517serine protease (ec 3.4.21.—) RXF08627 extracellular serine protease (ec3.4.21.—) RXF06281 Extracellular serine protease precursor (ec 3.4.21.—)RXF08978 extracellular serine protease (ec 3.4.21.—) RXF06451 serineprotease (ec 3.4.21.—) S9 (prolyl oligopeptidase family) RXF02003Protease ii (ec 3.4.21.83) RXF00458 Hydrolase S11 (D-Ala-D-Alacarboxypeptidase A RXF04657 D-alanyl-D-alanine- family) endopeptidase(ec 3.4.99.—) RXF00670 D-alanyl-D-alanine carboxypeptidase (ec 3.4.16.4)S13 (D-Ala-D-Ala peptidase C family) RXF00133 D-alanyl-meso- Acts insynthesis and remodelling diaminopimelate of bacterial cell walls.endopeptidase (ec 3.4.—.—) RXF04960 D-alanyl-meso- diaminopimelateendopeptidase (ec 3.4.—.—) S14 (ClpP endopeptidase family) RXF04567atp-dependent Clp clpP Thought to contribute to protease proteolyticelimination of damaged proteins subunit (ec 3.4.21.92) in heat shock.RXF04663 atp-dependent Clp clpP Thought to contribute to proteaseproteolytic elimination of damaged proteins subunit (ec 3.4.21.92) inheat shock. S16 (lon protease family) RXF04653 atp-dependent proteaseThought to contribute to La (ec 3.4.21.53) elimination of damagedproteins in heat shock. RXF08653 atp-dependent protease La (ec3.4.21.53) RXF05943 atp-dependent protease La (ec 3.4.21.53) S24 (LexAfamily) RXF00449 LexA repressor (ec 3.4.21.88) RXF03397 LexA repressor(ec 3.4.21.88) S26 (signal peptidase I family) RXF01181 Signal peptidaseI (ec Cleaves signal peptides from 3.4.21.89) secreted proteins. S33RXF05236 Proline iminopeptidase pip3 (ec 3.4.11.5) RXF04802 Prolineiminopeptidase pip1 (ec 3.4.11.5) RXF04808 Proline iminopeptidase pip2(ec 3.4.11.5) S41 (C-terminal processing peptidase RXF06586Tail-specific protease family) (ec 3.4.21.—) RXF01037 Tail-specificprotease (ec 3.4.21.—) S45 RXF07170 Penicillin acylase (ec pacB23.5.1.11) RXF06399 Penicillin acylase ii (ec pacB1 3.5.1.11) S49(protease IV family) RXF06993 possible protease sohb (ec 3.4.—.—)RXF01418 protease iv (ec 3.4.—.—) S58 (DmpA aminopeptidase family)RXF06308 D-aminopeptidase (ec 3.4.11.19) Threonine T1 (proteasomefamily) RXF01961 atp-dependent protease hslV Thought to contribute toPeptidases hslV (ec 3.4.25.—) elimination of damaged proteins in heatshock. T3 (gamma-glutamyltransferase family) RXF02342 Gamma- ggt1glutamyltranspeptidase (ec 2.3.2.2) RXF04424 Gamma- ggt2glutamyltranspeptidase (ec 2.3.2.2) Unclassified U32 RXF00428 protease(ec 3.4.—.—) Peptidases RXF02151 protease (ec 3.4.—.—) U61 RXF04715Muramoyltetrapeptide carboxypeptidase (ec 3.4.17.13) U62 RXF04971 PmbAprotein pmbA The product of the PmbA gene ({Escherichia coli})facilitates the secretion of the antibiotic peptide microcin B17,removing an N- terminal, 26-amino acid leader peptide (Madison et al.,1997). RXF04968 TldD protein Non MEROPS Proteases RXF00325 Repressorprotein C2 RXF02689 Microsomal dipeptidase (ec 3.4.13.19) RXF02739membrane dipeptidase (3.4.13.19) RXF03329 Hypothetical Cytosolic ProteinRXF02492 Xaa-Pro dipeptidase (ec 3.4.13.9) RXF04047 caax amino terminalprotease family RXF08136 protease (transglutaminase-like protein)RXF09487 Zinc metalloprotease (ec 3.4.24.—)

Certain proteases of E. coli origin are listed in Table B. TABLE B ClassFamily Code Peptidase or homologue (subtype) Gene Aspartic A8 A08.001signal peptidase II lspA Peptidases A24A A24.001 type IV prepilinpeptidase 1 (EtpN etpN protein (plasmid p0157)) A24.001 type IV prepilinpeptidase 1 (CofP cofP protein) A24.001 type IV prepilin peptidase 1(HofD hofD/hopD/hopO protein) A24.003 type IV prepilin peptidase 2 (HopDhopD/ECs4188 protein) A24 family A24A unassigned peptidasespppA/ORF_F310 unassigned (ORF_F310 protein) A24 family A24A unassignedpeptidases pilU unassigned (PilU protein (plasmid R721)) A24 family A24Aunassigned peptidases bfpP/bfpG unassigned (BfpP protein (plasmidpMAR2)) A24 family A24A unassigned peptidases PILU unassigned (PilUprotein) A26 A26.001 omptin ompT/ECS1663/B0565 A26.005 proteinase SopAsopA Cysteine C26 C26 family C26 unassigned peptidasesYCJL/Z2490/ECS1875 Peptidases unassigned C40 C40.004 spr g.p.(Escherichia-type) (spr spr protein) C40 family C40 unassignedpeptidases nlpC/C2104//Z2737/ unassigned (NlpC protein) ECS2415 C40family C40 unassigned peptidases YafL unassigned (YafL protein) C40family C40 unassigned peptidases unassigned (chitinase 3) C40 family C40unassigned peptidases ydhO unassigned (YdhO protein) C39 C39.005 colicinV processing peptidase (CvaB cvaB protein) C39.005 colicin V processingpeptidase (MtfB mtfB protein) C39 family C39 unassigned peptidasesmchF/MCLB unassigned (microcin H47 secretion protein MchF) C56 C56family C56 unassigned peptidases yhbo unassigned (YhbO protein) C56family C56 unassigned peptidases c4536 unassigned (c4536 protein)Metallopeptidases M1 M01.005 alanyl aminopeptidase pepN (proteobacteria)M3A M03.004 oligopeptidase A prlC/opdA M03.005 peptidyl-dipeptidase Dcpdcp/Z2160/ECS2147 M03.005 peptidyl-dipeptidase Dcp dcp M41 M41.001 FtsHendopeptidase hflB/ftsH/ECS4057 M66 M66.001 StcE protease stcE M15D M15subfamily M15D unassigned ddpX/vanX/B1488/ unassigned peptidases (VanXprotein) Z2222/ECS2092 M16A M16.001 pitrilysin ptr/ECs3678 M16B M16subfamily M16B unassigned pqqL/yddC unassigned peptidases (PqqL protein)M17 M17.003 aminopeptidase A (bacteria) pepA/xerB M17.004 PepBaminopeptidase pepB/Z3790/ECS3389 M24A M24.001 methionyl aminopeptidase1 map M24B M24.003 X-Pro dipeptidase (bacteria) pepQ/ECs4775 M24.004aminopeptidase P (bacteria) pepP M24 subfamily M24B unassignedyqhT/ypdF/B2385/ unassigned peptidases (YqhT protein) c2924 M20A M20.010DapE peptidase (succinyl- dapE/msgB/C2999 diaminopimelate desuccinylase)M20 subfamily M20A unassigned ygey unassigned peptidases (YgeY protein)M20B M20.003 peptidase T pepT/Z1832/ECS1572 M20C M20.007 X-Hisdipeptidase pepD/pepH/ECs0264 M20D M20 family M20D unassigned peptidasesydaJ/ECs1922 unassigned (YdaJ protein) M28A M28 subfamily M28Aunassigned yfbL unassigned peptidases (YfbL protein) M28C M28.005 IAPaminopeptidase iap M42 M42 family M42 unassigned peptidases yjhOunassigned (YjhO protein) M42 family M42 unassigned peptidases frvXunassigned (FrvX protein) M42 family M42 unassigned peptidasesfrvX/b2384/ypdE unassigned (FrvX protein) M38 M38.001 beta-aspartyldipeptidase iadA M22 M22.001 O-sialoglycoprotein endopeptidase ygjDM22.002 yeaZ protein yeaZ/C2211/Z2850/ ECS2516 M23B M23.006 YibPpeptidase (YibP protein) yibP M23 subfamily M23B unassigned yebAunassigned peptidases (YebA protein) M48B M48.002 HtpX endopeptidaseHtpX M48 subfamily M48B unassigned YGGG/C3521 unassigned peptidases M48subfamily M48B unassigned YFGC/C3011 unassigned peptidases M48 subfamilyM48B unassigned YggG/Z4280/ECS3811 unassigned peptidases (YggG protein)M48 subfamily M48B unassigned ycaL/C1047/Z1255/ unassigned peptidases(YcaL protein) ECS0992 M50A M50.004 YaeL protease (YAEL protein)ecfE/YAEL/B0176/ Z0187/ECS0178/C0213 M52 M52.001 HybD endopeptidase(HybD protein) hybD/ECS3878 M52.002 HyaD endopeptidase (HyaD protein)hyaD M52.003 HycI endopeptidase (HycI protein) hycI/C3277 Serine S1BS01.260 B1598 endopeptidase b1598 Peptidases S1C S01.273 protease DohtrA/degP S01.274 DegQ hhoA/degQ/ECS4107/ Z4593 S01.275 DegS hhoB/degSS6 S06.002 EspP g.p. (Escherichia coli) espP/pssA S06.003 Tsh peptidase(Escherichia coli) (Tsh tsh/hbp protein) S06.003 Tsh peptidase(Escherichia coli) c0393 S06.004 Pet endopeptidase sat S06.004 Petendopeptidase S06.005 Pic endopeptidase (Shigella flexneri) she/pic S6family S6 unassigned peptidases eatA unassigned (eatA protein) S6 familyS6 unassigned peptidases c0350 unassigned (c0350 protein) S6 family S6unassigned peptidases espC unassigned (EspC protein) S6 family S6unassigned peptidases epeA unassigned (epeA protein) S6 family S6unassigned peptidases unassigned S8A S8 subfamily S8A unassignedpeptidases unassigned S9A S09.010 oligopeptidase B ptrB S09.010oligopeptidase B ptrB/C2255 S9X S9 family S9 unassigned peptidasesYFHR/C3060/b2534/ unassigned Z3802 S11 S11.002 murein-DD-endopeptidasepbpG S11.003 penicillin-binding protein 6 dacC/Z1066/ECS0919 S11.003penicillin-binding protein 6 dacD/phsE/ECs2812 (penicillin-bindingprotein pbp-6B) S11.003 penicillin-binding protein 6 dacA S12 S12 familyS12 unassigned peptidases c2452 unassigned (c2452 protein) S12 familyS12 unassigned peptidases yaiH/C0480 unassigned (YaiH protein) S13S13.001 D-Ala-D-Ala peptidase C dacB/ECs4061 S14 S14.001 endopeptidaseClp (type 1) clpP/lopP/ECS0491 S14 family S14 unassigned peptidasesZ0967/ECS0829 unassigned (ECs0829 protein) S14 family S14 unassignedpeptidases H0022/Z2112/ECS2960/ unassigned (ECs2960 protein) L34 S16S16.001 lon protease lon/deg/ECs0493 S16 family S16 unassignedpeptidases lonB/Z1305/ECS1039 unassigned (ECS1039 protein) S16 familyS16 unassigned peptidases c1091 unassigned (c1091 protein) S24 S24.001repressor LexA (LexA protein) lexA/exrA S24.003 UmuD protein S24.003UmuD protein umuD/C1631 S26 S26A S26.001 signal peptidase I S26.014 traFplasmid-transfer protein (TraF traF protein) S33 S33 family S33unassigned peptidases bioH/C4189//Z4767/ unassigned (BioH protein)ECS4255 S41A S41.001 C-terminal processing protease-1 prc/tsp/ECS2540/Z2877//C2239 S45 S45.001 penicillin G acylase precursor pac S49 S49.001protease IV sppA/ECs2472//C2170 S49.002 sohB endopeptidasesohB/ECS1844/Z2538// C1737 S51 S51.001 dipeptidase E pepE S54 S54 familyS54 unassigned peptidases c0741 unassigned (c0741 protein) S54 familyS54 unassigned peptidases glpG/C4201//Z4784/ unassigned(glycerophosphate dehydrogenase) ECS4267 Threonine T1B T01.006 HslVcomponent of HslUV peptidase hslV Peptidases T2 T02.002 asparaginaseybiK/Z1051m/C0913 T3 T03.001 gamma-glutamyltransferase 1 ggt/C4236(bacterial) S41A S41.001 C-terminal processing protease-1prc/tsp/ECS2540/ Z2877//C2239 Unclassified U6 U06.001 mureinendopeptidase mepA/ECs3212//C2874 Peptidases U32 U32 unassigned familyU32 unassigned peptidases (YdcP protein) U32 family U32 unassignedpeptidases yegQ/C2611 unassigned (YegQ protein) U32 family U32unassigned peptidases YHBU/C3911/Z4519/ unassigned (YhbU protein)ECS4039 U35 U35 unassigned family U35 unassigned peptidases U35 familyU35 unassigned peptidases ECs4973 unassigned (ECs4973 protein) U49U49.001 Lit protease (Escherichia coli) U61 U61.001 muramoyl-tetrapeptide carboxypeptidase U61 family U61 unassigned peptidases mccFunassigned (MccF protein) U62 U62.001 microcin- processing peptidase 1U62.002 microcin-processing peptidase 2 tldD/ECs4117 M9G.035endopeptidase ECP 32 (Escherichia coli)

Certain proteases of S. cerevisiae origin are listed in Table C. TABLE CClass Family Code Peptidase or homologue (subtype) Gene Aspartic A1A01.015 barrierpepsin bar1 Peptidases A01.018 saccharopepsin pep4/pho9A01.030 yapsin 1 yap3 A01.031 yapsin 2 mkc7 A01.035 yapsin 3 YPS3A01.UPW family A1 unassigned peptidases YPS7/D9476.8/ YDR349C A01.UPWfamily A1 unassigned peptidases YIR039C YIR039C protein) A2D A02.022 Ty3transposon (Saccharomyces POL3/TY3-2 orfB/ cerevisiae) endopeptidaseTY3B (retrotransposon Ty3-1) A11B A11.003 Ty1 transposon (SaccharomycesTy1B cerevisiae) endopeptidase (transposon Ty1-17 protein B) A11.003 Ty1transposon (Saccharomyces Ty1B cerevisiae) endopeptidase (transposon Ty1protein B) A11.003 Ty1 transposon (Saccharomyces Ty1B cerevisiae)endopeptidase (transposon Ty1 protein B) A11X A11.UPW family A11unassigned peptidases (retrotransposon Ty4) A22B A22.008 YKL100c protein(Saccharomyces YKL100c cerevisiae) Cysteine C1B C01.085 bleomycinhydrolase (yeast) GAL6/YCP1/LAP3 Peptidases C2 C02.008 calpain-7YMR154C/Cp11/ Rim13 C12 C12.002 ubiquitinyl hydrolase YUH1 yuh1 C13C13.005 glycosylphosphatidylinositol:protein d9798.2 transamidase C19C19.002 Ubp1 ubiquitin peptidase ubp1 C19.003 Ubp2 ubiquitin peptidaseubp2 C19.004 Ubp3 ubiquitin peptidase ubp3 C19.005 Doa4 ubiquitinpeptidase DOA4 C19.006 Ubp5 ubiquitin peptidase ubp5 C19.079 UBP6(Saccharomyces cerevisiae) yfr010w (YFR010W protein) C19.UPW family C19unassigned peptidases YNL186W (YNL186W protein) C19.UPW family C19unassigned peptidases ubp9 (UBP9) C19.UPW family C19 unassignedpeptidases YBL067C (YBL067C protein) C19.UPW family C19 unassignedpeptidases UBP12/YBR058C (YBR058C protein) C19.UPW family C19 unassignedpeptidases UBP16/YPL072W/ (ubiquitin carboxy-terminal hydrolase LPF12W16) C19.UPW family C19 unassigned peptidases YMR304W/ (YMR304W protein)ym9952.06 C19.UPW family C19 unassigned peptidases YMR223W/ (YMR223Wprotein) ym9959.05 C19.UPW family C19 unassigned peptidases ubp7 (UBP7)C19.UPW family C19 unassigned peptidases ubp13 (UBP13) C44 C44.971glucosamine-fructose-6-phosphate aminotransferase C44.971glucosamine-fructose-6-phosphate gfa1 aminotransferase (glucosamine-fructose-6-phosphate aminotransferase) C48 C48.001 Ulp1 endopeptidaseYPL020c C48.005 Ulp2 endopeptidase (Smt4p protein) SMT4 C50 C50.001separase ESP1/YGR098C C54 C54.001 ATG4 peptidase (SaccharomycesApg4/Aut2 cerevisiae) C56 C56.004 YDR533C g.p. (SaccharomycesYDR533C/D9719.36 cerevisiae) C56.UPW family C56 unassigned peptidasesYPL280W (YPL280W protein) C56.UPW family C56 unassigned peptidasesYOR391C (YOR391C protein) I34 I34.001 saccharopepsin inhibitorPAI3/YMR174C/ YM8010 Metallopeptidases M1 M01.006 Ape2 aminopeptidaselap1/ape2 M01.007 Aap1′ aminopeptidase AAP1 M01.007 Aap1′ aminopeptidaseM01.017 Yin7 g.p. (Saccharomyces cerevisiae) yil137C M01.UPW family M1unassigned peptidases ynl045w (ynl045w protein) M3A M03.003saccharolysin prd1 M03.006 mitochondrial intermediate peptidase MIP1M16A M16.007 Axl1 peptidase axl1 M16.008 Ste23 peptidase ste23 M16.UPAsubfamily M16A unassigned peptidases orf1 (orf1 protein) M16B M16.003mitochondrial processing peptidase mas1/mif1 beta-subunit (beta) M16CM16.UPC subfamily M16C unassigned peptidases YDR430C (YDR430C protein)M16.UPC subfamily M16C unassigned peptidases YOL098C (YOL098C protein)M16X M16.971 mitochondrial processing peptidase mas2/mif2 non-peptidasealpha subunit (alpha) M16.974 UCR2_HUMAN (ubiquinol- ucr2/cor2/qcr2cytochrome c reductase core protein 2) M18 M18.001 aminopeptidase Iape1/lap4 M18.UPW family M18 unassigned peptidases YHR113W (YHR113Wprotein) M20A M20.005 cytosolic nonspecific dipeptidase YFR044C M20EM20.002 Gly-X carboxypeptidase cps1/cps M20.002 Gly-X carboxypeptidase(pseudogene; AOE110, AOE264, deduced from nucleotide sequence by AOE130MEROPS) M22 M22.003 Mername-AA017 peptidase YKR038C (YKR038C protein)M22.UPW family M22 unassigned peptidases QRI7 (QRI7 protein) M24AM24.001 methionyl aminopeptidase 1 map1 M24.002 methionyl aminopeptidase2 ybl091c M24B M24.009 aminopeptidase P1 YLL029w M24.026 aminopeptidaseP homologue YER078C (YER078C protein) M24.UPB subfamily M24B unassignedpeptidases yfr006w (YFR006W protein) M28A M28.001 aminopeptidase Y ape3M28E M28.006 Mername-AA063 peptidase (YDR415c YDR415c protein) M28XM28.974 glutaminyl cyclase YFR018C M28.UPW family M28 unassignedpeptidases YBR074W (YBR074W protein) M41 M41.002 Afg3 g.p.(Saccharomyces cerevisiae) agf3/yta10 (AGF3 protein) M41.003 m-AAAprotease (RCA1 protein) rca1/yta12 M41.004 i-AAA proteaseyme1/yta11/osd1 M48A M48.001 Ste24 endopeptidase STE24 M48B M48.018 Omalendopeptidase (Saccharomyces YKR087C/YKR407 cerevisiae) (YKR087Cprotein) M49 M49.001 dipeptidyl-peptidase III YOL057W M49.UPW family M49unassigned peptidases M67A M67.001 Poh1 peptidase RPN11/MPR1/ YFR004WM67.002 Jab1/MPN domain metalloenzyme YDL216c/D0888 M67.973 26Sproteasome non-ATPase RPN8/YOR261C regulatory subunit 7 SerinePeptidases S1C S01.434 Nma111 endopeptidase ynl123w (Saccharomycescerevisiae) (YNL123W protein) S8A S08.052 cerevisin prb1 S08.UPAsubfamily S8A unassigned peptidases YSP3 (YSP3 protein) S08.UPAsubfamily S8A unassigned peptidases YCR54C (YCR54C protein) S8B S08.070kexin kex2 S9B S09.005 dipeptidyl aminopeptidase A ste13/yci1 S09.006dipeptidyl aminopeptidase B (fungus) dap2 S9X S09.UPW family S9unassigned peptidases YNL320W (Ynl320w protein) S10 S10.001carboxypeptidase Y prc1 S10.007 kex carboxypeptidase kex1 S10.UPW familyS10 unassigned peptidases ybr139W (YBR139W protein) S16 S16.002 PIM1endopeptidase lon/pim1 S26A S26.002 mitochondrial inner membraneprotease imp1 1 (1) S26.012 mitochondrial inner membrane protease imp2 2(2) S26B S26.010 signalase (eukaryote) 21 kDa sec11 component S33.UPWfamily S33 unassigned peptidases ECM18/YDR125C S33.UPW family S33unassigned peptidases ECM18/YDR125C S54 S54.007 Pcp1 protein(Saccharomyces YGR101W cereviseae) (YGR101W protein) S59 S59.001nucleoporin 145 Nup145 Threonine T1A T01.010 proteasome catalyticsubunit 1 pre3 Peptidases T01.011 proteasome catalytic subunit 2 pup1T01.012 proteasome catalytic subunit 3 pre2/prg1 T01.983 proteasomesubunit beta 3 pup3 T01.984 proteasome subunit beta 2 pre1 T01.986proteasome subunit beta 1 pre7/prs3 T01.987 proteasome subunit beta 4pre4 T1X T01.971 proteasome subunit alpha 6 prs2/prc2 T01.972 proteasomesubunit alpha 2 pre8/prs4 T01.973 proteasome subunit alpha 4 pre9/prs5T01.974 proteasome subunit alpha 7 pre6 T01.975 proteasome subunit alpha5 pup2 T01.976 proteasome subunit alpha 1 pre5 T01.977 proteasomesubunit alpha 3 pre10/prs1/prc1 T3 T03.012 gamma-glutamyltransferaseL8003.4 (Saccharomyces) (YLR299w protein) T5 T05.001 ornithineacetyltransferase precursor arg7/emc40/ YMR062C Unclassified U48 U48.001prenyl protease 2 rce1 PeptidasesFolding Modulators

The identified up-regulated genes or gene products can be one or morefolding modulator. Folding modulators can for example be HSP70 proteins,HSP110/SSE proteins, HSP40 (DNAJ-related) proteins, GRPE-like proteins,HSP90 proteins, CPN60 and CPN10 proteins, Cytosolic chaperoning, HSP100proteins, Small HSPs, Calnexin and calreticulin, PDI andthioredoxin-related proteins, Peptidyl-prolyl isomerases, CyclophilinPPIases, FK-506 binding proteins, Parvulin PPIases, Individualchaperoning, Protein specific chaperones, or intramolecular chaperones.Folding modulators are generally described in “Guidebook to MolecularChaperones and Protein-Folding Catalysts” (1997) ed. M. Gething,Melbourne University, Australia.

The best characterized molecular chaperones in the cytoplasm of E. coliare the ATP-dependent DnaK-DnaJ-GrpE and GroEL-GroES systems. Based onin vitro studies and homology considerations, a number of additionalcytoplasmic proteins have been proposed to function as molecularchaperones in E. coli. These include ClpB, HtpG and IbpA/B, which, likeDnaK-DnaJ-GrpE and GroEL-GroES, are heat-shock proteins (Hsps) belongingto the stress regulon. The trans conformation of X-Pro bonds isenergetically favored in nascent protein chains; however, ˜5% of allprolyl peptide bonds are found in a cis conformation in native proteins.The trans to cis isomerization of X-Pro bonds is rate limiting in thefolding of many polypeptides and is catalyzed in vivo by peptidyl prolylcis/trans isomerases (PPIases). Three cytoplasmic PPIases, SlyD, SlpAand trigger factor (TF), have been identified to date in E. coli. TF, a48 kDa protein associated with 50S ribosomal subunits that has beenpostulated to cooperate with chaperones in E. coli to guarantee properfolding of newly synthesized proteins. At least five proteins(thioredoxins 1 and 2, and glutaredoxins 1, 2 and 3, the products of thetrxA, trxC, grxA, grxB and grxC genes, respectively) are involved in thereduction of disulfide bridges that transiently arise in cytoplasmicenzymes. Thus, identified genes can be disulfide bond forming proteinsor chaperones that allow proper disulfide bond formation.

Certain folding modulators in P. fluorescens are listed in Table D.TABLE D RXF gene function Family GroES/EL rxf02095 groES chaperone Hsp10rxf06767::rxf02090 groEL chaperone Hsp60 RXF01748 ibpA Small heat-shockprotein (sHSP) IbpA PA3126; Acts as Hsp20 a holder for GroESL foldingRXF03385 hscB Chaperone protein hscB Hsp20 Hsp70 (DnaK/J) rxf05399 dnaKchaperone Hsp70 RXF06954 dnaK chaperone Hsp70 RXF03376 hscA chaperoneHsp70 RXF03987 cbpA Curved dna-binding protein, dnaJ like activity Hsp40RXF05406 dnaJ Chaperone protein dnaJ Hsp40 RXF03346 dnaJ Molecularchaperones (DnaJ family) Hsp40 Hsp100 (Clp/Hsl) RXF04587 clpAatp-dependent clp protease atp-binding subunit clpA Hsp100 RXF08347 clpBClpB protein Hsp100 RXF04654 clpX atp-dependent clp protease atp-bindingsubunit clpX Hsp100 RXF01957 hslU atp-dependent hsl protease atp-bindingsubunit hslU Hsp100 RXF01961 hslV atp-dependent hsl protease atp-bindingsubunit hslV Hsp100 Hsp33 RXF04254 yrfI 33 kDa chaperonin (Heat shockprotein 33 homolog) Hsp33 (HSP33). Hsp90 RXF05455 htpG Chaperone proteinhtpG Hsp90 SecB RXF02231 secB secretion specific chaperone SecB SecBDisulfide Bond Isomerases RXF07017 dsbA disulfide isomerase DSBAoxidoreductase RXF08657 dsbA/dsbC/ disulfide isomerase DSBA dsbG/oxidoreductase fernA rxf01002 dsbA/dsbC disulfide isomerase DSBAoxidoreductase/Thioredoxin rxf03307 dsbC disulfide isomeraseglutaredoxin/Thioredoxin rxf04890 dsbG disulfide isomeraseglutaredoxin/Thioredoxin Peptidyl-prolyl cis-trans isomerases RXF03768ppiA Peptidyl-prolyl cis-trans isomerase A (ec 5.2.1.8) PPIase:cyclophilin type RXF05345 ppiB Peptidyl-prolyl cis-trans isomerase B.PPIase: cyclophilin type RXF06034 fklB Peptidyl-prolyl cis-transisomerase FklB. PPIase: FKBP type RXF06591 fklB/fkbP fk506 bindingprotein Peptidyl-prolyl cis-trans PPIase: FKBP isomerase (EC 5.2.1.8)type RXF05753 fklB; fkbP Peptidyl-prolyl cis-trans isomerase (ec5.2.1.8) PPIase: FKBP type RXF01833 slyD Peptidyl-prolyl cis-transisomerase SlyD. PPIase: FKBP type RXF04655 tig Trigger factor, ppiase(ec 5.2.1.8) PPIase: FKBP type RXF05385 yaad Probable FKBP-type 16 kDapeptidyl-prolyl cis-trans PPIase: FKBP isomerase (EC 5.2.1.8) (PPiase)(Rotamase). type RXF00271 Peptidyl-prolyl cis-trans isomerase (ec5.2.1.8) PPIase: FKBP type pili assembly chaperones (papD like) RXF06068cup Chaperone protein cup pili assembly papD RXF05719 ecpD Chaperoneprotein ecpD pili assembly papD RXF03406 ecpD; Chaperone protein ecpDpili assembly csuC papD RXF04296 ecpD; Chaperone protein ecpD piliassembly cup papD RXF04553 ecpD; Chaperone protein ecpD pili assemblycup papD RXF04554 ecpD; Chaperone protein ecpD pili assembly cup papDRXF05310 ecpD; Chaperone protein ecpD pili assembly cup papD RXF05304ecpD; Chaperone protein ecpD pili assembly cup papD RXF05073 gltFGram-negative pili assembly chaperone periplasmic pili assembly functionpapD

Certain folding modulators in E. coli are listed in Table E. TABLE EUniprot Accession Uniprot ID Annotation Family GroES/EL P05380CH10_ECOLI 10 kDa chaperonin Hsp10 P06139 CH60_ECOLI 60 kDa chaperoninHsp60 Hsp70 (DnaK/J) P04475 DNAK_ECOLI Chaperone protein dnaK Hsp70P77319 HSCC_ECOLI Chaperone protein hscC Hsp70 P36659 CBPA_ECOLI CurvedDNA-binding protein cbpA Hsp40 P31680 DJLA_ECOLI DnaJ-like protein djlA,rscG Hsp40 P08622 DNAJ_ECOLI Chaperone protein dnaJ Hsp40 P29131FTSN_ECOLI Cell division protein ftsN Hsp40 P09372 GRPE_ECOLI GrpEprotein GrpE P31658 HCHA_ECOLI Chaperone protein hchA Hsp31 Hsp100(Clp/Hsl) P15716 CLPA_ECOLI ATP-dependent Clp protease ATP-bindingHsp100 subunit clpA P03815 CLPB_ECOLI ClpB protein Hsp100 P33138CLPX_ECOLI ATP-dependent Clp protease ATP-binding Hsp100 subunit clpXP32168 HSLU_ECOLI ATP-dependent hsl protease ATP-binding Hsp100 subunithslU, clpY Small Heat Shock Proteins P29209 IBPA_ECOLI 16 kDa heat shockprotein A. Hsp16 P29210 IBPB_ECOLI 16 kDa heat shock protein B. Hsp16Not Part of a Larger Group P36662 TORD_ECOLI Chaperone protein torD TorDP15040 SECB_ECOLI Protein-export protein secB SecB P45803 HSLO_ECOLI 33kDa chaperonin Hsp33 P10413 HTPG_ECOLI Chaperone protein htpG Hsp90HscAB P36541 HSCA_ECOLI Chaperone protein hscA Hsp66 P36540 HSCB_ECOLICo-chaperone protein hscB Hsp20 Lipoprotein Carrier Protein P61316LOLA_ECOLI Outer-membrane lipoprotein carrier protein LolA precursorP61320 LOLB_ECOLI Outer-membrane lipoprotein lolB precursor LolBDisulfide Bond Isomerases P24991 DSBA_ECOLI Thiol: disulfide interchangeprotein dsbA precursor. P30018 DSBB_ECOLI Disulfide bond formationprotein B Disulfide Bond Oxidoreductase P21892 DSBC_ECOLI Thiol:disulfide interchange protein dsbC precursor. P36655 DSBD_ECOLI Thiol:disulfide interchange protein dsbD precursor (EC 1.8.1.8)(Protein-disulfide reductase) P33926 DSBE_ECOLI Thiol: disulfideinterchange protein dsbE (Cytochrome c biogenesis protein ccmG). P77202DSBG_ECOLI Thiol: disulfide interchange protein dsbG Disulfide Bondprecursor Oxidoreductase Peptidyl-prolyl cis-trans isomerases P22257TIG_ECOLI Trigger factor PPIase: FKBP type P45523 FKBA_ECOLI FKBP-typepeptidyl-prolyl cis-trans isomerase PPIase: FKBP type fkpA precursorP39311 FKBB_ECOLI FKBP-type 22 kDa peptidyl-prolyl cis-trans PPIase:FKBP type isomerase P22563 FKBX_ECOLI FKBP-type 16 kDa peptidyl-prolylcis-trans PPIase: FKBP type isomerase P30856 SLYD_ECOLI FKBP-typepeptidyl-prolyl cis-trans isomerase PPIase: FKBP type slyD P20752PPIA_ECOLI Peptidyl-prolyl cis-trans isomerase A precursor PPIase:Cyclophilin type P23869 PPIB_ECOLI Peptidyl-prolyl cis-trans isomerase BPPIase: Cyclophilin type P39159 PPIC_ECOLI Peptidyl-prolyl cis-transisomerase C PPIase: PPIC type P77241 PPID_ECOLI Peptidyl-prolylcis-trans isomerase D PPIase: PPIC type P21202 SURA_ECOLI Survivalprotein surA precursor PPIase: Parvulin type pili assembly chaperones(papD like) P53516 AFAB_ECOLI Chaperone protein afaB precursor PiliAssembly PapD P33128 ECPD_ECOLI Chaperone protein ecpD precursor PiliAssembly PapD P31697 FIMC_ECOLI Chaperone protein fimC precursor PiliAssembly PapD P77249 SFMC_ECOLI Chaperone protein sfmC precursor PiliAssembly PapD P75749 YBGP_ECOLI Hypothetical fimbrial chaperone ybgPprecursor Pili Assembly PapD P40876 YCBF_ECOLI Hypothetical fimbrialchaperone ycbF precursor Pili Assembly PapD P75856 YCBR_ECOLIHypothetical fimbrial chaperone ycbR precursor Pili Assembly PapD P33342YEHC_ECOLI Hypothetical fimbrial chaperone yehC precursor Pili AssemblyPapD P77599 YFCS_ECOLI Hypothetical fimbrial chaperone yfcS precursorPili Assembly PapD P28722 YHCA_ECOLI Hypothetical fimbrial chaperoneyhcA precursor Pili Assembly PapD P77616 YQIH_ECOLI Hypotheticalfimbrial chaperone yqiH precursor Pili Assembly PapD P42914 YRAI_ECOLIHypothetical fimbrial chaperone yraI precursor Pili Assembly PapD

Certain folding modulators of S. cervisia are shown in table F. TABLE FUniprot Accession Uniprot ID GO Source Annotation Family GroES/EL P19882HS60_YEAST GOA: interpro Heat shock protein 60, Hsp60 mitochondrialprecursor P38228 TC62_YEAST GOA: interpro Mitochondrial chaperone TCM62Hsp60 P38910 CH10_YEAST GOA: interpro 10 kDa heat shock protein, Hsp10mitochondrial Hsp70 (DnaK/J) P25491 MAS5_YEAST GOA: interproMitochondrial protein import Hsp40 protein MAS5, Ydj1 P10591 HS71_YEASTPMID: 9789005 Heat shock protein SSA1 Hsp70 P10592 HS72_YEAST PMID:9448096 Heat shock protein SSA2 Hsp70 P11484 HS75_YEAST Heat shockprotein SSB1 Hsp70 P40150 HS76_YEAST Heat shock protein SSB2 Hsp70P09435 HS73_YEAST PMID: 7867784 Heat shock protein SSA3 Hsp70 P22202HS74_YEAST Heat shock protein SSA4 Hsp70 P25294 SIS1_YEAST GOA: interproSIS1 protein Hsp40 P32527 ZUO1_YEAST GO: 0003754 Zuotin Hsp40 P35191MDJ1_YEAST GOA: interpro MDJ1 protein, mitochondrial Hsp40 precursorP12398 HS77_YEAST PMID: 8654364 Heat shock protein SSC1, Hsp70mitochondrial precursor P38523 GRPE_YEAST GOA: interpro GrpE proteinhomolog, GrpE mitochondrial precursor, MGE1 P14906 SC63_YEAST GOA: spkwTranslocation protein SEC63 Hsp40 P16474 GR78_YEAST GRP 78, BIP, Kar2Hsp70 P25303 SCJ1_YEAST GOA: interpro DnaJ-related protein SCJ1 Hsp40P39101 CAJ1_YEAST GOA: interpro CAJ1 protein Hsp40 P48353 HLJ1_YEASTGOA: interpro HLJ1 protein Hsp40 P39102 XDJ1_YEAST GOA: interpro XDJ1protein Hsp40 P52868 YGM8_YEAST GOA: interpro Hypothetical 41.0 kDaprotein in Hsp40 CEG1-SOH1 intergenic region P53940 YNH7_YEAST GOA:interpro Hypothetical 58.9 kDa protein in Hsp40 TPM1-MKS1 intergenicregion P38353 SSH1_YEAST Sec sixty-one protein homolog. Hsp70 P36016LHS1_YEAST GOA: spkw Heat shock protein 70 homolog Hsp70 LHS1, SSI1P38788 YHM4_YEAST PMID: 11054575 Heat shock protein 70 homolog Hsp70YHR064C Hsp110/Sse P32589 HS78_YEAST PMID: 10480867 Heat shock proteinhomolog SSE1 SSE P32590 HS79_YEAST Heat shock protein homolog SSE2 SSEHsp100 (Clp/Hsl) P31539 6H104_YEAST GOA: interpro Heat shock protein 104Hsp100 P33416 HSP7_YEAST GOA: spkw Heat shock protein 78, Hsp100mitochondrial precursor P38323 MCX1_YEAST GOA: interpro MitochondrialclpX-like Hsp100 chaperone MCX1 Small Heat Shock Proteins P15992HS26_YEAST PMID: 10581247 Heat shock protein 26 Small Hsp PrefoldinP48363 PFD3_YEAST GOA: interpro Probable prefoldin subunit 3 PrefoldinQ04493 PFD5_YEAST GOA: interpro Prefoldin subunit 5 Prefoldin P43573YFC3_YEAST GOA: interpro Hypothetical 91.4 kDa protein in PrefoldinSTE2-FRS2 intergenic region P46988 PFD1_YEAST GOA: spkw Prefoldinsubunit 1 KE2 P40005 PFD2_YEAST GOA: spkw Prefoldin subunit 2 KE2 P53900PFD4_YEAST GOA: spkw Prefoldin subunit 4 KE2 P52553 PFD6_YEAST GOA: spkwPrefoldin subunit 6 KE2 Hsp90 P02829 HS82_YEAST GOA: interpro Heat shockprotein HSP82 Hsp90 P15108 HS83_YEAST GOA: interpro Heat shock cognateprotein Hsp90 HSC82 P06101 CC37_YEAST GOA: spkw Hsp90 co-chaperone Cdc37Cdc37 P33313 CNS1_YEAST GOA: spkw Cyclophilin seven suppressor 1 CNS1P15705 STI1_YEAST PMID: 8972212 Heat shock protein STI1 Calnexin P27825CALX_YEAST GOA: spkw Calnexin homolog precursor Calnexin CytosolicChaperonins T-complex P12612 TCPA_YEAST GOA: interpro T-complex protein1, alpha TCP-1, Hsp60 subunit P39076 TCPB_YEAST GOA: interpro T-complexprotein 1, beta subunit TCP-1, Hsp60 P39078 TCPD_YEAST GOA: interproT-complex protein 1, delta TCP-1, Hsp60 subunit P40413 TCPE_YEAST GOA:interpro T-complex protein 1, epsilon TCP-1, Hsp60 subunit P39077TCPG_YEAST GOA: interpro T-complex protein 1, gamma TCP-1, Hsp60 subunitP42943 TCPH_YEAST GOA: interpro T-complex protein 1, eta subunit TCP-1,Hsp60 P47079 TCPQ_YEAST GOA: interpro T-complex protein 1, theta TCP-1,Hsp60 subunit P39079 TCPZ_YEAST GOA: interpro T-complex protein 1, zetasubunit TCP-1, Hsp60 Protein Specific P48606 TBCA_YEAST GOA: spkwTubulin-specific chaperone A protein specific P53904 TBCB_YEAST GOA:spkw Tubulin-specific chaperone B protein specific P46670 CIN2_YEASTGOA: spkw Tubulin-folding cofactor C Cin2 protein specific P40987CIN1_YEAST Tubulin-folding cofactor D Cin1 protein specific P39937PAC2_YEAST GOA: spkw Tubulin-folding cofactor E PAC2 protein specificP21560 CBP3_YEAST GOA: spkw CBP3 protein, mitochondrial protein specificprecursor Q12287 COXS_YEAST GOA: spkw Cytochrome c oxidase copperprotein specific chaperone P40202 LYS7_YEAST GOA: interpro Superoxidedismutase 1 copper chaperone Q02774 SHR3_YEAST PMID: 10564255 Secretorycomponent protein protein specific SHR3 P38293 UMP1_YEAST GOA: spkwProteasome maturation factor protein specific UMP1 P38784 VM22_YEASTPMID: 7673216 Vacuolar ATPase assembly protein specific protein VMA22P38072 SCO2_YEAST GOA: spkw SCO2 protein, mitochondrial protein specificprecursor P53266 SHY1_YEAST PMID: 11389896 SHY1 protein protein specificP40046 VTC1_YEAST GOA: spkw Vacuolar transporter chaperone 1 proteinspecific P38958 PT00_YEAST PMID: 11498004 PET100 protein, mitochondrialprotein specific precursor Disulfide Bond Isomerases P17967 PDI_YEASTPMID: 11157982 Protein disulfide isomerase Disulfide bond precursoroxidoreductase P32474 EUG1_YEAST PMID: 11157982 Protein disulfideisomerase EUG1 Disulfide bond precursor oxidoreductase Q12404 MPD1_YEASTPMID: 11157982 Disulfide isomerase MPD1 Disulfide bond precursoroxidoreductase Q99316 MPD2_YEAST PMID: 11157982 Protein disulfideisomerase MPD2 Disulfide bond precursor (EC 5.3.4.1) oxidoreductaseQ03103 ERO1_YEAST PMID: 9659913 Endoplasmic oxidoreductin 1 Disulfidebond precursor (EC 1.8.4.—) oxidoreductase (Endoplasmic oxidoreductaseprotein 1). P38866 FMO1_YEAST PMID: 10077572 Thiol-specificmonooxygenase Disulfide bond (EC 1.14.13.—) (Flavin-dependentoxidoreductase monooxygenase). Peptidyl-prolyl cis-trans isomerasesP14832 CYPH_YEAST GOA: interpro Peptidyl-prolyl cis-trans PPIase:isomerase cyclophilin Cyclophilin Type A/Cpr1/Cyp1/CPH1/Scc1 P23285CYPB_YEAST GOA: interpro Peptidyl-prolyl cis-trans PPIase: isomerasecyclophilin Cyclophilin Type B/Cpr2/Cyp2 P25719 CYPC_YEAST GOA: interproPeptidyl-prolyl cis-trans PPIase: isomerase C/CYP3/CPR3, CyclophilinType mitochondrial P25334 CYPR_YEAST GOA: interpro Peptidyl-prolylcis-trans PPIase: isomerase CPR4/Scc3 Cyclophilin Type P35176 CYPD_YEASTGOA: interpro Peptidyl-prolyl cis-trans PPIase: isomerase D CypD/Cpr5Cyclophilin Type P53691 CYP6_YEAST PMID: 10942767 Peptidyl-prolylcis-trans PPIase: isomerase CPR6 Cyclophilin Type P47103 CYP7_YEASTPMID: 10942767 Peptidyl-prolyl cis-trans PPIase: isomerase CYP7Cyclophilin Type P53728 CYP8_YEAST GOA: interpro Peptidyl-prolylcis-trans PPIase: isomerase CYP8 Cyclophilin Type Q02770 Q02770 GOA:interpro Yp1064cp PPIase: Cyclophilin Type P20081 FKBP_YEAST GOA:interpro FK506-binding protein 1 PPIase: FKBP FKB1/RBP1 Type P32472FKB2_YEAST GOA: interpro FK506-binding protein 2, FKBP- PPIase: FKBP13/FKBP-15/FKB2, FPR2 Type P38911 FKB3_YEAST GOA: interpro FK506-bindingnuclear protein PPIase: FKBP FKBP-70/Npi46/Fpr3/ Type Q06205 FKB4_YEASTGOA: interpro FK506-binding protein 4 FPR4 PPIase: FKBP Type P22696ESS1_YEAST GOA: spkw ESS1 protein PPIase: Parvulin Type Miscellaneouspoorly characterised P27697 ABC1_YEAST GOA: spkw ABC1 protein,mitochondrial ABC1 precursor P53193 YGB8_YEAST GOA: interproHypothetical 21.8 kDa protein in Hsp20 CKB1-ATE1 intergenic regionP28707 YKL7_YEAST PMID: 9632755 24.1 kDa protein in VMA12- p23/wos2 APN1intergenic region P38932 VP45_YEAST PMID: 11432826 Vacuolar proteinsorting- SEC1 like associated protein 45 Q12019 MDN1_YEAST GOA: spkwMidasinGenetic Manipulation

In step iii), the process includes changing expression of the identifiedcompensatory gene or gene product in the recombinant cell by geneticmodification to provide a modified recombinant cell. Afteridentification of one or more up-regulated genes, proteins or metabolicprocesses, the genome of the host may be modified. Certain genes or geneproducts, although identified as up-regulated, may not be available formodulation because they are essential to the cell or are known to affectother processes that may be essential to the cell or organism.

The genome may be modified by including an exogenous gene or promoterelement in the genome or in the host with an expression vector, byenhancing the capacity of an identified gene to produce mRNA or protein,or by deleting or disrupting a gene or promoter element, or by reducingthe capacity of a gene to produce mRNA or protein. The genetic code canbe altered, thereby affecting transcription and/or translation of agene, for example through substitution, deletion (“knock-out”),co-expression or insertion (“knock-in”) techniques. Additional genes fora desired protein or regulatory sequence that modulate transcription ofan existing sequence can also be inserted.

Recombination

The genome of the host cell expressing recombinant protein or peptidecan be modified via a genetic targeting event, which can be by insertionor recombination, for example homologous recombination. Homologousrecombination refers to the process of DNA recombination based onsequence homology. Homologous recombination permits site-specificmodifications in endogenous genes and thus novel alterations can beengineered into a genome. One step in homologous recombination is DNAstrand exchange, which involves a pairing of a DNA duplex with at leastone DNA strand containing a complementary sequence to form anintermediate recombination structure containing heteroduplex DNA (see,for example Radding, C. M. (1982) Ann. Rev. Genet. 16: 405; U.S. Pat.No. 4,888,274). The heteroduplex DNA can take several forms, including athree DNA strand containing triplex form wherein a single complementarystrand invades the DNA duplex (Hsieh, et al., Genes and Development 4:1951 (1990); Rao, et al., (1991) PNAS 88:2984)) and, when twocomplementary DNA strands pair with a DNA duplex, a classical Hollidayrecombination joint or chi structure (Holliday, R., Genet. Res. 5: 282(1964)) can form, or a double-D loop (“Diagnostic Applications ofDouble-D Loop Formation” U.S. Ser. No. 07/755,462, filed Sep. 4, 1991).Once formed, a heteroduplex structure can be resolved by strand breakageand exchange, so that all or a portion of an invading DNA strand isspliced into a recipient DNA duplex, adding or replacing a segment ofthe recipient DNA duplex. Alternatively, a heteroduplex structure canresult in gene conversion, wherein a sequence of an invading strand istransferred to a recipient DNA duplex by repair of mismatched basesusing the invading strand as a template (Genes, 3^(rd) Ed. (1987) Lewin,B., John Wiley, New York, N.Y.; Lopez, et al., Nucleic Acids Res. 15:5643(1987)). Whether by the mechanism of breakage and rejoining or bythe mechanism(s) of gene conversion, formation of heteroduplex DNA athomologously paired joints can serve to transfer genetic sequenceinformation from one DNA molecule to another.

In homologous recombination, the incoming DNA interacts with andintegrates into a site in the genome that contains a substantiallyhomologous DNA sequence. In non-homologous (“random” or “illicit”)integration, the incoming DNA integrates not at a homologous sequence inthe genome but elsewhere, at one of a large number of potentiallocations. A number of papers describe the use of homologousrecombination in mammalian cells.

Various constructs can be prepared for homologous recombination at aidentified locus. Usually, the construct can include at least 10 bp, 20bp, 30 bp, 40 bp, 50 bp, 70 bp, 100 bp, 500 bp, 1 kbp, 2 kbp, 4 kbp, 5kbp, 10 kbp, 15 kbp, 20 kbp, or 50 kbp of sequence homologous with theidentified locus. Various considerations can be involved in determiningthe extent of homology of identified DNA sequences, such as, forexample, the size of the identified locus, availability of sequences,relative efficiency of double cross-over events at the identified locusand the similarity of the identified sequence with other sequences.

The targeting DNA can include a sequence in which DNA substantiallyisogenic flanks the desired sequence modifications with a correspondingidentified sequence in the genome to be modified. The substantiallyisogenic sequence can be at least about 95%, 97-98%, 99.0-99.5%,99.6-99.9%, or 100% identical to the corresponding identified sequence(except for the desired sequence modifications). The targeting DNA andthe identified DNA can share stretches of DNA at least about 10, 20, 30,50, 75, 150 or 500 base pairs that are 100% identical.

The DNA constructs can be designed to modify the endogenous, identifiedgene product. The homologous sequence for identifieding the constructcan have one or more deletions, insertions, substitutions orcombinations thereof designed to disrupt the function of the resultantgene product. In one embodiment, the alteration can be the insertion ofa selectable marker gene fused in reading frame with the upstreamsequence of the identified gene.

The genome can also be modified using insertional deletion. In thisembodiment, the genome is modified by recombining a sequence in the genethat inhibits gene product formation. This insertion can either disruptthe gene by inserting a separate element, or remove an essential portionof the gene. In one embodiment, the insertional deletion includesinsertion of a gene coding for resistance to a particular stressor, suchas an antibiotic, or for growth in a particular media, for example forproduction of an essential amino acid.

The genome can also be modified by use of transposons, which are geneticelements capable of inserting at sites in prokaryote genomes bymechanisms independant of homologous recombination. Transposons caninclude, for example, Tn7 in E. coli, Tn554 in S. aureus, IS900 in M.paratuberculosis, IS492 from Pseudomonas atlantica, IS116 fromStreptomyces and IS900 from M. paratuberculosis. Steps believed to beinvolved in transposition include cleavage of the end of the transposonto yield 3′ OH; strand transfer, in which transposase brings togetherthe 3′OH exposed end of transposon and the identified sequence; and asingle step transesterification reaction to yield a covalent linkage ofthe transposon to the identified DNA. The key reaction performed bytransposase is generally thought to be nicking or strand exchange, therest of the process is done by host enzymes.

In one embodiment, a process is provided to increase the level of aidentified gene or homologue thereof by incorporating a genetic sequenceencoding the gene or homologue into the genome by recombination. Inanother embodiment, a promoter is inserted into the genome to enhancethe expression of the identified gene or homologue. In a separateembodiment, a process is provided for decreasing the expression of aidentified gene or homologue thereof by recombination with an inactivegene. In another embodiment, a sequence that encodes a different gene,which can have a separate function in the cell or can be a reporter genesuch as a resistance marker or an otherwise detectable marker gene canbe inserted into a genome through recombination. In yet anotherembodiment, a copy of at least a portion of the identified gene that hasbeen mutated at one or more locations is inserted into the genomethrough recombination. The mutated version of the identified gene cannot encode a protein, or the protein encoded by the mutated gene can berendered inactive, the activity can be modulated (either increased ordecreased), or the mutant protein can have a different activity whencompared to the native protein.

There are strategies to knock out genes in bacteria, which have beengenerally exemplified in E. coli. One route is to clone a gene-internalDNA fragment into a vector containing an antibiotic resistance gene(e.g. ampicillin). Before cells are transformed via conjugativetransfer, chemical transformation or electroporation (Puehler, et al.(1984) Advanced Molecular Genetics New York, Heidelberg, Berlin, Tokyo,Springer Verlag), an origin of replication, such as the vegetativeplasmid replication (the oriV locus) is excised and the remaining DNAfragment is re-ligated and purified (Sambrook, et al. (2000) Molecularcloning: A laboratory manual, third edition Cold Spring Harbor, N.Y.,Cold Spring Harbor Laboratory Press). Alternatively,antibiotic-resistant plasmids that have a DNA replication origin can beused. After transformation, the cells are plated onto e.g. LB agarplates containing the appropriate antibiotics (e.g. 200 μg/mLampicillin). Colonies that grow on the plates containing the antibioticspresumably have undergone a single recombination event (Snyder, L., W.Champness, et al. (1997) Molecular Genetics of Bacteria Washington DC,ASM Press) that leads to the integration of the entire DNA fragment intothe genome at the homologous locus. Further analysis of theantibiotic-resistant cells to verify that the desired gene knock-out hasoccurred at the desired locus is e.g. by diagnostic PCR (McPherson, M.J., P. Quirke, et al. (1991) PCR: A Practical Approach New York, OxfordUniversity Press). Here, at least two PCR primers are designed: one thathybridizes outside the DNA region that was used for the construction ofthe gene knock-out; and one that hybridizes within the remaining plasmidbackbone. Successful PCR amplification of the DNA fragment with thecorrect size followed by DNA sequence analysis will verify that the geneknock-out has occurred at the correct location in the bacterialchromosome. The phenotype of the newly constructed mutant strain canthen be analyzed by e.g. SDS polyacrylamide gel electrophoresis(Simpson, R. J. (2003) Proteins and Proteomics—A Laboratory Manual. ColdSpring Harbor, N.Y., Cold Spring Harbor Laboratory Press).

An alternate route to generate a gene knock-out is by use of atemperature-sensitive replicon, such as the pSC101 replicon tofacilitate gene replacement (Hamilton, et al. (1989) New process forgenerating deletions and gene replacements in Escherichia coli. Journalof Bacteriology 171(9): 4617-22). The process proceeds by homologousrecombination between a gene on a chromosome and homologous sequencescarried on a plasmid temperature sensitive for DNA replication. Aftertransformation of the plasmid into the appropriate host, it is possibleto select for integration of the plasmid into the chromosome at 44° C.Subsequent growth of these cointegrates at 30° C. leads to a secondrecombination event, resulting in their resolution. Depending on wherethe second recombination event takes place, the chromosome will eitherhave undergone a gene replacement or retain the original copy of thegene.

Other strategies have been developed to inhibit expression of particulargene products. For example, RNA interference (RNAi), particularly usingsmall interfering RNA (siRNA), has been extensively developed to reduceor even eliminate expression of a particular gene product. siRNAs areshort, double-stranded RNA molecules that can target complementary mRNAsfor degradation. RNAi is the phenomenon in which introduction of adouble-stranded RNA suppresses the expression of the homologous gene.dsRNA molecules are reduced in vivo to 21-23 nt siRNAs which are themediators of the RNAi effect. Upon introduction, double stranded RNAsget processed into 20-25 nucleotide siRNAs by an RNase III-like enzymecalled Dicer (initiation step). Then, the siRNAs assemble intoendoribonuclease-containing complexes known as RNA-induced silencingcomplexes (RISCs), unwinding in the process. The siRNA strandssubsequently guide the RISCs to complementary RNA molecules, where theycleave and destroy the cognate RNA (effecter step). Cleavage of cognateRNA takes place near the middle of the region bound by the siRNA strand.RNAi has been successfully used to reduce gene expression in a varietyof organisms including zebrafish, nematodes (C. elegans), insects(Drosophila melanogaster), planaria, cnidaria, trypanosomes, mice andmammalian cells.

Mutation

The genome can also be modified by mutation of one or more nucleotidesin a open reading frame encoding an identified gene, particularly anidentified protease. Techniques for genetic mutation, for instance sitedirected mutagenesis are well known in the art. Some approaches focus onthe generation of random mutations in chromosomal DNA such as thoseinduced by X-rays and chemicals. Mutagenesis targeted to a definedregion of DNA includes many techniques, some more popular than others.In vitro approaches to site-directed mutagenesis can be groupedgenerally into three categories: i) processes that restructure fragmentsof DNA, such as cassette mutagenesis; ii) localized random mutagenesis;and iii) oligonucleotide-directed mutagenesis.

Oligonucleotide-directed mutagenesis is based on the concept that anoligonucleotide encoding a desired mutation(s) is annealed to one strandof the DNA of interest and serves as a primer for initiation of DNAsynthesis. In this manner, the mutagenic oligonucleotide is incorporatedinto the newly synthesized strand. Mutagenic oligonucleotidesincorporate at least one base change but can be designed to generatemultiple substitutions, insertions or deletions. Examples includePCR-based processes and practically all of the non-PCR-based processesin use today. These techniques include positive antibiotic selection(Lewis, M. K. and Thompson, D. V. (1990) Nucl. Acids Res. 18, 3439;Bohnsack, R. N. (1996) Meth. Mol. Biol. 57, 1; Vavra, S. and Brondyk, W.H. (1996) Promega Notes 58, 30; Altered Sites® II in vitro MutagenesisSystems Technical Manual #TM001, Promega Corporation), uniquerestriction site selection (Deng, W. P. and Nickoloff, J. A. (1992)Anal. Biochem. 200, 81), uracil incorporation (Kunkel, T. A. (1985)Proc. Natl. Acad. Sci. USA 82, 488; Kunkel, T. A., Roberts, J. D. andZakour, R. A. (1987) Meth. Enzymol. 154, 367), and phosphorothioateincorporation (Taylor, J. W., Ott, J. and Eckstein, F. (1985) Nucl.Acids Res. 13, 8764; Nakamaye, K. and Eckstein, F. (1986) Nucl. AcidsRes. 14, 9679). Oligonucleotides can also encode a library of mutationsby randomizing the base composition at sites during chemical synthesisresulting in degenerate or “doped” oligonucleotides. The ability tolocalize and specify mutations is greatly enhanced by the use ofsynthetic oligonucleotides hybridized to the DNA insert-containingplasmid vector.

The general format for site-directed mutagenesis is: denaturation ofplasmid DNA containing the template of interest (cDNA, promoter, etc.)to produce single-stranded regions; annealing of a synthetic mutantoligonucleotide to the identified strand; synthesis of a newcomplementary strand using, for example, T4 DNA Polymerase; and sealingthe resulting nick between the end of the new strand and theoligonucleotide, for example using T4 DNA Ligase. The resultingheteroduplex is propagated by transformation, for example in E. coli.Selection and enrichment processes have been incorporated intomutagenesis processes to greatly improve the efficiency of mutant strandrecovery and rates approaching 80-90% are possible. Numerous processesexist to generate different types of mutations and to enhance for theselection of the mutant. Examples of processes to enhance for theselection of the mutant include positive antibiotic selection of themutant strand, using a uracil-containing DNA strand which can beselectively degraded in vivo, and dNTP analog incorporation, which canrender one strand of heteroduplex DNA impervious to digestion. Someapproaches can be combined, such as cassette mutagenesis and the use of“doped” oligonucleotides to create a library of random mutations in asmall, defined region.

An extension of the so-called “standard” processes of site-directedmutagenesis includes those that rely on DNA amplification, specificallythe polymerase chain reaction (PCR). The major commonality insite-directed mutagenesis is the use of a mutagenic oligonucleotide. Themutagenic oligonucleotide should hybridize efficiently to the template.For efficient hybridization, there can be, for example, 100% basepairing at either end of the identified sequence without secondarystructure formation, but can also be less than 100% identify, such as98%, 95%, 92%, 90%, 85%, 80%, 70% or only a portion of the sequence canbe identical. For small substitutions, 10-15 bases hybridizing on eitherside of the mismatch are usually sufficient. The composition of the3′-end of the primer is particularly important as polymerases do nottypically extend from a mismatched or poorly hybridized 3′-end.

The basis for site-directed mutagenesis by positive antibiotic selectionis that a selection oligonucleotide or oligonucleotides aresimultaneously annealed, with the mutagenic oligonucleotide, to repairan antibiotic resistance gene (10-13). Selection for the mutant strandis enabled by antibiotic resistance of the mutated DNA and sensitivityof the nonmutated strand. This approach offers a very efficient means togenerate an indefinite number of the desired mutations with littlehands-on time.

Site-directed mutagenesis by the use of a unique restriction site isbased on the processes of Deng and Nickoloff (Deng, W. P. and Nickoloff,J. A. (1992) Anal. Biochem. 200, 81). In this approach, a selectionoligonucleotide containing a mutated sequence for a unique restrictionsite is annealed simultaneously with the mutagenic oligonucleotide. Theselection oligonucleotide renders the nonessential site immune torestriction by the corresponding enzyme. Selection for the mutant strandis enhanced by digesting the resulting pool of plasmids with the uniquerestriction enzyme. The digestion linearizes the parental plasmidthereby effectively decreasing its ability to transform bacteria.

Site-directed mutagenesis by deoxyuridine incorporation relies on theability of a host strain to degrade template DNA that contains uracil(U) in place of thymidine (T). A small number of dUTPs are incorporatedinto the template strand in place of dTTP in a host that lacks dUTPase(dut−) and uracil N-deglycosidase (ung−) activities. (Uracil per se isnot mutagenic and it base pairs with adenine.) Normally, dUTPasedegrades deoxyuridine and uracil N-deglycosidase removes anyincorporated uracil. Post-mutation replication in a dut+ ung+ strain isused then to degrade nonidentified strand DNA. This approach requiresthat single-stranded DNA be used so that only one strand contains the Uswhich are susceptible to degradation.

The phosphorothioate incorporation approach to site-directed mutagenesisrests on the ability of a dNTP analog containing a thiol group to renderheteroduplex DNA resistant to restriction enzyme digestion. The mutantstrand is extended from the mutagenic oligonucleotide and synthesized inthe presence of dCTPalphaS. Unused template DNA is removed by digestionwith an exonuclease. Theoretically, only circular, heteroduplex DNAremains. The heteroduplex is then nicked, but not cut, at therestriction site(s). Exonuclease III is used to digest the nicked strandand the remaining fragment then acts as a primer for repolymerization,creating a mutant homoduplex.

In the polymerase chain reaction (PCR) based approach to generate amutation in DNA, a template is amplified using a set of gene-specificoligonucleotide primers except that one oligonucleotide, or more inprotocols that use multiple amplifications, contains the desiredmutation. Variations include altering the hybridization site of theoligonucleotides to produce multiple, overlapping PCR fragments with themutation in the overlap and the “megaprimer” approach, which uses threeoligonucleotides and two rounds of amplification wherein a productstrand from the first amplification serves as a primer in the secondamplification.

In the overlap extension approach, complementaryoligodeoxyribonucleotide (oligo) primers and the polymerase chainreaction are used to generate two DNA fragments having overlapping ends.These fragments are combined in a subsequent ‘fusion’ reaction in whichthe overlapping ends anneal, allowing the 3′ overlap of each strand toserve as a primer for the 3′ extension of the complementary strand. Theresulting fusion product is amplified further by PCR. Specificalterations in the nucleotide (nt) sequence can be introduced byincorporating nucleotide changes into the overlapping oligo primers.

Vector Constructs

In a separate embodiment, the host cell is modified by including one ormore vectors that encode a identified gene, typically a foldingmodulator or a cofactor of a folding modulator. In another embodiment,the host cell is modified by enhancing a promoter for a foldingmodulator or a cofactor for a folding modulator, including by adding anexogenous promoter to the host cell genome.

In another embodiment, the host cell is modified by including one ormore vectors that encode an inhibitor of an identified compensatorygene, such as a protease inhibitor. Such an inhibitor can be anantisense molecule that limits the expression of the identifiedcompensatory gene, a cofactor of the identified gene or a homologue ofthe identified gene. Antisense is generally used to refer to a nucleicacid molecule with a sequence complementary to at least a portion of theidentified gene. In addition, the inhibitor can be an interfering RNA ora gene that encodes an interfering RNA. In Eukaryotic organisms, such aninterfering RNA can be a small interfering RNA or a ribozyme, asdescribed, for example, in Fire, A. et al. (1998) Nature 391:806-11,Elbashir et al. (2001) Genes & Development 15(2):188-200, Elbashir etal. (2001) Nature 411(6836):494-8, U.S. Pat. Nos. 6,506,559 to CarnegieInstitute, 6,573,099 to Benitec, U.S. patent application Nos.2003/0108923 to the Whitehead Inst., and 2003/0114409, PCT PublicationNos. WO03/006477, WO03/012052, WO03/023015, WO03/056022, WO03/064621 andWO03/070966. The inhibitor can also be another protein or peptide. Theinhibitor can, for example, be a peptide with a consensus sequence forthe protease or protease protein. The inhibitor can also be a protein orpeptide that can produce a direct or indirect inhibitory molecule forthe protease or protease protein in the host. Protease inhibitors caninclude Amastatin, E-64, Antipain, Elastatinal, APMSF, Leupeptin,Bestatin, Pepstatin, Benzamidine, 1,10-Phenanthroline, Chymostatin,Phosphoramidon, 3,4-dichloroisocoumarin, TLCK, DFP, TPCK. Over 100naturally occurring protein protease inhibitors have been identified sofar. They have been isolated in a variety of organisms from bacteria toanimals and plants. They behave as tight-binding reversible orpseudo-irreversible inhibitors of proteases preventing substrate accessto the active site through steric hindrance. Their size are alsoextremely variable from 50 residues (e.g BPTI: Bovine Pancreatic TrypsinInhibitor) to up to 400 residues (e.g alpha-1PI: alpha-1 ProteinaseInhibitor). They are strictly class-specific except proteins of thealpha-macroglobulin family (e.g alpha-2 macroglobulin) which bind andinhibit most proteases through a molecular trap mechanism.

An exogenous vector or DNA construct can be transfected or transformedinto the host cell. Techniques for transfecting and transformingeukaryotic and prokaryotic cells respectively with exogenous nucleicacids are well known in the art. These can include lipid vesiclemediated uptake, calcium phosphate mediated transfection (calciumphosphate/DNA co-precipitation), viral infection, particularly usingmodified viruses such as, for example, modified adenoviruses,microinjection and electroporation. For prokaryotic transformation,techniques can include heat shock mediated uptake, bacterial protoplastfusion with intact cells, microinjection and electroporation. Techniquesfor plant transformation include Agrobacterium mediated transfer, suchas by A. tumefaciens, rapidly propelled tungsten or goldmicroprojectiles, electroporation, microinjection and polyethelyneglycol mediated uptake. The DNA can be single or double stranded, linearor circular, relaxed or supercoiled DNA. For various techniques fortransfecting mammalian cells, see, for example, Keown et al. (1990)Processes in Enzymology Vol. 185, pp. 527-537.

For recombination events, the constructs can include one or moreinsertion sequences, which can insert or transpose one or more nucleicacid sequence into a different sequence. However, the construct can bedesigned for exogenous expression of an identified compensatory gene orhomologue thereof without incorporation into the existing cellularDNA/genome.

The constructs can contain one, or more than one, internal ribosomeentry site (IRES). The construct can also contain a promoter operablylinked to the nucleic acid sequence encoding at least a portion of theidentified gene, or a cofactor of the identified gene, a mutant versionof at least a portion of the identified compensatory gene, or in thecase of proteases, an inhibitor of the identified gene. Alternatively,the construct can be promoterless. In cases in which the construct isnot designed to incorporate into the cellular DNA/genome, the vectortypically contains at least one promoter element. In addition to thenucleic acid sequences the expression vector can contain selectablemarker sequences. The expression constructs can further contain sitesfor transcription initiation, termination, and/or ribosome bindingsites. The identified constructs can be inserted into and can beexpressed in any prokaryotic or eukaryotic cell, including, but notlimited to bacterial cells, such as P. fluorescens or E. coli, yeastcells, mammalian cells, such as CHO cells, or plant cells.

Cloning vectors can include e.g. plasmid pBR322 (Bolivar, Rodriguez etal. 1977), the pUC series of plasmids (Vieira and Messing 1982),pBluescript (Short, Fernandez et al. 1988), pACYC177 and pACYC184 (Changand Cohen 1978). Exogenous promoters for use in such constructs,include, but are not limited to, the phage lambda PL promoter, E. colilac, E. coli trp, E. coli phoA, E. coli tac promoters, SV40 early, SV40late, retroviral LTRs, PGKI, GALI, GALIO genes, CYCI, PH05, TRPI, ADHI,ADH2, forglymaldehyde phosphate dehydrogenase, hexokinase, pyruvatedecarboxylase, phosphofructokinase, triose phosphate isomerase,phosphoglucose isomerase, glucokinase alpha-mating factor pheromone,PRBI, GUT2, GPDI promoter, metallothionein promoter, and/or mammalianviral promoters, such as those derived from adenovirus and vacciniavirus. Other promoters will be known to one skilled in the art.

Promoters for exogenous vectors, or exogenous promoters designed to beinserted into the genome can be based on specific response elements in acell. For example, promoters can be responsive to chemical compounds,for example to anthranilate or benzoate, as described in PCT PublicationNo. WO 2004/005221. The constructs can include one or more promoters.These can be independent, or can be in tandem. For example the promoterscan be designed so that a identified compensatory gene is up- ordown-regulated in a particular time frame with the recombinant proteinor peptide. For example, in a case in which the identified gene is afolding modulator, the folding modulator or cofactor can be inducedshortly before induction of the recombinant protein or peptide.Promoters can include, but are not limited to the following: Promotersource regulation induction lac E. coli lacI, lacI^(q) IPTG lacUV5 E.coli lacI, lacI^(q) IPTG tac (hybrid) E. coli lacI, lacI^(q) IPTG trc(hybrid) E. coli lacI, lacI^(q) IPTG P_(syn) (synthetic) E. coli lacI,lacI^(q) IPTG trp E. coli tryptophan starvation araBAD E. coli araCl-arabinose lpp^(a) E. coli IPTG, lactose lpp-lac (hybrid) E. coli lacIIPTG phoA E. coli phoB (positive) phosphate phoR (negative) starvationrecA E. coli lexA nalidixic acid proU E. coli osmolarity cst-1 E. coliglucose starvation tetA E. coli tetracyclin cadA E. coli cadR pH nar E.coli fnr anearobic conditions p_(L) λ λ cIts857 thermal (shift to 42°C.) cspA E. coli thermal (shift to below 20° C.) T7 T7 λ cIts857 thermalT7-lac operator T7 lacI^(q) IPTG T3-lac operator T3 lacI^(q) IPTG T5-lacoperator T5 lacI, lacI^(q) IPTG T4 gene 32 T4 T4 infection nprM-lacoperator Bacillus lacI^(q) IPTG VHb Vitreoscilla oxygen Protein A S.aureus

Constructs can include selection markers to identify modified cells.Suitable selectable marker genes include, but are not limited to: genesconferring the ability to grow on certain media substrates, such as thetk gene (thymidine kinase) or the hprt gene (hypoxanthinephosphoribosyltransferase) which confer the ability to grow on HATmedium (hypoxanthine, aminopterin and thymidine); the bacterial gpt gene(guanine/xanthine phosphoribosyltransferase) which allows growth on MAXmedium (mycophenolic acid, adenine, and xanthine). See, for example,Song, K-Y., et al. (1987) Proc. Nat'l Acad. Sci. U.S.A. 84:6820-6824;Sambrook, J., et al. (1989) Molecular Cloning—A Laboratory Manual, ColdSpring Harbor Laboratory, Cold Spring Harbor, N.Y., Chapter 16. Otherexamples of selectable markers include: genes conferring resistance tocompounds such as antibiotics, genes conferring the ability to grow onselected substrates, genes encoding proteins that produce detectablesignals such as luminescence, such as green fluorescent protein,enhanced green fluorescent protein (eGFP). A wide variety of suchmarkers are known and available, including, for example, antibioticresistance genes such as the neomycin resistance gene (neo) (Southern,P., and P. Berg, (1982) J. Mol. Appl. Genet. 1:327-341); and thehygromycin resistance gene (hyg) ((1983) Nucleic Acids Research11:6895-6911, and Te Riele, H., et al. (1990) Nature 348:649-651). Otherselectable marker genes include: acetohydroxy acid synthase (AHAS),alkaline phosphatase (AP), beta galactosidase (LacZ), beta glucoronidase(GUS), chloramphenicol acetyltransferase (CAT), green fluorescentprotein (GFP), red fluorescent protein (RFP), yellow fluorescent protein(YFP), cyan fluorescent protein (CFP), horseradish peroxidase (HRP),luciferase (Luc), nopaline synthase (NOS), octopine synthase (OCS), andderivatives thereof. Multiple selectable markers are available thatconfer resistance to ampicillin, bleomycin, chloramphenicol, gentamycin,hygromycin, kanamycin, lincomycin, methotrexate, phosphinothricin,puromycin, and tetracycline. Additional selectable marker genes usefulin this invention, for example, are described in U.S. Pat. Nos:6,319,669; 6,316,181; 6,303,373; 6,291,177; 6,284,519; 6,284,496;6,280,934; 6,274,354; 6,270,958; 6,268,201; 6,265,548; 6,261,760;6,255,558; 6,255,071; 6,251,677; 6,251,602; 6,251,582; 6,251,384;6,248,558; 6,248,550; 6,248,543; 6,232,107; 6,228,639; 6,225,082;6,221,612; 6,218,185; 6,214,567; 6,214,563; 6,210,922; 6,210,910;6,203,986; 6,197,928; 6,180,343; 6,172,188; 6,153,409; 6,150,176;6,146,826; 6,140,132; 6,136,539; 6,136,538; 6,133,429; 6,130,313;6,124,128; 6,110,711; 6,096,865; 6,096,717; 6,093,808; 6,090,919;6,083,690; 6,077,707; 6,066,476; 6,060,247; 6,054,321; 6,037,133;6,027,881; 6,025,192; 6,020,192; 6,013,447; 6,001,557; 5,994,077;5,994,071; 5,993,778; 5,989,808; 5,985,577; 5,968,773; 5,968,738;5,958,713; 5,952,236; 5,948,889; 5,948,681; 5,942,387; 5,932,435;5,922,576; 5,919,445; and 5,914,233.

Deletions can be at least about 5 bp, 10 bp, 20 bp, 30 bp, 40 bp or 50bp, commonly at least about 100 bp, and generally not more than about 20kbp, where the deletion can normally include at least a portion of thecoding region including a portion of or one or more exons, a portion ofor one or more introns, and can or can not include a portion of theflanking non-coding regions, particularly the 5′-non-coding region(transcriptional regulatory region). Thus, the homologous region canextend beyond the coding region into the 5′-non-coding region oralternatively into the 3′-non-coding region. Insertions can generallynot exceed 10 kbp, usually not exceed 5 kbp, generally being at least 50bp, more usually at least 200 bp.

The region(s) of homology can include mutations, where mutations canfurther inactivate the identified gene, in providing for a frame shift,or changing a key amino acid, or the mutation can correct adysfunctional allele, etc. Usually, the mutation can be a subtle change,not exceeding about 5% of the homologous flanking sequences.

The construct can be prepared in accordance with processes known in theart, various fragments can be brought together, introduced intoappropriate vectors, cloned, analyzed and then manipulated further untilthe desired construct has been achieved (see, for example FIGS. 5-11).Various modifications can be made to the sequence, to allow forrestriction analysis, excision, identification of probes, etc. Silentmutations can be introduced, as desired. At various stages, restrictionanalysis, sequencing, amplification with the polymerase chain reaction,primer repair, in vitro mutagenesis, etc. can be employed. Processes forthe incorporation of antibiotic resistance genes and negative selectionfactors will be familiar to those of ordinary skill in the art (see,e.g., WO 99/15650; U.S. Pat. No. 6,080,576; U.S. Pat. No. 6,136,566;Niwa, et al., J. Biochem. 113:343-349 (1993); and Yoshida, et al.,Transgenic Research, 4:277-287 (1995)).

The construct can be prepared using a bacterial vector, including aprokaryotic replication system, e.g. an origin recognizable by aprokaryotic cell such as P. fluorescens or E. coli. A marker, the sameas or different from the marker to be used for insertion, can beemployed, which can be removed prior to introduction into the identifiedcell. Once the vector containing the construct has been completed, itcan be further manipulated, such as by deletion of certain sequences,linearization, or introducing mutations, deletions or other sequences inthe homologous sequence. After final manipulation, the construct can beintroduced into the cell.

The process can be iterative. In one embodiment, after modification ofthe host and expression of the recombinant protein in the modified host,a genetic profile of the modified host cell is analyzed to identify oneor more further identified genes the expression of which is changed inthe modified host cell. In particular, compensatory genes can be thosethat show increased expression in the modified host expressingrecombinant protein when compared to a modified host cell not expressingthe recombinant protein or peptide, or when compared to an unmodifiedhost cell. The process further includes changing the expression of thefurther identified gene or genes and expressing the protein or peptidein the doubly modified cell. These steps can be iterated to improveprotein expression and can be repeated one, two, three, four, five, six,seven, eight, nine, or at least ten times.

Production of Protein

The process of the invention optimally leads to increased production ofrecombinant protein or peptide in a host cell. The increased productioncan include an increased amount of protein per gram of host protein in agiven amount of time, or can include an increase in the length of timethe host cell is producing recombinant protein or peptide. The increasedproduction can also include an improvement in the requirements forgrowth of the recombinant host cell. The increased production can be anincreased production of full length protein or peptide. If theimprovement is in increased levels of protein, the protein or peptidecan be produced in one or more inclusion bodies in a host cell.

The increased production alternatively can be an increased level ofactive protein or peptide per gram of protein produced, or per gram ofhost protein. The increased production can also be an increased level ofrecoverable protein or peptide, such as soluble protein, produced pergram of recombinant or per gram of host cell protein. The increasedproduction can also be any combination of increased total level andincreased active or soluble level of protein.

Increased production is typically measured by comparing the level ofproduction after a certain period of induction in a modified cell to thesame induction in the unmodified cell.

Soluble/Insoluble

The improved expression of recombinant protein can be an increase in thesolubility of the protein. The recombinant protein or peptide can beproduced and recovered from the cytoplasm, periplasm or extracellularmedium of the host cell. The protein or peptide can be insoluble orsoluble. The protein or peptide can include one or more targetingsequences or sequences to assist purification.

In certain embodiments, the invention provides a process for improvingthe solubility of a recombinant protein or peptide in a host cell. Theterm “soluble” as used herein means that the protein is not precipitatedby centrifugation at between approximately 5,000 and 20,000×gravity whenspun for 10-30 minutes in a buffer under physiological conditions.Soluble, active proteins are capable of exhibiting function, and are notpart of an inclusion body or other precipitated mass.

The invention can also improve recovery of active recombinant proteinsor peptides. For example, the interaction between a identified and aparent polypeptide, polypeptide variant, segment-substituted polypeptideand/or residue-substituted polypeptide can be measured by any convenientin vitro or in vivo assay. Thus, in vitro assays can be used todetermine any detectable interaction between a identified andpolypeptide, e.g. between enzyme and substrate, between hormone andhormone receptor, between antibody and antigen, etc. Such detection caninclude the measurement of colorimetric changes, changes inradioactivity, changes in solubility, changes in molecular weight asmeasured by gel electrophoresis and/or gel exclusion processes, etc. Invivo assays include, but are not limited to, assays to detectphysiological effects, e.g. weight gain, change in electrolyte balance,change in blood clotting time, changes in clot dissolution and theinduction of antigenic response. Generally, any in vivo assay can beused so long as a variable parameter exists so as to detect a change inthe interaction between the identified and the polypeptide of interest.See, for example, U.S. Pat. No. 5,834,250.

Cytoplasmic/Periplasmic/Secreted

In certain embodiments, the protein can also be secreted into theperiplasm if fused to an appropriate signal secretion sequence. In oneembodiment, the signal sequence can be a phosphate binding protein, aLys-Arg-Orn binding protein (LAObp or KRObp) secretion signal peptide,an Outer Membrane Porin E (OprE) secretion signal peptide, an azurinsecretion signal peptide, an iron (III) binding protein [Fe(III)bp]secretion signal peptide, or a lipoprotein B (LprB) secretion signalpeptide.

In one embodiment, no additional disulfide-bond-promoting conditions oragents are required in order to recover disulfide-bond-containingidentified polypeptide in active, soluble form from the modified hostcell or doubly or multiply modified cell. In one embodiment, thetransgenic peptide, polypeptide, protein, or fragment thereof has afolded intramolecular conformation in its active state. It has beenfound that complex mammalian proteins soluble in the cytoplasm canconfigure appropriately with the proper positioning of the thiol groupsfor later disulfide bond formation in the periplasm. In one embodiment,the transgenic peptide, polypeptide, protein, or fragment contains atleast one intramolecular disulfide bond in its active state; and perhapsup to 2, 4, 6, 8, 10, 12, 14, 16, 18, or 20 or more disulfide bonds.

In one embodiment, more than 50% of the expressed, transgenic peptide,polypeptide, protein, or fragment thereof produced will be produced assingle, functional peptides, polypeptides, proteins, or fragmentsthereof in soluble, active form or insoluble easily renatured form inthe cytoplasm or periplasm. In another embodiment about 60% , 70%, 75%,80%, 85%, 90%, 95% of the expressed protein is obtained in or easilyrenatured into active form.

EXAMPLES

The bacterial strains used in the current study are listed in Table 1.Strains of P. fluorescens were grown in shake-flasks at 30° C. OD₅₇₅ wasrecorded for each strain at various time points. TABLE 1 Overview ofbacterial strains Relevant Strain Strain Genotype Plasmid RecombinantProtein MB214 P. fluorescens host strain DC206 pyrF⁻ DC240 pyrF⁻pDOW2415 nitrilase DC271 pyrF⁻ pDOW1323 pbp:hGH DC280 pyrF⁻ pDOW1339vector only plasmid DC369 pyrF⁻ pDOW1426 hGH DC462 pyrF⁻ pDOW3501 GrpE,DnaKJ DC463 pyrF⁻ pDOW3501, GrpE, DnaKJ, hGH pDOW1426 HJ104 pyrF⁻pDOW1349 hGH-COP DC370 pyrF⁻, hslU⁻ DC372 pyrF⁻, hslU⁻ pDOW1426 hGHDC373 pyrF⁻, hslU⁻ pDOW1323 pbp:hGH HJ105 pyrF⁻, hslU⁻ pDOW1349 hGH-COPDC417 pyrF⁻, hslUV⁻ HJ115 pyrF⁻, hslUV⁻ pDOW1426 hGH HJ117 pyrF⁻, hslUV⁻pDOW1349 hGH-COP

Plasmids used in the following experiments are listed in Table 2. TABLE2 Overview of plasmids Plasmids Relevance pDOW2236 cloning vectorpDOW2240 Ptac grpE-dnaKJ, pyrF⁺ pDOW2247 Pmtl no recombinant gene; emptyvector pDOW3501 Pmtl grpE-dnaKJ, pyrF⁺ pDOW1349 pyrF⁺, hGH::COP pDOW1426pyrF⁺, hGH pDOW1261-2 suicide vector, pyrF⁺ pDOW2050 used forconstruction of the hslUV deletion strainsSample Collection and RNA Isolation

All samples were collected from a 200 ml standard shake flasksexperiments. Samples were taken at different time points as indicated inthe figures. At each time point, 10 ml of cell culture from the shakeflasks was collected and mixed with 10 ml of RNAlater (Ambion, Austin,Tex.) reagent to stabilize RNA.

Microarray Hybridization and Data Analysis

For each RNA sample, the fluorescent nucleotides Cy3-dUTP or Cy5-dUTP(Amersham Pharmacia, Piscataway, N.J.) were incorporated into cDNA in areverse transcription (RT) reaction using random hexamer primer(Amersham). The two labeled cDNA pools were combined and applied to amicroarray slide. The microarray slides contains 50mer amino-modifiedoligodeoxyribonucleotides (oligos) representing each ORF of P.fluorescens. Each oligo was printed twice for duplicate spots atdifferent location using the SDDC-2 robot (Virtek, Toronto, Canada—nowdistributed through Bio-Rad Laboratories, Hercules, Calif.) and SMP3pins (TeleChem International Inc., Sunnyvale, Calif.). The microscopeslides used were coated with a positively charged epoxy resin forefficient DNA binding (MWG Inc, Alameda, Calif.). After printing, theslides were post-processed according to MWG's specifications. A softwarepackage from BioDiscovery Inc. (El Segundo, Calif.) was used tofacilitate the data analysis. This package consists of CloneTracker™,ImaGene™, GeneSight™ modules and the GeneDirector™ database. Eachhybridized slide was scanned using ScanArray 5000 (Packard BioScience,Billerica, Mass.) to measure fluorescence of the Cy3- and Cy5-labeledcDNA bound to the microarray. The acquired images were quantified inImaGene™ and raw data was processed in GeneSight™. During the datapreparation, the spot intensity for each gene was background-corrected;the signal for the Cy5 channel was normalized to the Cy3 channel usingthe total signal intensity for the entire array; the normalized ratio ofCy5 to Cy3 for each gene was log2 transformed, and replicates werecombined.

Protein Expression Analysis by SDS-PAGE

Culture aliquots were harvested at various time points after IPTGinduction, normalized to OD₆₀₀ of 10. Cell lysates were separated intosoluble and insoluble fractions by centrifugation at 11000 g for 5 min.Aliquots of 2.5 ul were combined with 5 ul 2×NuPAGE LDS sample buffer(Invitrogen, San Diego, Calif.), 50 uM DTT, and H₂O to 10 μl, thenheated at 95° C. for 5 min. The proteins were separated and visualizedon 12% Nupage gels stained with Coomassie Blue using Simply BlueSafestain (Invitrogen, San Diego, Calif.).

Fluorescence Activity Measurement

Protein yield was also measured by fluorescence activity of the fusionof green fluorescence protein (COP) and human growth hormone (hGH). Thehgh::COP fusion construct was transformed into wild-type or hslU mutantstrains and selected on the M9 glucose agar plate without uracil. TheIPTG-induced cell culture were normalized to OD₆₀₀ of five. Relativefluorescence (RF) activity was measured using the Spectramax Geminimicroplate spectrofluorimeter (Molecular Devices, Sunnyvale, Calif.)under the appropriate setting (Ex485, Em538530 bandpass filter).

Example 1

Gene Expression Analysis of Strains Producing Cytoplasmic andPeriplasmic Proteins—Comparison of Different Time Points

To study the FMs and protease gene expression during the production ofheterologous protein, P. fluorescens strains DC206, 280, 240 and 271were used in the initial microarray experiments. DC206 is the hoststrain and was used as a control for cell growth; DC280 has avector-only plasmid and was used as a control for the microarrayexperiments; DC240 is DC206 with a plasmid encoding cytoplasmicnitrilase enzyme that is soluble; DC271 is DC206 with a plasmid encodingthe periplasmic human growth hormone (pbp::hGH) that is partlyinsoluble. Strains were grown in 200 ml of shake flask medium and cellgrowth was monitored by measuring OD₅₇₅. IPTG induction was performed 24hrs after inoculation. All strains grew similarly and culture sampleswere taken just before (0 hr) and 4 hrs after induction for RNAisolation and transcriptional profiling (TxP) using DNA microarrays(FIG. 1).

The genetic profiles, ie. transcriptional profiles were based on thecomparison of the 4 hrs after induction time point sample with that of 0hr sample, the two samples were labeled with fluorescent dyes, eitherCy3-dUTP or Cy5-dUTP, and co-hybridized to the same slide for eachstrain. Each hybridization was duplicated with dye-swap experiments(i.e., samples were labeled with either Cy3-dUTP or Cy5-dUTP) (Table 3,slides 1 to 6). The hybridized slides were scanned using a confocallaser scanner. Signal intensity for each gene was determined andprocessed using the microarray software package from Biodiscovery (ElSegundo, Calif.). The expression ratio of the two time points for eachgene was calculated and ratios for all the genes across the strains wereclustered based on the ratio value and trend among the three strains(DC280, DC240 and DC271) (FIG. 2). TABLE 3 Summary of microarrayexperiments performed in Examples 1-3 Experiment Slide Cy3 Cy5 DC280 1 4hr sample 0 hr sample 2 0 hr sample 4 hr sample DC240 3 4 hr sample 0 hrsample 4 0 hr sample 4 hr sample DC271 5 4 hr sample 0 hr sample 6 0 hrsample 4 hr sample 0 hr 7 DC240 DC271 8 DC271 DC240 4 hr 9 DC240 DC27110 DC271 DC240 DC369 11 4 hr sample 0 hr sample 12 0 hr sample 4 hrsample

To focus on FM and protease gene expression in P. fluorescens under thestress imposed by high level recombinant protein production, a list ofFM and protease genes was compared to the cluster analysis. Afterhierarchical clustering analysis of all the genes from DC280, DC240 andDC271, FMs and proteases were identified in two clusters (lines inclusters 6 and 7; FIG. 2).

Four genes in cluster 7 show significant higher expression in DC271expressing mainly insoluble periplasmic human growth hormone as comparedto DC240 producing soluble cytoplasmic nitrilase or DC280, which doesnot overproduce any protein. The four genes are rxf01961 encoding HslV,rxf01957 encoding HslU, rxf03987 encoding CbpA and rxf05455 encodingHtpG. The E. coli HslV (ClpQ) and HslU (ClpY) together form acytoplasmic protease. The small subunit, HslV, is a peptidase related tothe proteasomal α-subunits of eukaryotes. The large subunit, HslU, is anATPase with homology to other Clp family ATPases such as ClpA and ClpX.CbpA of E. coli is an analogue of the well-characterized co-chaperoneDnaJ as judged from not only its structure but also its function. Thephenotype of lesions in DnaJ, such as temperature sensitivity forgrowth, are restored upon introduction of the cbpA gene on a multicopyplasmid. HtpG of E. coli functions as an ATP-independent molecularchaperone in vitro. It recognizes and transiently binds non-nativefolding intermediates, reducing their free concentration in solution andthus preventing unspecific aggregation.

The genes in cluster 6 of FIG. 2 were clustered again using hierarchicalclustering to identify less pronounced effects. FIG. 3 shows that FMsand proteases were identified in two main clusters (lines in cluster 6and 8). The two FMs in cluster 8 are DnaK and DnaJ, two main chaperonesthat are well known to work together to fold numerous proteins. Furtheranalysis of expression values of genes from cluster 6 identified anadditional FM, ClpX that is higher expressed in DC271 producing pbp::hGHas compared to DC240 producing nitrilase or DC280, which does notoverproduce any protein. The E. coli ClpX heat shock protein ishomologous to members of prokaryotic and eukaryotic HSP100/Clp ATPasesfamily. ClpX of E. coli was isolated as a specific component of theATP-dependent Clp proteases, which maintain certain polypeptides in aform competent for proteolysis by the ClpP protease subunit. ClpX canact as a molecular chaperone, in the absence of ClpP, by activating theinitiation proteins involved in DNA replication. Identified FMs andproteases important for periplasmic hGH production are listed in Table4. TABLE 4 List of FM and protease genes whose steady-state mRNA ratiolevels are higher in DC271 as compared to DC240 and DC280. The valueslisted are the ratio of 4 hr after IPTG induction to 0 hr. DC280 DC240DC271 Gene ID (4 hr vs. 0 hr) (4 hr vs. 0 hr) (4 hr vs. 0 hr) GeneFunction RXF05455_1 0.8 0.6 5.3 htpG Chaperone protein HtpG RXF03987_11.0 0.5 5.2 cbpA Curved DNA-binding protein RXF01961_1 0.9 0.4 5.0 hslVATP-dependent protease HslV (ec 3.4.25.—) RXF01957_1 1.0 4.8 hslUATP-dependent Hsl protease, ATP-binding subunit HslU RXF05399 1.0 0.63.3 dnaK* Chaperone protein DnaK RXF05399_1 1.3 0.6 3.0 dnaK* Chaperoneprotein DnaK RXF05406_1 1.2 0.7 3.0 dnaJ Chaperone protein DnaJRXF04654_1 1.1 0.9 2.0 clpX ATP-dependent Clp protease, ATP-bindingsubunit ClpX*For dnaK, two probes are present on the microarray chip and thus twogene expression values are provided.

Example 2

Gene Expression Analysis of Strains Producing Cytoplasmic andPeriplasmic Proteins—Direct Comparison of Different Strains

In order to confirm the results obtained above, additional microarrayexperiments were performed by direct comparison of the two strains DC271and DC240 (slides 7 to 10 in Table 3). The comparison of the two strainsat the 4 hrs after induction time point confirmed that an almost

identical set of FM and protease genes were up-regulated in cellsexpressing partially soluble pbp::hGH (Table 5). All genes listed inTable 5 are significantly (i.e. ≧2-fold) higher expressed in strainsproducing the partly insoluble hGH as compared to cells producing fullysoluble nitrilase. In the direct comparison of DC271 to DC240, a fewadditional proteins were identified as compared to the time pointcomparison (see Table 4) that showed significantly higher geneexpression values during partially insoluble hGH production. Those genesincluded rxf08347 encoding ClpB, rxf04587 encoding ClpA, and rxf05753encoding FkbP. The E. coli ClpB homologue is involved in reactivation ofinclusion bodies together with DnaKJ-GrpE. ClpA from E. coli has achaperone function or, when together with ClpP, degrades proteins. In E.coli, FkbP

functions as a peptidyl-prolyl isomerase. TABLE 5 List of FM andprotease genes whose steady-state mRNA levels are higher in DC271 ascompared to DC240. The values listed are the ratio of DC271 to DC240 at4 hr after IPTG induction. DC271 vs. DC271 vs. Gene ID DC240 at 0 hrDC240 at 4 hr Gene Function RXF03987_1 0.8 10.8 cbpA Curved DNA-bindingprotein RXF01957_1 0.9 10.0 hslU ATP-dependent Hsl protease, ATP-binding subunit HslU RXF01961_1 0.7 10.0 hslV ATP-dependent proteaseHslV (ec 3.4.25.—) RXF05455_1 0.7 7.8 htpG Chaperone protein HtpGRXF05406_1 1.0 4.7 dnaJ Chaperone protein DnaJ RXF08347_1 0.6 3.8 clpBClpB protein RXF05399_1 1.0 3.7 dnaK* Chaperone protein DnaK RXF053990.9 2.9 dnaK* Chaperone protein DnaK RXF04587_1 0.9 2.8 clpAATP-dependent Clp protease, ATP- binding subunit ClpA RXF05753_1 1.1 2.1fkbP Peptidyl-prolyl cis-trans isomerase (ec 5.2.1.8) RXF04654_1 1.2 2.0clpX ATP-dependent Clp protease, ATP- binding subunit ClpX*For dnaK, two probes are present on the microarray chip and thus twogene expression values are provided.

Example 3

Gene Expression Analysis of a Strain Producing an Insoluble CytoplasmicProtein

Since DC271 expresses partially periplasmic human growth hormone(pbp::hGH), it was investigated if similar or different FMs and proteasegenes were up-regulated in a strain expressing mainly insolublecytoplasmic hGH. DC369 was used in this experiment. The 4 hrs afterinduction sample was compared with that of the 0 hr time point sample,and microarray experiments were performed as shown in Table 3 (slides 11and 12). Again, similar FM and protease genes were found to beup-regulated indicating that the identified genes are involved in

cytoplasmic rather than periplasmic folding and protein degradation(Table 6). A summary of which genes were identified in which experimentalong with the fold up-regulation is shown in the Venn diagram of FIG.4. TABLE 6 List of FM and protease genes whose steady-state mRNA levelsare higher in DC369 at 4 hrs after induction as compared to time zero.The values listed are the ratio of 4 hr after IPTG induction to 0 hr(just before induction). DC369 Gene ID (4 hr vs. 0 hr) Gene FunctionRXF01961_1 4.8 hslV ATP-dependent protease HslV (ec 3.4.25.—) RXF01957_14.3 hslU ATP-dependent Hsl protease, ATP-binding subunit HslU RXF03987_14.1 cbpA Curved DNA-binding protein RXF05455_1 3.3 htpG Chaperoneprotein HtpG RXF05406_1 2.3 dnaJ Chaperone protein DnaJ RXF08347_1 2.2clpB ClpB protein RXF05399_1 2.1 dnaK* Chaperone protein DnaK RXF02095_12.0 groES 10 kDa Chaperonin GroES RXF06767_1 2.0 groEL 10 kDa ChaperoninGroEL RXF05399 1.8 dnaK* Chaperone protein DnaK RXF04587_1 1.7 clpAATP-dependent Clp protease, ATP-binding subunit ClpA*For dnaK, two probes are present on the microarray chip and thus twogene expression values are provided.

Example 4

Generation of an hslU Mutant Strain in P. fluorescens DC206

The two genes hslVU were found to be among the most highly up-regulatedidentified genes. HslU is a cytoplasmic ATPase. The homologous proteinin E. coli can act in combination with a second protein to promoteenergy dependent protein degradation in E. coli. HslU interacts withHslV, a protein with homology to the a subunits of proteasome. The E.coli HslVU homologues were reported to be involved in overallproteolysis of misfolded proteins in Missiakas, D., et al. (1996)Identification and characterization of HsIV HsIU (ClpQ ClpY) proteinsinvolved in overall proteolysis of misfolded proteins in Escherichiacoli. Embo J 15:6899-909. DNA sequence analysis suggested that the P.fluorescens hslVU genes are likely to be part of a bicistronic operon(FIG. 5).

In order to verify that HslVU are indeed involved in the degradation ofhGH, an hslU knockout strain was constructed. Such a strain wasgenerated by insertional inactivation of hslU (FIG. 6). An approximately550 bp DNA fragment internal to hslU was cloned into thekanamycin-resistant pCR2.1-TOPO vector. Since this vector has an originof replication (ColE1) that is functional in E. coli but not in P.fluorescens, the constructed plasmids will integrate into the chromosomeof DC206 through homologous recombination in order to confer kanamycinresistance. The correct insertion site for the kanamycin resistantcolonies was confirmed by diagnostic colony PCR using primers thathybridize to the outside of the originally amplified region and withinthe plasmid backbone (Table 3). The constructed hslU mutant strain wasdesignated DC370.

Primers were designed that would amplify a ˜550 bp internal region ofthe hslU gene (Table 7). The internal fragment was amplified using TaqPolymerase (Promega), purified, and cloned into pCR2.1-TOPO vector(Invitrogen, San Diego, Calif.). The plasmids were transformed intocompetent P. fluorescens DC206 and selected on the M9 glucose agarplates supplemented with 250 μg/ml uracil and 50 μg/ml kanamycin. TABLE7 Primers Primers Sequence Purpose hslU_sens accgaagtcggctatgtggg usedin PCR (SEQ ID NO:1) amplification hs1U_antis aatcgcgctgcacgccttcg ofthe (SEQ ID NO:2) internal hs1U fragment hs1_F2 ttcatcaaggtcgaagcg usedin (SEQ ID NO:3) diagnostic PCR hs1_R2 tcagtcttgaccatgcc (SEQ ID NO:4)M13_R caggaaacagctatgac (SEQ ID NO:5) M13_F taaaacgacggccag (SEQ IDNO:6) hs1-Up gtggcagccaccaaggctgc used in SOE (SEQ ID NO:7) PCR the up-hs1_middleUp ccacattgagtgaggcttac and down- DNA aaggggagagtctccacgfragment of (SEQ ID NO:8) hs1UV hs1_middleDown cgtggagactctccccttgtaagcctcactcaatgtggg (SEQ ID NO:9) hs1_down ggccaatggttggccacgcg (SEQ IDNO:10) hs1_UpUp tgccgacgccacaggtgc used in (SEQ ID NO:11) diagnostic PCRhs1_DownDown gcctggtactgcgactcg (SEQ ID NO:12) RC199atatactagtaggaggtaac used in ttatggctgacgaacagac cloning the gca (SEQ IDNO:13) grpE-DnaKJ RC200 atattctagattacaggtcg ccgaagaagc (SEQ ID NO:14)Protein Expression Comparison by SDS-PAGE Analysis

To study the effect of the hslU gene knockout, two exogenous proteinexpression were compared between the parent strain DC206 and the newlyconstructed mutant strain DC370. The plasmids harboring the geneencoding pbp::hGH (pDOW1323), and hGH (pDOW1426) were each transformedinto competent DC370 cells and resulted in strains DC373 and DC372,respectively. Standard shake-flask growth experiments were performedwith the four strains. FIG. 7 shows that the wild-type and mutantstrains have similar growth rates. Samples were run on SDS-PAGE gels(FIGS. 8 and 9). The results suggest that the mutant produced higheramounts of proteins due to the deletion of the protease subunit HslU.

Protein Expression Comparison by Fluorescence Activity

Since the observed effect of the lack of HslU on the yield of hGH isdifficult to quantitate using SDS-PAGE analyses, the temporal profile ofprotein production was monitored by the fluorescence of a fusion proteinbetween COP green fluorescent protein and hGH. A plasmid containing anhGH::COP fusion was constructed and transformed into the parent strainDC206 and the hslU gene deletion strain DC370 resulting in strains HJ104and HJ105 (Table 1). Standard shake flask experiments were performed andsamples were taken at various time points for fluorescence measurements(FIG. 10). The readings from the fluorimeter clearly showed that thehslU protease mutant strain had significantly higher protein expressionlevels compared to that of the parental strain (FIG. 11). This findingcorroborates the results obtained by SDS-PAGE analysis. Comparing to thewild type strain, the hslU mutant increased 33.05% of the relativefluorescence at 24 hrs after induction (see insert in FIG. 11).

Example 5

Construction of an hslUV Clean Knockout Strain

The Hsl protease consists of two subunits:: an ATP-binding subunitencoded by hslU, and a protease subunit encoded by hslV. The previouslyconstructed Hsl protease knock-out strain is an insertional inactivationof the hslU gene. To remove the concern that HslV might still functionas a protease by being able to couple with an ATP-binding subunit ofanother protease, a deletion strain was constructed that had both thehslU and hslV genes removed from the chromosome.

As shown in FIG. 13, plasmid pDOW2050 was constructed by PCRamplification of two DNA fragments flanking the hslUV region, the twofragments were subsequently fused using the Splicing by OverlapExtension (SOE) PCR method (see Ho, S. N. (1991) Method for genesplicing by overlap extension using the polymerase chain reaction.Application: U.S. patent 89-3920955023171). The fused DNA fragments werethen ligated into the SrfI site of vector pDOW1261-2. The deletionplasmid was named pDOW2050 after the insert was confirmed by DNAsequencing.

Plasmid pDOW2050 was electroporated in DC206 and plated onto M9 agarplates supplemented with 1% glucose and 15 μg/ml tetracycline.Tetracycline-resistance is due to an integration event that recombinesthe entire plasmid into the chromosome at one of the two homologousregions within the genome (FIG. 13). To select for cells that have adeletion of the hslUV genes resulting from a second homologousrecombination between the integrated plasmid and the homologous DNAregion in the chromosome, the tetracycline resistant colonies were grownto stationary phase in LB medium supplemented with 250 μg/ml uracil.Cells are then plated onto LB agar plates supplemented with 500 μg/ml5-fluoroorotic acid (5-FOA). Cells that lost the integrated plasmid by asecond recombination event also have lost the pyrF gene and thus areresistant to 5-FOA, resulting in the desired chromosomal hslUV deletionstrain, called DC417.

Phenotypic Analysis of hslUV Deletion Strain

SDS-PAGE analysis of the hslUV deletion strain expressing hGH protein(strain HJ115) showed much higher protein yield than the wild-typestrain DC369, similar to what was observed earlier using the hslUinsertional mutant strain DC372 (data not shown).

Protein yield was also measured by fluorescence activity of the hGH::COPfusion using the same method described earlier. Plasmid pDOW1349containing the hGH::COP fusion was transformed into wild-type and mutantstrains resulting in strains HJ104 and HJ117, respectively. Standardshake flask experiments were performed and samples were taken at varioustime points for relative fluorescence measurements (FIG. 14). Thereadings from the fluorimeter indicated that the hslUV protease deletionstrain had significantly higher proteins expression levels (about 50%yield increase) as compared to that of the wild-type strain. This resultis similar to what was observed previously with the hslU knock-outstrain.

Example 6

Iterative Target Identification Using DNA Microarray Technology

To investigate if a new set of proteases are up-regulated in the hslUVprotease deletion strain, DNA microarray experiments were conducted.Standard shake flask experiments were performed using the wild type(DC369) and mutant strain (HJ115) expressing hGH. For each strain, the 4hrs after induction samples were compared to that of the 0 hr time pointsample Oust before heterologous protein induction) and DNA microarrayexperiments were performed. Comparing the ratio of the two time pointsbetween the wild-type and mutant strains, a new list of protease genesthat are up-regulated in the hslUV protease deletion strain wasidentified (Table 8). These newly identified genes encoding proteasescan now be the targets for a second round of gene deletion events tofurther improve the yield of heterologous protein production. TABLE 8Protease genes whose steady-state mRNA levels are higher in the hslUVprotease deletion strain (HJ115) as compared to the wild type strain(DC369), based on the ratio of 4 hr after IPTG induction to 0 hr (justbefore induction). Curated ORFID Function Sequence rxf00133 D-alanyl-atgcactttggaaaatggtttcacaccagcaccctgctggtcggcttgagttttgtgctgggcgg meso-ctgcgccagcgtctcccaaacctccaccccggcaaccctggataagctgttgagcgacccgg diaminop-cgctgcaaggcgccaccgtctcgctgatggtgcgtgatgcccgcacaggcaccacgctgtat imelatecagcacaacccacgcacccggctggtgcccgcgtccaacctcaagctgttgaccacggcgg endopep-cagccatggatgtattggggccgcagtaccgcttcgccacgcaactgctgagcaatggcctac tidasegccagggcgaccggctgactggcaacctgtacctgcgtggcttgggcgacccgagtattcag (ec3.4.—.—) tttgccgactatcaggcgctcgccgcgcaattggccagccagggcgtgcgccaggtgcagggtgacctggtgttcgacgacacttggttcgatgccgagcggctgggcgtggactggtcccatgatgatgaaaccacctactacggcgcgcagatttcagcgctgaccgtggcgcccaataccgactttgatgctggcagcgtgctggtcaccgccaaggcgccgttgcacgtcggctcgccggtcggcgtggagatctacccgcccaccgactacctgcaactgaataaccgcgccgtcagcgggccgggtaacagctatgggatcaaccgtcgccatggcaccaacctgctgcagctcagcggcgcggtggcgcctggccggcagagccagcaattgatcagcgtgtgggagccgacgcaactggtggccaacctgtttgagcaagccttggcgcagcagggcatcaaggtgctggggcgtcgggtgatgggcggggcaagtcctgctggggtgacggtgctggccgagcaccaatcggcgccgttgcaggagctgatcgtgccgctgctcaagctctcgaacaacgccatgtccgaagccgtgctcaaggccatgggccgccagacggccagcagcggcacggcggcggcgggcgccgtggcggtggccgactttctcaagcgccaggggctggacaccagcgctgtgagccaagtggacggctccggcctgtcgcggcgtaacctggtgtcgtcgcaaaccctcaccgacctgctgctggcggccagcaaacaaccctggttcgacgcctggtacaacgcgctgccggttgccggcaatgccgaccgtatgaccggcggcagcctgggttaccgcctgcgcggcacggctgcggaaaataacctgcatgccaagaccggctccatggccggcgtgtcgtcattgagcggttacatcaccgatgctcacgggcgcaagctggtgttcgcgatgttgaccaacaactatgtggtcgctggcgcgcaggtaaaagccgtggaaaaccgcgtcgccgtggccctgtcccacagcgaagactga rxf01918 zinc proteaseatgagtgatcgcaaaaacagccgcctgatcctgcccggcctgatcgccgtcaccctgatggcg (ec3.4.99.—) gccagcgccgtttacttcttgcgccccagcgagtcggtcgccagccaggccctggacaaggctcaaacggccagcaccctgcaatccctggcggaactggatggcaaggcaccgaccaaccgcaagctcgacgtacaaacctggaccaccgccgaaggcgccaaggtgctgttcgtcgaagcccatgagttgccgatgttcgacatgcgcctgctgttcgccgccggcagcagccaggatggcgacgtgccaggcctggcgctgatgaccaacgccatgctcaacgaaggcgtgccgggcaaggacgtcagccagatcgccagtggcttcgaaggcctgggggccgactttggcaacggcgcctaccgcgacatggcgctggtgaccctgcgcagcctgagcgacagcgccaagcgcgacgccgccctgtcactgttcaaccaggtgatcggccagccgactttcccggcagactcactggcacgcatcaagaaccagatcctggccggtttcgagtaccagaagcagaaccccggcaaactggcgagcatcgaactgttcaagcgcctgtacggcgaccacccttacgcacacccgagcgaaggcacccccgagagcgtgccgaagattaccctggcgcagttgcaggcgttccacgccaaggcctatgcagcgggtaacgcggtgattgcagtggtgggcgacctgacccgcgccgaagctgaagccatgacggccaaggtgtccgcgtcgctgcccaaaggcccggctatggccaagatcgcccagccgaccgagccaaaagccggcctgagccgtatcgagttcccgtccaagcaaacccacctgctgtttgcgcagttgggcatcgaccgtgccgacccggattacgcagccttgtccctgggtaaccagatcctcggcggcggtggcttcggcacccgcttgatgagcgaagtgcgtgaaaagcgcggcctgacctacggcgtgtattccggtttctcaccaatgcaggcgcgcggcccgttcatgatcaacctgcagacccgcgccgaaatgagcggtggcaccttgcgcctggtggaggacgtactggctgactacctcaagaccggcccgacgcaaaaggaactggatgacgccaagcgcgagctggccggcagcttcccgctgtccaccgccagcaacgccgatatcgtcgggcagttgggcgccatgggtttctacaacctgccgctgagctatctggaagatttcatgaaacaatcccaggccctgaccgtcgatcaggtcaaggctgcaatgaataaacacttgagcgccgacaagatggtcatcgtgaccgccggcccgacgattgcgcaaaagccactaccgccccccactgataaacctgccgagcagccgctcggggttccggagc attaarxf02689 Microsomalttgtcgtggattgacgctttcggcaattcccctgtcgtttttgcacccggctccgtcggtgcctggdipeptidasegcatatgctggccccaaagcgccggcagacgattcggcgcatgaatcgccaataaggggac (ec3.4.13.19)gcctgatgagcccagccgagttgcacgccgacagcatcgttatcgacggtctgattattgccaagtggaaccgcgacctgttcgaagacatgcgcaaaggtggcctcaccgccgccaattgcacggtgtcggtgtgggaaggcttccaggccacgatcaataacatcgttgccagccagaccctgatccgcgaaaacagcgacctggtgatcccggtgaaaaccaccgccgacatccgccgcgccaaggagctgggcaagactggcatcatcttcggcttccagaatgcccatgcctttgaggaccagctcggctatgtcgagatcttcaagcagctcggcgtgggcgtggtgcagatgtgctacaacacccagaacctggtgggcaccggttgctacgagcgcgatggcggcctgtcgggtttcgggcgtgagatcgtcggcgagatgaaccgcgtcggcatcatgtgcgacctgtcccacgtgggctccaagaccagcgaagaggtcatcctcgaatcgaaaaagccggtgtgctactcccactgtctgccgtccgggcttaaagagcacccgcgcaacaagtccgatgaagagctgaagttcatcgccgaccatggcggatttgtcggtgtgaccatgttcgcgccgtttttggccaagggcatcgactcgactatcgacgactatgccgaagccatcgaatacaccatgaacatcgtcggcgaagacgccatcggcatcggcaccgacttcacccagggccatggccaggatttcttcgaaatgctcacccatgacaagggctacgcccgccgcctgaccagcttcggcaagatcatcaacccgctgggcatccgcaccgtgggtgagttccccaacctcaccgagaccctgctcaagcgcggccacagcgagcgcgtggtgcgcaagatcatgggcgagaactgggtcaacgtgctcaaggacgtctggggcgaataa rxf05113 Extracellularatgacaatttggcccagggggcgaacacagggctatcctgaaaaccgttacccggacgttcacmetallopro-cacacgccaaaaaggagccagctcatgtgtgttcgccaaccgcgcaacccgattttttgcctga teasetcccgccgtacatgctcgaccagatcgcacgccacggcgacaaagcccaacgggaagtcgc precursorattacgcacgcgtgccaaggacagcacgtttcgttcgttgcgcatggtcgcggtacccgccaa (ec3.4.24.—) ggggccggcccgcatggcactggccgtgggcgccgagaagcaacgctcgatctacagtgccgaaaacaccgacagcctgcccggcaagctgatccgcggcgaagggcagcccgccagtggcgatgccgcggtggacgaagcctatgacggcctgggcgcgaccttcgatttttttgaccaggtctttgatcgcaattccatcgacgatgcgggcatggcgctggacgccacggtgcacttcggccaggactacaacaatgcgttctggaattcgacccagatggtgttcggcgatggcgaccagcagttgttcaaccgctttaccgtggcactcgacgtcattgggcatgagttggcccatggcgtgactgaggatgaggccaagctgatgtacttcaaccagtccggtgcgctgaacgagtcgttgtcggacgtgttcggttcgctgatcaagcagtacgcgttaaagcaaacggccgaggatgccgactggttgatcggcaaggggttgtttaccaaaaagatcaagggcacggcgctgcgctcgatgaaggcgccaggcactgcgtttgatgacaagctgctgggcaaagacccgcagcctgggcacatggatgattttgtgcaaacttacgaggacaatgggggcgtgcatatcaattccggcattcccaaccatgcgttctaccaggtggcgatcaatataggcgggttcgcctgggagcgtgccgggcgtatctggtatgacgcactgcgcgattcgcggttgcggcccaattccgggttcttgcgttttgcgcgcattacccacgatattgccggccagctttatggcgtgaacaaagctgagcagaaggcagtcaaggaaggctggaaagcggtgggcataaacgtttga rxf05400 Cell divisionttgaacgatatggcaaagaatctgatcctgtggttgatcatcgcggctgtcctggtgacggtgatprotein FtsHgaacaacttctccagccctaacgagccgcagaccctcaactattccgacttcatccagcaagtt (ec3.4.24.—) aaggatggcaaggtcgagcgcgtagcggttgatggctacgtgattaccggtaagcgcaacgatggcgacagcttcaagaccattcgtcctgccattcaggacaacggtctcatcggtgacctggtggataacaaggtcgttgtggaaggcaagcagcctgaacagcaaagcatctggacccagctcctggtggccagcttcccgatcctggtgattatcgccgtgttcatgttcttcatgcgccagatgcaaggcggtgcgggaggcaagggcgggccgatgagcttcggcaaaagcaaggcgcgcctgctctccgaagaccaggtgaagaccaccctggctgacgtcgcaggttgcgacgaagccaaggaagaagtcggtgagttggtcgagttcctgcgtgatccgggcaagttccagcgcctgggtggccgtattcctcgcggtgtgctgatggtggggcctccgggtaccggtaaaaccttgctggccaaggcgattgccggcgaagccaaggtgcctttcttcacgatttccggttctgacttcgtcgagatgtttgtcggcgtcggcgccagccgtgttcgcgatatgttcgagcaggccaagaagcacgcgccatgcatcatcttcatcgacgaaatcgatgccgttggtcgccatcgtggcgcgggcatggggggtggtcacgatgagcgtgagcagaccctcaaccagttgctggtagagatggatggtttcgagatgaatgacggcattatcgtcatcgccgcaaccaaccgtcccgacgttctcgaccctgcgttgctgcgtccgggccgtttcgaccgtcaggttgtggtcggcctgccggacattcgtggtcgtgagcagatcctgaaagtacacatgcgcaaggtgccaatgggtgacgacgtggctccggctgtgatcgcccgtggtactcccggtttctccggtgctgatctggcgaacctggtcaacgaggcttcgctgttcgctgcccgtactggcaagcgcatcgttgagatgaaagagttcgaattggcgaaagacaagatcatgatgggcgccgagcgcaaatccatggtcatgtccgagaaagagaagcagaacaccgcttatcacgaggccggtcacgccattgtaggtcgcgttgtgcctgagcatgaccccgtctacaaagtgtcgatcattcctcgtggtcgggcactgggtgtgaccatgttcctgccggaagaagatcgctacagcctctccaagcgtgcgctgatcagccagatctgctcgctgtatggcggtcgtattgctgaggaaatgacccttggcttcgacggtgtgaccactggtgcctccaatgacatcatgcgtgccagccagatcgcacgaaacatggtgaccaagtggggcttgtcggaaaaactcggcccattgatgtacgccgaagaggaaggcgaagtgttcctggggcgtggcggcggtgggcaaagcgccagcttctcgggtgagacagccaagctgatcgactccgaagttcgcagcatcattgaccagtgctatggcacggccaagcagattttgactgacaaccgtgacaagctggacgccatggctgatgcgttgatgaagtacgaaaccatcgatgccgaccagatcgacgacatcatggcgggccgtacgccgcgtgagccgcgcgactgggaaggtggttcgggtacttcgggcactccgcctgtggtgcagaatgagcgccctgaaacgcctatcggcggcccggcagctgatcactaa

Example 7

Co-Overexpression of Folding Modulators Increases Solubility of TargetProtein hGH

Based on the transcriptional profiling data shown in FIG. 4, expressionof folding modulators (FMs) DnaK and DnaJ was increased in strainsproducing recombinant protein compared to control strains (see Tables 4and 5). A strain that co-overproduced GrpE, DnaK and DnaJ along with hGHwas produced and tested to identify if this resulted in the accumulationof increased levels of soluble hGH.

Construction of grpE-dnaKJ-Containing Plasmid for Co-Overexpression withhGH

The P. fluorescens grpE-dnaKJ genes were amplified using chromosomal DNAisolated from MB214 (DNeasy; Qiagen, Valencia, Calif.) as a template,RC199 (5′-ATATACTAGTAGGAGGTAACTTATGGCTGACGAACAGACGCA-3′) and RC200(5′-ATATTCTAGATTACAGGTCGCCGAAGAAGC-3′) as primers, PfuTurbo (Stratagene,La Jolla, Calif.) was used following the manufacturer's recommendations.The resulting PCR product (4 kb) was digested with SpeI and XbaI(restriction sites underlined in the primers above) and ligated topDOW2236 to create pDOW2240 containing the grpE-dnaKJ genes under thecontrol of the tac promoter. Plasmid pDOW2240 was digested with SpeI andHindIII and the resulting grpE dnaKJ-containing 4.0 kb fragment wasgel-purified using Qiaquick (Qiagen) and ligated to pDOW2247 alsodigested with SpeI and HindIII. The resulting plasmid, pDOW3501,containing grpE-dnaKJ under the control of the mannitol promoter, wastransformed into DC388 by selecting on M9 glucose plates supplementedwith 250 μg/ml uracil. Finally, pDOW1426 was electroporated into theabove strain (DC462) and selected on M9 glucose plates, resulting instrain DC463 with two inducible plasmids: 1) pDOW1426 carrying P_(tac)hGH and 2) pDOW3501 carrying P_(mtl) grpE-dnaKJ.

Shake Flask Fermentation, Sample Collection and Analysis

Duplicate cultures of DC463 were grown in shake flasks. Proteininduction was accomplished by addition of 0.1 mM IPTG for hGH and 0.5%mannitol for GrpE-DnaKJ at 24 hrs after inoculation. Samples werecollected at 0, 4, 8, 24 and 48 hours after induction. At each timepoint, 20 OD₆₀₀ cells normalized in 1 mL were harvested, lysed usingEasyLyse™ (Epicentre, Madison, Wis.) and separated into soluble andinsoluble fractions by centrifugation at 14000 rpm for 30 minutes. Equalvolumes of samples were combined with BioRad (Hercules, Calif.) 2×Laemmli buffer, heated at 95° C. for 5 minutes with 30 μL loaded onto aBioRad 15% Tris HCl Criterion gel using 1× Tris Glycine SDS runningbuffer (BioRad). The proteins were visualized with Simply Blue Safestain(Invitrogen, Carlsbad, Calif.) as shown in FIG. 15. The resultingCoomassie-stained gels were scanned using a Molecular Devices PersonalDensitometer (Molecular Devices, Sunnyvale, Calif.) with analysesperformed using ImageQuant and Excel. As shown in FIG. 15,co-overexpression of GrpE, DnaKJ significantly increased the solubilityof hGH, converting almost 100% of the target protein into the solublefraction, albeit at a lower total protein yield. Additional experimentsrepeating growth and induction of DC463 using the simultaneous additionof IPTG and mannitol closely mimicked the results shown here, althoughwith a varying degree of hGH solubility (between 50-100%; data notshown), when GrpE DnaKJ were co-overproduced. These findings furtherdemonstrate that targeted strain engineering based on transcriptionalprofiling can lead to a rational strain design to increase solubilityand/or yield of a recombinant protein.

The invention has been described with reference to certain embodimentsand non-limiting examples. It will be clear to one of skill in the artthat other embodiments of the invention are also possible.

1. A process for improving the expression of a recombinant protein orpeptide in a host cell or organism comprising: i) expressing therecombinant protein or peptide in the recombinant host cell or organism;ii) analyzing a genetic profile of the recombinant cell to identify oneor more compensatory gene(s) or gene product(s) that are expressed at ahigher level in the recombinant cell than in either a host cell that hasnot been modified to express the recombinant protein or a recombinantcell that is not expressing the recombinant protein; and iii) changingexpression of the identified compensatory gene or gene product in therecombinant cell by genetic modification to provide a modifiedrecombinant cell that achieves an increase in recombinant proteinexpression, activity or solubility.
 2. The process of claim 1 furthercomprising expressing the protein or peptide in the modified recombinantcell.
 3. The process of claim 1 further comprising: (a) expressing therecombinant protein or peptide in the modified recombinant cell; (b)analyzing a genetic profile of the modified recombinant cell to identifyat least one second gene(s) or gene product(s) that are differentiallyexpressed in the modified recombinant cell; (c) changing expression ofthe second identified gene product in the modified recombinant cell toprovide a doubly modified cell; and (d) expressing the protein orpeptide in the doubly modified recombinant cell.
 4. The process of claim3 further comprising repeating steps a) to d).
 5. The process of claim 4comprising repeating steps a) to d) until cell viability is affected bychanging the expression of the identified gene(s) or gene product(s). 6.The process of claim 4 comprising repeating steps a) to d) untilexpression of the recombinant protein or peptide reaches a targetedendpoint.
 7. The process of claim 1 wherein a genetic profile isanalyzed by comparing a genetic profile of the recombinant cell to asecond genetic profile of the host cell.
 8. The process of claim 1wherein the genetic profile is a transcriptome profile.
 9. The processof claim 8 wherein the transcriptome profile is determined through amicroarray.
 10. The process of claim 1 wherein the genetic profile is aproteome profile.
 11. The process of claim 10 wherein the proteomeprofile is determined through two dimensional gel electrophoresis, ICATor LC/MS.
 12. The process of claim 10 wherein the proteome profile isdetermined through a peptide array.
 13. The process of claim 12 whereinthe peptide array is an antibody array.
 14. The process of claim 1wherein the identified gene product is a protease, a subunit of aprotease, a cofactor of a protease, a cellular or a genetic modulatoraffecting expression of a protease.
 15. The process of claim 14 whereinthe identified gene product is a protease.
 16. The process of claim 14wherein the identified gene product is a subunit of a protease.
 17. Theprocess of claim 14 wherein the identified gene product is a cofactor ofa protease.
 18. The process of claim 14 wherein the identified geneproduct is a cellular or genetic modulator affecting expression of aprotease.
 19. The process of claim 14 wherein the identified geneproduct is selected from the group consisting ofD-alanyl-meso-diaminopimelate endopeptidase, zinc protease, microsomaldipeptidase, extracellular metalloprotease precursor, cell divisionprotein ftsH and gene products derived from genes hslV, hslU, clpX, clpAand clpB.
 20. The process of claim 14 wherein identified gene productmRNA level is up-regulated when the recombinant protein or peptide isexpressed in the host cell.
 21. The process of claim 14 wherein theidentified gene product is removed from a host cell genome.
 22. Theprocess of claim 21 wherein the identified gene product is removed byhomologous recombination.
 23. The process of claim 1 wherein theidentified gene product is a folding modulator, a subunit of a foldingmodulator, a cofactor of a folding modulator, or a cellular or geneticmodulator affecting the expression of a folding modulator.
 24. Theprocess of claim 23 wherein the identified gene product is a foldingmodulator.
 25. The process of claim 23 wherein the identified geneproduct is a subunit of a folding modulator.
 26. The process of claim 23wherein the identified gene product is a cofactor of a foldingmodulator.
 27. The process of claim 23 wherein the identified geneproduct is a cellular or genetic modulator affecting the expression of afolding modulator.
 28. The process of claim 23 wherein the foldingmodulator is a chaperone protein.
 29. The process of claim 23 whereinthe folding modulator is selected from the group consisting of geneproducts of the genes cbpA, htpG, dnaK, dnaJ, fkbP2, groES and groEL.30. The process of claim 23 wherein the expression of the identifiedgene product is changed by increasing expression of the identified gene,a cofactor of a identified gene, or a cellular or genetic modulator ofthe identified gene.
 31. The process of claim 30 wherein the increasedexpression is by inclusion of a DNA encoding the identified geneproduct.
 32. The process of claim 30 wherein the increased expression isby insertion of a promoter into a host cell genome.
 33. The process ofclaim 30 wherein the increased expression is by inclusion of anexogenous vector into the host cell.
 34. The process of claim 1 whereinthe host cell is a microbial cell.
 35. The process of claim 1 whereinthe host cell is a Pseudomonad.
 36. The process of claim 1 wherein thehost cell is a P. fluorescens cell.
 37. The process of claim 1 whereinthe host cell is an E. coli cell.
 38. The process of claim 1 wherein thehost cell is selected from the group consisting of an insect cell, amammalian cell, a yeast cell, a fungal cell and a plant cell.
 39. Theprocess of claim 9 wherein the microarray comprises samples of bindingpartners to at least 50% of a genome of the host cell.
 40. The processof claim 9 wherein the microarray technique comprises samples of bindingpartners to at least 80% of a genome of the host cell.
 41. The processof claim 9 wherein the microarray comprises samples of binding partnersto at least 90% of a genome of the host cell.
 42. The process of claim 9wherein the microarray comprises samples of binding partners to at least95% of a genome of the host cell.
 43. The process of claim 1 wherein theimproved expression is an increase in the amount of recombinant proteinor peptide.
 44. The process of claim 1 wherein the improved expressionis an increased solubility of the recombinant protein or peptide. 45.The process of claim 1 wherein the improved expression is an increasedactivity of the recombinant protein or peptide.
 46. The process of claim1 wherein the genetic profile is a profile of genes in a gene family.47. The process of claim 1 wherein the profile comprises proteases andfolding modulators.
 48. The process of claim 46 wherein the profileconsists essentially of proteases.
 49. A host cell or organism thatexpresses a recombinant protein that has been genetically modified toreduce the expression of at least two proteases.
 50. A host cell ororganism that expresses a recombinant protein that has been geneticallymodified to reduce the expression of at least one protease selected fromthe group consisting of D-alanyl-meso-diaminopimelate endopeptidase,zinc protease, microsomal dipeptidase, extracellular metalloproteaseprecursor, cell division protein ftsH and gene products derived fromgenes hslV, hslU, clpX, clpA and clpB.
 51. A host cell or organism thatexpresses a recombinant mammalian derived protein that has beengenetically modified to reduce the expression of at least one protease.52. The host cell or organism of claims 52 wherein the recombinantprotein is human growth hormone.
 53. A host cell or organism thatexpresses a recombinant protein that has been genetically modified toincrease the expression of at least two folding modulators that are notfolding modulator subunits.